Research Feeds

What was reviewed?

This review comprehensively examined lactoferrin, a multifunctional iron-binding glycoprotein, highlighting its capacity as a natural immunomodulator that bridges innate and adaptive immunity. The paper assessed lactoferrin’s roles in infection, inflammation, oxidative stress, and immune system regulation, including its therapeutic potential in systemic inflammatory response syndrome (SIRS), sepsis, and bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA).

Who was reviewed?

The review synthesized findings from preclinical in vivo and in vitro studies, particularly in murine models, along with limited human data, to explore the immune mechanisms regulated by lactoferrin. It included evidence across diverse immune cell types, including macrophages, neutrophils, dendritic cells, and T and B lymphocytes.

What were the most important findings?

Lactoferrin significantly modulates immune function through both direct and indirect pathways. It acts as an antimicrobial by binding iron, limiting pathogen proliferation, and neutralizing lipopolysaccharides (LPS). In the microbiome context, this review emphasizes that lactoferrin plays a regulatory role by reducing oxidative stress through iron sequestration and decreasing reactive oxygen species (ROS), which often rise during inflammatory and infectious states.

Lactoferrin dampens excessive immune responses during sepsis and endotoxemia by suppressing mitochondrial ROS and pro-inflammatory cytokines such as IL-6 and TNF-α. It also protects mucosal integrity by reducing bacterial translocation, especially in gut-associated lymphoid tissue. Notably, in both Gram-negative (E. coli) and Gram-positive (MRSA) infection models, lactoferrin improved survival and reduced inflammatory biomarkers. Regarding adaptive immunity, lactoferrin promotes Th1 responses, enhances antigen presentation via dendritic cells and macrophages, and drives T-cell maturation and B-cell isotype switching—thereby reinforcing host microbial surveillance and immunological memory.

Microbiome relevance lies in lactoferrin’s ability to preserve mucosal immunity, reduce gut inflammation, and prevent dysbiosis-linked bacterial dissemination, especially under systemic infectious stress. These actions suggest lactoferrin supports a microbiome-resilient host immune state.

What are the implications of this review?

This review highlights lactoferrin’s potential as a natural immunomodulatory intervention. Its ability to simultaneously enhance protective immunity while dampening harmful inflammation makes it a promising candidate for clinical use in sepsis, autoimmune diseases, infections, and potentially microbiome-targeted therapies. Its role in bridging innate and adaptive immunity also supports its use as a vaccine adjuvant, especially for pathogens requiring strong Th1-type responses. For microbiome-focused clinicians, lactoferrin’s action on mucosal immunity and bacterial translocation pathways suggests a powerful tool for managing dysbiosis-linked systemic inflammation.

What was studied?

This original research study investigated whether the metallomic signature of dementia with Lewy bodies (DLB) differs from Alzheimer’s disease (AD) and Parkinson’s disease dementia (PDD). The study sought to determine if post-mortem changes in elemental concentrations—particularly in essential metals—could help differentiate these often-overlapping neurodegenerative conditions. Using Inductively Coupled Plasma–Mass Spectrometry (ICP-MS), the authors quantified concentrations of nine elements (Na, Mg, K, Ca, Mn, Fe, Cu, Zn, and Se) across 10 brain regions from DLB patients and age-/sex-matched controls. These findings were directly compared to previously published metallomic profiles for AD and PDD, produced using identical methodologies. Multivariate analyses (PCA and PLS-DA) were employed to assess the potential for disease discrimination based on metal signatures.

Who was studied?

The study analyzed post-mortem brain tissue from 23 DLB patients and 20 controls, collected across ten distinct brain regions. Comparative analyses included prior datasets from similarly matched AD and PDD patient cohorts.

What were the most important findings?

In this study, region-specific metallomic signatures profiling revealed distinct trace element alterations in Dementia with Lewy Bodies (DLB). Copper (Cu) levels were consistently decreased in five of ten DLB brain regions, including the cingulate gyrus (CG), middle temporal gyrus (MTG), primary visual cortex (PVC), substantia nigra (SN), and putamen (PUT), suggesting a widespread Cu deficiency. Sodium (Na) was elevated in four regions—medulla (MED), cerebellum (CB), MTG, and CG—while more localized changes were observed for other metals. Iron (Fe) levels were increased in the motor cortex (MCX) and CG, whereas manganese (Mn) was decreased in both the PVC and MED. Calcium (Ca) was specifically reduced in the hippocampus, and selenium (Se) was also decreased in the PVC.

No significant differences in magnesium, potassium, or zinc levels were observed between DLB and control brains. Multivariate analyses, including Principal Component Analysis (PCA) and Partial Least Squares-Discriminant Analysis (PLS-DA), demonstrated that DLB could be distinctly separated from Alzheimer’s disease (AD) and Parkinson’s disease dementia (PDD) based on metallomic signatures. Specifically, CG, MTG, and PVC profiles enabled discrimination between DLB and AD, while the PVC alone differentiated DLB from PDD. Notably, copper depletion emerged as the only common alteration across DLB, AD, and PDD, underscoring its potential central role in the pathogenesis of neurodegenerative diseases. The authors propose that these metallomic signatures in dementia may reflect disease-specific mechanisms, including variations in oxidative stress, protein aggregation, and mitochondrial dysfunction.

What are the greatest implications of this study?

This study provides compelling evidence that distinct metallomic signatures exist across DLB, AD, and PDD, despite shared pathology such as copper depletion. It strengthens the emerging concept that trace metal dysregulation is disease-specific, rather than a general byproduct of neurodegeneration. The findings support the idea that metallomic signatures profiling—potentially via cerebrospinal fluid or advanced imaging in living patients—could improve differential diagnosis of dementia with overlapping clinical features. Furthermore, the study reinforces the hypothesis that metal dyshomeostasis, particularly copper depletion, may be a contributing pathogenic mechanism, impairing antioxidant defenses and mitochondrial function. These findings could inform new diagnostic tools and therapeutic targets.

Citation

Scholefield M, Church SJ, Xu J, Cooper GJS. Metallomic analysis of brain tissues distinguishes between cases of dementia with Lewy bodies, Alzheimer's disease, and Parkinson's disease dementia. Front Neurosci. 2024 Jun 26;18:1412356. doi: 10.3389/fnins.2024.1412356.

What was studied?

In this experimental study, the authors investigated how the nickel chelator dimethylglyoxime inhibits amyloid beta aggregation, focusing specifically on the recombinant human Aβ40 peptide and its interaction with transition metals, particularly nickel. Using inductively coupled plasma mass spectrometry (ICP-MS), thioflavin T (ThT) aggregation assays, isothermal titration calorimetry (ITC), and high-resolution mass spectrometry, they quantified the metal content of a commercial recombinant Aβ40 preparation, characterized the impact of Cu²⁺, Zn²⁺, and Ni²⁺ on in vitro aggregation kinetics, and tested whether the nickel chelator dimethylglyoxime (DMG) inhibits amyloid beta aggregation under different metal and pH conditions. They further evaluated whether dimethylglyoxime forms stable complexes with various metals and explored the capacity of orally administered dimethylglyoxime to reach the brain in a murine model, situating these findings within the broader “metal hypothesis” and “infection hypothesis” of Alzheimer’s disease.

Who was studied?

This is an in vitro biochemical and biophysical study using commercially available recombinant human Aβ40 peptide expressed in Escherichia coli, not a clinical or animal efficacy trial. The peptide preparation was analyzed for multi-element metal content and then subjected to aggregation and binding assays in buffered solutions. For the pharmacokinetic aspect, C57BL mice received repeated oral doses of dimethylglyoxime, after which brain tissue was harvested to detect dimethylglyoxime or dimethylglyoxime–metal complexes by FTICR-MS and NMR, although this arm was limited to detection rather than evaluation of behavioral or neuropathological outcomes. No human subjects or clinical Alzheimer’s disease populations were included; the work is best interpreted as mechanistic preclinical data that inform future translational strategies for metal-targeted interventions in Alzheimer’s disease.

Most important findings

ICP-MS of the recombinant Aβ40 peptide revealed substantial metal contamination intrinsic to the preparation, with selenium and nickel being most abundant and appreciable levels of aluminum, copper, manganese, zinc, barium, and strontium also detected, whereas iron was below detection limits. The table on page 3 (Table 1) quantifies a metal: peptide ratio of approximately 0.073 mol Ni per mol Aβ40, indicating that the peptide is already nickel-bound before any experimental supplementation. Functionally, ThT aggregation assays showed that exogenous Ni²⁺ significantly accelerated Aβ40 aggregation in a concentration-dependent manner, with a 2.5-fold increase in aggregation rate at 10 µM Ni²⁺ and 5.7-fold at 100 µM compared with metal-free control, while Zn²⁺ produced even larger enhancements and Cu²⁺ had minimal effect at neutral pH. pH modulation demonstrated that Ni-induced aggregation was facilitated under mildly acidic conditions (pH 6.5) and abolished at alkaline pH 8.5, reinforcing pH-sensitive nickel–peptide interactions. ITC confirmed direct nickel binding to Aβ40 with an apparent Kd of ~4.2 µM and a stoichiometry of ~0.7 Ni per peptide, and thermodynamic parameters (ΔH −5 kJ/mol, positive ΔS) consistent with an exothermic, spontaneous binding reaction.

Dimethylglyoxime robustly inhibited Aβ40 aggregation when added to metal-containing peptide preparations. In the absence of added metal, 100 µM dimethylglyoxime reduced aggregation by 40–85 %, and 500–1000 µM essentially abolished ThT signal, implying that chelation of intrinsic metals within the recombinant peptide (notably Ni²⁺) is sufficient to block β-sheet–rich fibril formation. In the presence of 100 µM Ni²⁺, dimethylglyoxime produced complete inhibition of aggregation at higher chelator concentrations, whereas inhibition in the presence of Cu²⁺ was partial and Zn²⁺-driven aggregation remained only partially suppressible even at 1 mM dimethylglyoxime, mirroring its weaker coordination with zinc. FTICR-MS confirmed stable [DMG]₂–Ni and [DMG]₂–Cu complexes and an absence of similar complexes with Fe, Zn, or Se, explaining the metal-selective chelation pattern. The schematic model on page 8 (Figure 4) integrates these findings into a dual mechanism in which nickel contributes to Alzheimer’s disease both by directly enhancing Aβ aggregation and by supporting nickel-dependent bacterial enzymes in pathogens implicated in Alzheimer’s pathology; dimethylglyoxime occupies an intersection point by depleting nickel for both Aβ and microbial systems. Attempts to detect dimethylglyoxime or its complexes in mouse brain after repeated oral dosing were unsuccessful, suggesting poor blood-brain barrier penetration or rapid metabolism under the tested conditions.

Key implications

The study provides strong mechanistic support for considering nickel as an under-recognized contributor to Aβ40 aggregation and, by extension, to the metal-driven component of Alzheimer’s disease pathogenesis. For clinicians and translational researchers, the data highlight that not all metal chelation strategies are equivalent: a nickel-selective agent such as dimethylglyoxime can inhibit amyloid aggregation driven by nickel while sparing essential metal pools for zinc and iron, at least at the level of direct coordination chemistry.

From a microbiome and microbial metallomics perspective, the work is particularly relevant because many candidate Alzheimer’s-associated pathogens, including Helicobacter pylori, Escherichia coli, and Salmonella Typhimurium, rely on nickel-dependent enzymes such as urease and NiFe hydrogenases; systemic nickel chelation might therefore modulate both host amyloidogenic processes and the viability or virulence of nickel-requiring pathobionts that could participate in brain infection or peripheral immune priming. In the microbiome signatures framework, these nickel-dependent taxa could be considered major microbial associations in an Alzheimer’s disease metallomic-microbiomic axis. However, the inability to demonstrate brain penetration of orally administered dimethylglyoxime underscores a key translational barrier: any clinical strategy based on nickel chelation will require optimization of pharmacokinetics, delivery route, and tissue targeting to influence central nervous system amyloid dynamics. Overall, the findings justify further preclinical work combining nickel chelation, microbiome-targeted interventions, and in vivo Alzheimer's models.

Citation

Benoit SL, Maier RJ. The nickel-chelator dimethylglyoxime inhibits human amyloid beta peptide in vitro aggregation. Sci Rep. 2021;11:6622. doi:10.1038/s41598-021-86060-1.

What was studied?

The study investigated the impact of iron deficiency anemia (IDA) on maternal cognition, behavioral performance, mother-infant interaction, and infant development during the postpartum period. The focus was on how iron status, particularly in anemic mothers, affected their emotional well-being and cognitive function post-childbirth.

Who was studied?

The study focused on a cohort of 81 South African mothers who had normal birth weight, full-term babies. These mothers were divided into three groups: non-anemic controls, anemic mothers receiving a placebo, and anemic mothers receiving daily iron supplementation. The mothers were followed for 9 months postpartum.

What were the most important findings?

The study revealed that iron-deficient anemic mothers exhibited cognitive and emotional deficits compared to their non-anemic counterparts. Specifically, mothers receiving iron supplementation showed a 25% improvement in depression, stress, and cognitive function (measured through Raven’s Progressive Matrices and Digit Symbol tests). In contrast, the placebo group did not show any significant improvement. Furthermore, the study identified strong associations between maternal iron status (hemoglobin, mean corpuscular volume, and transferrin saturation) and behavioral variables such as anxiety, stress, and depression. These findings suggest a direct relationship between maternal iron deficiency and impaired cognitive and emotional functioning.

What are the greatest implications of this study?

The study highlights the critical role of iron in maternal mental health and cognitive function during the postpartum period. The findings suggest that correcting iron deficiency through supplementation can significantly improve mood, stress, and cognitive functioning in postpartum mothers. This has profound implications for public health strategies, particularly in resource-poor settings where iron deficiency is prevalent. It also underscores the importance of early screening and treatment of IDA to prevent long-term negative effects on both maternal well-being and infant development. The potential for iron supplementation to improve mother-infant interactions and promote healthier developmental outcomes for infants is a key area for future research.

What Was Reviewed?

This review investigates the hypothesis that severe anemia contributes to the elevated risk of invasive bacterial infections in African children through dysregulation of iron homeostasis, including the disruption of hepcidin—a hepatic hormone that governs iron availability in the body. The authors synthesize evidence from epidemiological, mechanistic, and experimental studies, proposing that the interplay between anemia, haemolysis, immune dysfunction, and gut permeability collectively facilitates systemic infections. The paper places particular emphasis on how bacterial pathogens exploit iron and haem to thrive under conditions of anemia-induced iron dysregulation, especially in regions with high burdens of infectious disease and malnutrition.

Who Was Reviewed?

The review draws on research concerning sub-Saharan African children who commonly experience severe anemia due to malaria, nutritional deficiencies, sickle cell disease, and HIV. It includes human observational data, animal model findings, and in vitro studies related to bacterial infections, immune response, and iron regulation pathways.

What Were the Most Important Findings?

Severe anemia in African children correlates strongly with an increased risk of invasive bacterial infections, particularly with Gram-negative organisms such as non-typhoidal Salmonella (NTS), E. coli, and Haemophilus influenzae, as well as Gram-positive organisms including Staphylococcus aureus and Streptococcus pneumoniae. This elevated susceptibility is mechanistically linked to increased erythropoietic drive and haemolysis, both of which suppress hepcidin via the erythroid hormone erythroferrone (ERFE). Reduced hepcidin enhances plasma iron levels and promotes the release of iron from macrophage stores, thereby removing the “nutritional immunity” that would otherwise limit iron availability to pathogens. Simultaneously, haemolysis releases non-transferrin-bound iron (NTBI) and free haem, which are more readily exploited by pathogens through siderophore-mediated and haem-binding iron acquisition systems.

Of particular relevance to microbiome researchers, the review notes that severe anemia can disrupt gut barrier integrity and provoke dysbiosis. The increased gut permeability facilitates the translocation of enteric pathogens, notably NTS and E. coli, into systemic circulation. This breach is exacerbated by inflammation, destabilization of tight junction proteins like ZO-1, and macrophage-mediated changes to mucosal immunity. The review references mouse models where anemia-induced epithelial dysfunction was dependent on macrophage-driven cytokine signaling, especially IFN-γ, as well as bacterial studies showing enhanced virulence and iron uptake capacity in haem-rich or iron-rich conditions. Importantly, these microbial strategies overlap with the exact niches disrupted in severe anemia, such as haem overload, NTBI availability, and compromised mucosal defenses.

Major microbial associations (MMAs) include:

What Are the Greatest Implications of This Review?

The review suggests that treating severe anemia in high-infection-burden areas like sub-Saharan Africa should involve caution, particularly regarding iron supplementation. While iron repletion is essential, excessive or unregulated iron can exacerbate infection risk, especially in the presence of low hepcidin levels. This carries profound public health implications, as many iron supplementation programs do not account for concurrent infectious burdens or the child's hepcidin status. Clinically, these insights demand a reevaluation of iron therapy protocols, particularly in settings where malaria, HIV, or bacterial sepsis are endemic. The review also encourages further exploration of therapies that modulate iron availability (e.g., hepcidin agonists or iron chelators) and highlights the need for comprehensive microbiome assessments in anaemic populations. The tight interconnection between gut microbiota, intestinal permeability, and systemic iron overload represents a mechanistic intersection worth pursuing in microbiome-targeted interventions.

What was studied?

This study focused on the effects of zinc supplementation on postpartum depression and anemia in women who had undergone cesarean sections. Specifically, it aimed to investigate the relationship between zinc supplementation and the reduction of postpartum depression symptoms (as assessed by the Edinburgh Postnatal Depression Scale or EPDS) and its effect on the hematological status, including hemoglobin and hematocrit levels, of postpartum women.

Who was studied?

The study enrolled 197 postpartum women who had undergone cesarean sections and had postpartum anemia. These women were monitored for their zinc and hematological levels, and a subset of 148 women was included in the analysis concerning the relationship between zinc supplementation and postpartum depression.

What were the most important findings?

The study found that postpartum zinc supplementation significantly improved maternal zinc levels and reduced the risk of developing postpartum depression. In contrast, the combination of oral zinc and iron supplementation showed a transient negative effect on hemoglobin and hematocrit levels, though this effect was not clinically significant and resolved within a month postpartum. Zinc supplementation did not cause any severe adverse effects but did temporarily affect hematological parameters when combined with oral iron supplementation.

What are the greatest implications of this study?

The findings suggest that postpartum zinc supplementation could be a beneficial intervention for preventing or alleviating postpartum depression, which is a major public health concern affecting a significant proportion of new mothers. This intervention appears to be relatively safe and could be considered as part of postpartum care, especially for women experiencing depression. However, clinicians should be cautious when combining zinc with iron supplementation, as this may cause short-term hematological disturbances. The study's limitations include its retrospective design and small sample size, which suggest that further research, particularly prospective studies, is necessary to confirm these findings and explore the optimal dosages and combination treatments for postpartum depression and anemia.

What was studied?

The study focused on the reversal of autism spectrum disorder (ASD) symptoms among dizygotic female twins through a personalized, multidisciplinary therapeutic approach, including microbiome-targeted interventions (MBTIs). The approach primarily targeted modifiable lifestyle and environmental factors believed to contribute to the condition. Following the reversal of autism symptoms in twins, the case report aimed to document the twins' improvements and review the related literature on environmental and lifestyle influences on ASD.  

Who was studied?

The subjects of the study were dizygotic (fraternal) female twin toddlers who were diagnosed with Level 3 severity ASD, which requires very substantial support. The diagnosis was made when the twins were approximately 20 months old. The case report included detailed documentation of the twins' medical history, diagnostic evaluations, and therapeutic interventions over a two-year period.  

What were the most important findings of this case study?

Reversal of Autism Symptoms: Both twins exhibited dramatic improvements in their ASD symptoms, as evidenced by significant reductions in their Autism Treatment Evaluation Checklist (ATEC) scores. One twin's ATEC score decreased from 76 to 32, while the other's decreased from 43 to 4.

Sustained Improvement: The improvements in the twins' symptoms remained relatively stable for six months following the last assessment.

Multidisciplinary Approach: The therapeutic interventions involved a variety of licensed clinicians and focused on environmental and lifestyle modifications tailored to each twin's symptoms, lab results, and other outcome measures. Interventions included dietary changes, nutritional supplements, physical therapies, and environmental modifications.

Parental Involvement: The parents played a crucial role in implementing and achieving the interventions, demonstrating exceptional motivation, compliance, and communication with practitioners.

What are the greatest implications of this case study?

Potential for ASD Reversal: The case report provides encouraging evidence that ASD symptoms can be significantly improved and potentially reversed through a comprehensive, personalized approach that targets modifiable environmental and lifestyle factors.

Role of Environmental and Lifestyle Factors: The findings highlight the significant impact that environmental and lifestyle factors can have on ASD, suggesting that these factors may play a more substantial role than genetic factors in some cases.

Need for Personalized Medicine: The success of the personalized, multidisciplinary approach underscores the importance of individualized treatment plans that consider the unique needs and risk factors of each patient.

Challenges: While the results are promising, the comprehensive and resource-intensive nature of the interventions may not be easily generalizable to all families due to financial and accessibility constraints. This highlights the need for more accessible and cost-effective treatment options.

Future Research: The study calls for prospective studies to further investigate the effectiveness of personalized, multi-modality treatment approaches in reversing ASD symptoms and to establish more precise estimates of the contributions of genetic versus environmental factors in ASD etiology.

What was studied?

This review investigates the role of zinc in Clostridium difficile infection (CDI), particularly focusing on how zinc influences pathogen colonization, host immune responses, and disease severity. The study explores the concept of nutritional immunity, wherein the host restricts metal availability to combat pathogen invasion. It highlights the potential negative effects of excess dietary zinc on the gut microbiota and its relationship with increased susceptibility to CDI. Through a mouse model of infection, the review examines how high levels of zinc impact the gut's microbial composition and promote CDI, even in the absence of major pathogen colonization.

Who was studied?

The study primarily focuses on animal models, particularly mice, to explore the relationship between dietary zinc levels, microbiota composition, and CDI susceptibility. Mice were divided into different groups based on their zinc intake, ranging from low to excessive levels. The review also discusses the potential implications of these findings for humans, particularly patients with conditions such as inflammatory bowel disease (IBD), who may have altered zinc absorption and are at a higher risk for CDI.

Most important findings

The study reveals that excess dietary zinc significantly alters the structure of the gut microbiota, leading to a reduction in microbial diversity. In particular, the Enterococcus genus showed a significant bloom in response to high zinc levels, while other microbial populations were diminished. The zinc-induced alterations in the microbiota were associated with increased susceptibility to CDI, especially when antibiotics were introduced. Interestingly, although high zinc did not significantly increase C. difficile colonization, it exacerbated disease severity, causing more significant epithelial damage, inflammation, and increased toxin production. These findings underscore the importance of zinc in modulating gut microbial ecology and its potential to influence the severity of CDI.

Key implications

The review highlights the need for careful management of zinc intake, particularly in populations at risk for CDI, such as those receiving antibiotics or suffering from conditions like IBD. Excessive zinc intake may exacerbate disease severity by promoting dysbiosis and reducing colonization resistance, thus enhancing susceptibility to pathogens like Clostridium difficile. This understanding suggests that controlling dietary zinc, particularly in high-risk patients, could serve as a potential strategy for preventing or managing CDI. Further research is necessary to explore the mechanisms by which zinc influences microbial community dynamics and pathogen virulence, potentially leading to novel therapeutic approaches.

What was studied?

The study focused on the pathogenesis of Crohn’s disease (CD), with particular emphasis on the role of epithelial barrier dysfunction and microbial dysbiosis. CD is characterized by chronic inflammation of the gastrointestinal tract, which primarily affects the ileum and colon. The research explored how the failure of the intestinal epithelial barrier allows microbial infiltration, triggering immune system activation and contributing to the perpetuation of inflammation. It also discussed the role of genetic predispositions and environmental factors in disrupting the barrier integrity, which exacerbates the disease.

Who was studied?

The study did not specifically identify patient groups or subjects as part of its methodology, as it is a review of existing literature. However, it examined a broad range of research involving human and animal models, including those with genetic susceptibilities and environmental exposures that influence CD development. The study drew upon various sources to illustrate how microbiota imbalances and impaired epithelial functions contribute to disease onset, progression, and flare-ups.

Most important findings

Key findings of the study include the central role of the epithelial barrier in protecting the gastrointestinal tract. When this barrier is compromised, luminal bacteria and other substances breach the submucosa, leading to immune activation and persistent inflammation. This dysbiosis, or imbalance in the gut microbiome, exacerbates inflammation and disrupts mucosal healing. Genetic factors, such as mutations in the MUT2 and FUT2 genes, impair barrier function, allowing for increased pathogen penetration. Furthermore, environmental factors like diet, smoking, and pollutants further weaken the epithelial barrier and exacerbate microbial dysbiosis, creating a vicious cycle of inflammation.

Recent studies have also highlighted the role of tight junction proteins (like occludins and claudins) in maintaining the barrier integrity. The degradation of these proteins in Crohn’s disease facilitates the entry of harmful microbes, promoting an inflammatory response. The study underscores the importance of restoring this barrier and balancing the microbiome to prevent disease progression.

Key implications

This review underscores the need for therapeutic strategies that focus on restoring the integrity of the epithelial barrier and addressing microbial dysbiosis in Crohn’s disease patients. Treatments aimed at increasing mucus production, enhancing tight junction function, and rebalancing gut microbiota could significantly reduce inflammation and maintain long-term remission. Understanding the interactions between genetic, environmental, and microbial factors offers new avenues for personalized treatment approaches and early intervention strategies, ultimately improving patient outcomes.

What was studied?

This article explores the link between ankylosing spondylitis (AS), Crohn's disease (CD), Klebsiella pneumoniae, and starch consumption. The study investigates how these elements interact and contribute to the development of AS and CD. Both AS and CD are chronic diseases associated with inflammation, and their onset is thought to be influenced by genetic and environmental factors. The study discusses the hypothesis that Klebsiella pneumoniae, a gut microbe, plays a key role in the initiation and progression of these diseases, especially in individuals genetically predisposed, such as those carrying the HLA-B27 allelotypes. The article emphasizes the role of diet, particularly the consumption of starch, in triggering the growth of Klebsiella in the gut, which may activate immune responses leading to inflammation in both the joints (AS) and the gut (CD).

Who was studied?

This review does not focus on a specific cohort of patients but synthesizes data from various studies involving patients diagnosed with AS and CD. The focus is on individuals with genetic susceptibility, specifically those carrying the HLA-B27 allele, which is strongly associated with AS and has been implicated in IBD. The studies referenced in this review discuss patients from different geographical regions, particularly those in Europe, North America, and parts of Asia. The research explores the role of gut microbes, specifically Klebsiella, in patients with AS and CD. Additionally, the review includes studies on the impact of dietary factors, particularly starch consumption, on the gut microbiota and disease progression in these conditions.

Most important findings

This study highlights several significant findings that help explain the link between AS, CD, Klebsiella pneumoniae, and starch consumption. One of the key points is the role of Klebsiella pneumoniae as a potential microbial trigger for both AS and CD. The bacteria are more likely to proliferate in the gut of individuals who consume high levels of starch, which is thought to provide a favorable environment for Klebsiella growth. The research shows that high starch consumption, notably resistant starch, increases the bacterial load of Klebsiella in the gut, which can exacerbate both AS and CD. This finding suggests a dietary intervention as a potential therapeutic approach to manage these diseases. Additionally, the study underscores the molecular mimicry hypothesis, where immune responses to Klebsiella antigens cross-react with self-antigens, particularly HLA-B27, leading to autoimmune inflammation in the joints (AS) and gut (CD).

Another critical finding is the potential of a low-starch diet to reduce disease activity in AS and CD patients. Evidence from clinical trials and observational studies indicates that reducing starch intake can help decrease inflammation, as it limits the growth of Klebsiella and potentially other pathogenic microbes. This is especially significant when combined with conventional treatments such as biologics and anti-inflammatory drugs.

Key implications

The findings of this review have several important clinical implications. First, they highlight the need for a more integrated approach to managing AS and CD, where dietary modification could be considered alongside pharmacological treatments. Specifically, a low starch diet may help reduce disease activity and improve patient outcomes, particularly in those with AS and CD linked to Klebsiella infections. Furthermore, the research underscores the importance of understanding the gut-liver and gut-joint interactions in autoimmune diseases. Clinicians should consider dietary factors when managing patients with these conditions, particularly in patients who exhibit elevated levels of anti-Klebsiella antibodies or show signs of microbiome dysbiosis.

What was studied?

This review article focuses on the comorbidity of primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD), specifically ulcerative colitis (UC) and Crohn's disease (CD). It provides an update on the current evidence surrounding this association. PSC-IBD is a unique disease phenotype that poses a significant challenge in clinical management. The article delves into the pathogenetic mechanisms underlying this comorbidity, including genetic predispositions, immune dysregulation, and the role of microbiota. It also highlights the distinct clinical characteristics of IBD in patients with PSC, noting differences in disease presentation and severity compared to IBD patients without PSC. The increased risk of colorectal cancer (CRC) and hepatobiliary malignancies in PSC-IBD patients is discussed, alongside the current approaches to screening and management.

Who was studied?

The review consolidates data from various studies involving patients diagnosed with both PSC and IBD. While the study doesn't involve new patient cohorts, it summarizes findings from cohort studies, meta-analyses, and population-based studies, primarily from North America, Europe, and some parts of Asia. The patients studied typically have PSC associated with UC, though a smaller proportion has PSC with CD. The research on PSC-IBD includes both adults and pediatric populations, with an emphasis on the different clinical outcomes seen in these groups. The studies also assess the risk of malignancies such as CRC, cholangiocarcinoma (CCA), and gallbladder carcinoma (GBC), and the impact of IBD severity on the progression of PSC.

Most important findings

The review confirms that patients with PSC have a significantly higher incidence of IBD, particularly UC, compared to the general population. The data suggest that approximately 60-80% of PSC patients also have IBD, with UC being the most common form of IBD in these individuals. Interestingly, the clinical presentation of IBD in PSC patients is typically milder than in IBD alone. For example, PSC-IBD patients often exhibit pancolitis with a right-to-left intestinal inflammatory gradient, with rectal sparing and backwash ileitis being common features. However, despite this relatively quiescent clinical course, these patients are at a higher risk for developing CRC and other hepatobiliary malignancies, such as CCA and GBC. The review also emphasizes the importance of vigilant screening for these malignancies in PSC-IBD patients, suggesting annual colonoscopies and liver function tests.

Key implications

The findings have significant implications for the management of PSC-IBD patients. Clinicians should be aware of the unique clinical phenotype of PSC-IBD, which may present with less severe symptoms despite extensive colitis. These patients require close monitoring, especially given their increased risk of malignancy. Surveillance for CRC, CCA, and GBC should be a priority, with regular screening intervals recommended based on disease severity and the presence of risk factors such as age and comorbidities. The review underscores the need for personalized treatment approaches, as the management of PSC-IBD differs from that of PSC or IBD alone. Additionally, the potential role of microbiota dysbiosis in disease progression highlights the need for further research into microbiome-based therapies. Finally, the review calls for more robust clinical trials and research to establish evidence-based guidelines for the management and screening of PSC-IBD patients, particularly focusing on the relationship between IBD severity and PSC progression.

What was studied?

This original investigation employed a two‑sample Mendelian randomization (MR) framework to test whether genetically predicted variation in gut microbiota (GM) composition exerts causal effects on six thyroid diseases (TDs): nontoxic diffuse goiter (NDG), nontoxic multinodular goiter (NMG), nontoxic single thyroid nodule (NSTN), Graves’ disease (GD), Plummer disease (PD) and thyrotoxicosis with toxic single thyroid nodule (TSTN). Genome‑wide association study (GWAS) summary statistics for 119 genera (1,531 SNPs) served as exposures, while disease outcomes were derived from large population‑based GWAS datasets. IVW was the primary MR method, complemented by weighted median, MR‑Egger, and sensitivity checks for heterogeneity and pleiotropy.

Who was studied?

GM data originated from the MiBioGen consortium (18,340 primarily European participants), and thyroid phenotypes came from FinnGen Release 10 (906–6,699 cases and ≥ 349,000 controls per phenotype, all of European ancestry). Thus, the analytic sample represents adult Europeans with genotyped data and harmonized microbial and thyroid phenotypes.

Most important findings

MR identified 32 genera with putative causal links to TDs. Protective associations included Clostridium innocuum group, Ruminiclostridium 5 and Lachnoclostridium for NDG (OR ≈ 0.59–0.72), Bifidobacterium and Sutterella for NMG (OR ≈ 0.77–0.83), and Ruminiclostridium 9, Victivallis and Butyricimonas for GD (OR ≈ 0.75–0.85). Conversely, taxa such as Alistipes, Methanobrevibacter, Ruminococcaceae UCG014 (NDG), Ruminococcus gauvreauii group and Rikenellaceae RC9 (NMG), Eubacterium rectale group and Desulfovibrio (GD), and Dorea, Eggerthella and Phascolarctobacterium (PD) increased disease risk (OR 1.2–2.3). For TSTN, Parasutterella was protective, whereas Sutterella, Oscillibacter and Clostridium sensu stricto 1 conferred marked risk (OR ~ 2–3.4).  

Key implications

These results strengthen the concept of a gut–thyroid axis by demonstrating genus‑level causal effects, not mere correlations. Protective genera often produce short‑chain fatty acids (e.g., butyrate), enhance epithelial barrier integrity and modulate T‑cell differentiation, whereas risk genera have pro‑inflammatory or lipopolysaccharide (LPS)‑rich profiles. Clinically, microbiome‑targeted interventions (MBTIs) such as fiber supplementation, next‑generation probiotics or microbiota‑directed drugs may complement iodine optimisation and immunomodulation for TD prevention or adjunctive therapy. However, the findings pertain to European ancestry and genus‑level resolution; host–microbe–immune interactions and sex‑specific effects warrant validation in multi‑ethnic, mechanistic, and longitudinal cohorts.

What was studied?

This review article explores extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD), particularly focusing on Crohn’s disease (CD) and ulcerative colitis (UC). EIMs are systemic conditions that occur outside the gastrointestinal tract but are linked to the underlying inflammatory processes of IBD. The study explores the pathophysiology, clinical features, and treatment strategies for various EIMs, which can involve the musculoskeletal, dermatological, ocular, and hepatobiliary systems. It also discusses the mechanisms underlying these manifestations, including immune responses, microbial factors, and genetic predispositions, as well as the impact of therapies used to treat IBD on EIMs.

Who was studied?

The study does not focus on a single cohort but rather synthesizes findings from various studies involving patients with Crohn’s disease and ulcerative colitis. It draws on data from clinical studies, cohort analyses, and patient registries, including large sample sizes, to better understand the prevalence and impact of EIMs in IBD patients. The patients studied were diagnosed with IBD and presented with various extraintestinal manifestations, such as arthritis, uveitis, and hepatobiliary disorders. The study includes data on patients with both active and remission stages of IBD, offering a comprehensive view of how EIMs can occur at different disease stages and how they influence patient quality of life.

Most important findings

The review highlights several key findings related to the pathophysiology and treatment of EIMs. First, it emphasizes that EIMs can arise from immune responses either extending from intestinal inflammation or occurring as independent inflammatory events in organs outside the gastrointestinal tract. This is driven by mechanisms such as immune cross-reactivity, microbial dysbiosis, and genetic susceptibility. Specifically, the article notes that certain microbial communities, such as reduced levels of Coprococcus and Ruminococcus species, are associated with inflammatory arthritis and psoriasis in IBD patients, suggesting a link between gut microbiota alterations and systemic inflammation.

The article also examines the impact of IBD therapies on EIMs, particularly biologics like anti-TNF-α agents, which are effective in managing both IBD and its associated extraintestinal conditions. The review shows that anti-TNF therapies, such as infliximab (IFX) and adalimumab (ADA), have high efficacy in treating musculoskeletal EIMs like arthritis and skin manifestations like pyoderma gangrenosum. However, it also cautions about potential paradoxical effects, where biologics may induce or worsen certain conditions, such as psoriasis or uveitis, in a small subset of patients.

Key implications

The findings underscore the importance of a multidisciplinary approach to managing IBD, given the wide range of potential EIMs. Early identification and appropriate management of these extraintestinal conditions are critical for improving the overall quality of life for IBD patients. The review suggests that treatments should be tailored not only to control intestinal inflammation but also to address systemic manifestations. For example, while biologic therapies like anti-TNF agents can effectively manage both IBD and EIMs, careful monitoring for paradoxical effects is essential. The study advocates for the use of a precision medicine approach, which considers genetic, environmental, and microbiome factors, to better predict and treat EIMs in IBD patients. Future research is needed to explore the role of gut microbiota in EIM pathogenesis further and to develop more targeted therapies that can address both intestinal and systemic manifestations of IBD.

What was studied?

This review article examines the ocular extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD), with a focus on pathophysiology, epidemiology, clinical presentation, and management strategies. The study particularly emphasizes the impact of conditions like episcleritis, scleritis, and uveitis in patients with IBD, exploring their association with both disease activity and the impact of IBD treatments. The article also delves into how emerging therapies, including biologics, influence ocular health, particularly through potential iatrogenic effects, which may complicate disease management.

Who was studied?

The review synthesizes findings from various studies that involved patients diagnosed with IBD, specifically Crohn's disease (CD) and ulcerative colitis (UC). It highlights that ocular manifestations are more common in patients with CD than UC, with variations in prevalence depending on factors like disease duration, smoking, and age. The article draws attention to studies that have examined the incidence of ocular manifestations in large cohorts, as well as research on the genetic and environmental factors that may influence the occurrence of these conditions. Gender, ethnicity, and other demographics are also considered in understanding the risk factors associated with IBD-related ocular conditions.

Most important findings

The most common ocular EIMs associated with IBD include episcleritis, uveitis, and scleritis. Episcleritis, affecting 2–5% of IBD patients, often correlates with active disease flares and typically presents with mild to moderate discomfort. Uveitis, particularly anterior uveitis, is seen in 0.5–3.5% of IBD patients and tends to occur independently of gastrointestinal symptoms, occasionally even preceding the diagnosis of IBD. The prevalence of uveitis is significantly higher in patients with CD, with a notable genetic association with the HLA-B27 allele, commonly linked to ankylosing spondylitis.

Scleritis, though rarer, is of particular concern due to its severity and the potential for ocular complications such as visual impairment or ocular perforation. Treatment of scleritis involves systemic therapy, including oral NSAIDs and corticosteroids, with immunosuppressants being used in refractory cases. Interestingly, biologics such as infliximab are effective in treating ocular manifestations like episcleritis, though they may also paradoxically trigger new cases of uveitis.

Key implications

The findings underscore the need for heightened awareness and early detection of ocular manifestations in IBD patients, as these conditions can occur independently of gastrointestinal symptoms and may precede the diagnosis of IBD. The risk of ocular complications is significant, with conditions like scleritis potentially leading to irreversible vision damage. This highlights the importance of multidisciplinary care involving both gastroenterologists and ophthalmologists to ensure timely diagnosis and appropriate management.

Emerging treatment strategies for IBD, including biologics, offer new hope in managing ocular manifestations, but the iatrogenic risks, such as the potential for triggering uveitis, warrant caution. It is crucial for clinicians to carefully monitor ocular health in patients undergoing treatment with corticosteroids, immunomodulators, and biologics to prevent or mitigate ocular complications. Additionally, understanding the microbiome's role in the pathogenesis of ocular EIMs and exploring microbial modulation could open new avenues for preventive and therapeutic strategies.

What was studied?

This paper reviews recent developments in the understanding of Crohn's Disease (CD), particularly focusing on its pathogenesis and the emerging role of the microbiome in shaping disease outcomes. It also delves into the influence of epigenetics, immune responses, and the interplay between environmental factors and microbial communities. The review synthesizes data on how these factors contribute to the disease's chronicity and provides insights into potential therapeutic strategies, such as microbiome-targeted treatments.

Who was studied?

The review addresses studies that examine a broad spectrum of individuals affected by Crohn's Disease, with an emphasis on genetic, environmental, and microbial influences. It considers both pediatric and adult populations, as well as patients with varying phenotypes of CD, such as inflammatory, fistulizing, and stricturing forms. The review highlights how differences in microbiota composition may influence disease severity and response to treatment, particularly in treatment-naïve individuals and those with diverse environmental exposures.

Most important findings

The most significant findings from the review underscore the role of dysbiosis (microbial imbalance) in Crohn's Disease, notably how reduced microbial diversity and the overgrowth of pathogenic bacteria contribute to the inflammation seen in CD patients. Specific microbiome signatures are now linked with disease severity, and these microbial imbalances may also influence immune system dysregulation. T-helper (Th) cells, particularly Th17, play a central role in driving the inflammation in CD, and microbial interactions may exacerbate this process. The paper also explores the growing evidence of how environmental factors—such as diet, antibiotics, and pollution—can influence the microbiome and contribute to disease onset and progression.

Recent studies also point to the potential for personalized therapies that target the microbiome, such as fecal microbiota transplantation (FMT) or microbiome modulation to restore balance and alleviate symptoms. Furthermore, advancements in multi-omics technologies and single-cell transcriptomics are offering more profound insights into the genetic and immune pathways involved, enabling more targeted and effective therapeutic strategies.

Key implications

The review highlights several key implications for clinical practice. First, a better understanding of microbiome dysbiosis could lead to innovative, non-invasive diagnostic tools that predict disease severity and response to treatment. The evolving microbiome-targeted therapies provide promising avenues for personalized medicine, especially in patients who do not respond to conventional therapies. Moreover, the identification of specific microbial signatures for Crohn’s Disease could lead to novel biomarkers for early diagnosis and for monitoring disease progression in real-time. Finally, the intersection of epigenetics and microbiome alterations opens new paths for preventative strategies, particularly in genetically predisposed populations, emphasizing early-life interventions.

What was studied?

This study investigates the potential link between psoriasis and inflammatory bowel disease (IBD), specifically Crohn's disease (CD) and ulcerative colitis (UC), using a nationally representative Korean cohort. The objective was to determine whether psoriasis serves as a risk factor for the subsequent development of IBD, based on a large-scale, retrospective, nested case-control study. The study also sought to explore whether the relationship varies between the two subtypes of IBD and across different demographic and clinical subgroups.

Who was studied?

The study focused on individuals from the Korean National Health Insurance Service (NHIS) National Sample Cohort, which includes over a million participants with detailed medical records from 2002 to 2019. A total of 10,966 IBD patients (with CD or UC) were matched to 43,864 controls based on key demographic variables like age, sex, income, region, and index date. The participants were further categorized into various subgroups based on factors such as age, sex, income level, residential area, and Charlson Comorbidity Index (CCI) score. Psoriasis history was assessed using diagnostic codes before the index date for IBD diagnosis, and psoriasis subtypes were identified for completeness, though detailed analysis of subtypes was not conducted.

Most important findings

The study found that individuals with a history of psoriasis had a significantly higher risk of developing IBD. Psoriasis was linked to a higher likelihood of developing UC across most subgroups, while the association with CD was statistically significant only in those under 45 years of age. The association between psoriasis and IBD was observed to be more pronounced in individuals with higher comorbidity burdens, those living in urban areas, and those with lower income. These findings suggest that psoriasis could be a significant risk factor for developing IBD, particularly UC.

Key implications

The results from this study suggest that clinicians should be vigilant for gastrointestinal symptoms in patients with psoriasis, as these individuals may have an increased risk of developing IBD. Since the association was stronger for UC, healthcare providers should closely monitor psoriasis patients for early signs of UC, particularly those in high-risk subgroups, such as younger individuals, men, and those with higher comorbidity burdens. The study also highlights the importance of considering gastrointestinal comorbidities when managing psoriasis, particularly in light of the shared immune pathways, such as the IL-23/IL-17 axis, that contribute to both psoriasis and IBD. Although the study does not establish causality, the findings underscore the need for further research to understand the underlying mechanisms driving this association and to develop targeted prevention strategies for individuals at risk of both conditions.

What was studied?

This study, titled "Intestinal microbiota changes in Graves’ disease: a prospective clinical study," specifically investigated the alterations in gut microbiota composition and diversity in patients with Graves’ disease (GD) compared to healthy controls. Using a cross-sectional design, the researchers employed 16S rRNA gene sequencing of fecal samples to characterize the intestinal microbial profiles. The primary aim was to elucidate whether GD, an autoimmune thyroid disorder, is associated with distinct changes in the gut microbiota. The study explored both alpha and beta diversity metrics, as well as the abundance of specific microbial taxa, to determine key differences that might serve as microbiome signatures for GD. This focus on the "Graves’ disease gut microbiota signature" is crucial for understanding the interplay between thyroid autoimmunity and the intestinal ecosystem.

Who was studied?

The study cohort consisted of 39 patients diagnosed with GD and 17 healthy controls, all recruited from Beijing Haidian Hospital, China, between April and December 2017. Participants were matched for age, sex, and body mass index (BMI) to reduce confounders. GD patients were newly diagnosed, untreated, and had no recent exposure to antibiotics, prebiotics, or medications affecting gut flora. Both groups had no history of gastrointestinal diseases. The GD group included 11 males and 28 females (ages 15–67), while the control group had 6 males and 11 females (ages 13–62). All participants adhered to a light diet prior to sample collection to minimize dietary variation effects on gut microbiota.

Most important findings

The analysis revealed a significant reduction in gut microbial diversity among GD patients compared to healthy controls, as evidenced by lower Chao1 and Shannon indices. Principal coordinate analysis (PCoA), non-metric multidimensional scaling (NMDS), and principal component analysis (PCA) all demonstrated that the overall microbial communities in GD patients were distinctly separated from those of controls, confirming disease-associated dysbiosis.

Crucially, the study identified a unique microbiota signature associated with GD. The relative abundances of several taxa were markedly altered:

Linear discriminant analysis effect size (LEfSe) confirmed these taxa as potential biomarkers, with LDA scores above 3. Notably, increases in Prevotella and Megamonas have been linked to immune modulation and may impact the efficacy of certain therapies. The diminished presence of Ruminococcus, Rikenellaceae, and Alistipes aligns with findings in other autoimmune and inflammatory conditions, suggesting a possible shared microbial mechanism underlying immune dysregulation.

Key implications

This study provides evidence that GD is characterized by a distinct gut microbiota signature, marked by reduced diversity and specific shifts in microbial taxa. The "Graves’ disease gut microbiota signature"—notably increased Bacilli, Lactobacillales, Prevotella, Megamonas, Veillonella, and decreased Ruminococcus, Rikenellaceae, Alistipes—may serve as potential biomarkers for disease presence and progression. These findings highlight the potential utility of gut microbiome profiling in the diagnosis and management of GD, and open avenues for future research into microbiome-targeted interventions. Clinicians should consider that GD-associated dysbiosis may influence disease pathogenesis and responsiveness to treatment. However, causality cannot be inferred due to the study’s cross-sectional design, and results may not be generalizable beyond the Chinese population. The study lays foundational knowledge for integrating microbiome data into precision medicine approaches for autoimmune thyroid diseases.

What was studied?

This study investigated the intestinal microbiota composition and diversity in patients with Graves’ disease (GD) compared to healthy controls, aiming to identify specific microbial changes associated with GD. The research addresses the knowledge gap regarding how autoimmune thyroid dysfunction may alter gut microbiota, potentially influencing disease pathogenesis and progression. The focus keyphrase, "intestinal microbiota changes in Graves’ disease," is central to the study, as the authors performed high-throughput 16S rRNA gene sequencing on fecal samples to comprehensively profile and compare the gut microbial communities between the two groups. By elucidating these microbial signatures, the study provides foundational data for understanding the interplay between gut bacteria and autoimmune thyroid disease.

Who was studied?

The study included 39 patients with newly diagnosed, untreated Graves’ disease (GD) and 17 healthy controls, all recruited from Beijing Haidian Hospital, China, between April and December 2017. The GD group comprised 11 males and 28 females, aged 15–67 years, while the control group included 6 males and 11 females, aged 13–62 years, and was matched for age, sex, and body mass index. Both groups excluded individuals with a history of gastrointestinal diseases, recent antibiotic or prebiotic use, hormonal medication, Chinese herbal medicine, pregnancy, smoking, or excessive alcohol consumption. All participants adhered to a light diet for one week prior to fecal sampling to minimize dietary confounding. Diagnosis of GD followed established Chinese Society of Endocrinology criteria, ensuring a well-defined study population.

Most important findings

The major findings revealed a marked reduction in microbial diversity (both richness and evenness) in GD patients compared to healthy controls, as assessed by Chao1 and Shannon diversity indices. Beta-diversity analyses (PCoA, NMDS, PCA, and PLS-DA) demonstrated clear separation between the microbiota profiles of GD patients and controls, indicating significant compositional shifts. Linear discriminant analysis effect size (LEfSe) pinpointed specific taxa altered in GD: Bacilli, Lactobacillales, Prevotella, Megamonas, and Veillonella were significantly increased in GD patients, whereas Ruminococcus, Rikenellaceae, and Alistipes were decreased. These taxa changes suggest a dysbiotic state characterized by expansion of potentially pro-inflammatory or immune-modulating bacteria and loss of genera often associated with gut health and metabolic regulation. The increased abundance of Prevotella, in particular, may have implications for immune modulation and drug responsiveness, while decreased Ruminococcus and Alistipes have been linked to other autoimmune and inflammatory conditions. These microbial shifts represent a distinct intestinal microbiota signature for GD, relevant for inclusion in a microbiome signatures database.

Key implications

The study’s findings underscore a significant association between Graves’ disease and gut microbiota dysbiosis, marked by decreased diversity and characteristic alterations in microbial taxa. These changes may contribute to or reflect underlying immune dysregulation in GD and could influence disease activity, response to therapy, or development of comorbidities. The identification of specific bacterial changes provides potential biomarkers for GD diagnosis or monitoring and highlights new avenues for investigating microbiota-targeted interventions, such as probiotics or dietary modification, in autoimmune thyroid disorders. However, as a cross-sectional study, causality cannot be established, and results may be influenced by regional dietary patterns. Further longitudinal and mechanistic studies are needed to clarify the causal links and therapeutic potential of modulating the gut microbiome in GD.

What was studied?

This paper investigates the prevalence, pathogenesis, and treatment of osteoporosis in patients with Crohn’s disease (CD), a condition known for its gastrointestinal involvement but also associated with several extra-intestinal complications. It explores the multifactorial causes of osteoporosis in CD, including inflammation, malnutrition, and the use of glucocorticoids. The review highlights the mechanisms contributing to low bone mineral density (BMD), the link between CD-related cytokine activity and bone resorption, and the role of steroid treatment in accelerating bone loss. The article also assesses therapeutic strategies, including steroid-sparing medications, bisphosphonates, calcium, and vitamin D supplementation, emphasizing their role in both managing CD symptoms and improving bone density.

Who was studied?

The study focuses on Crohn’s disease patients, particularly those diagnosed with osteoporosis or osteopenia as extra-intestinal complications of the disease. It encompasses individuals of various ages, though particular attention is given to those in the long-term stages of CD or those undergoing surgical interventions like bowel resections, which further increase the risk for low BMD. The review synthesizes data from studies involving both male and female patients, addressing the role of cytokines, glucocorticoids, and malabsorption in the pathophysiology of osteoporosis within the context of CD. Research findings are drawn from cohorts with varying levels of disease severity, from mild to moderate and severe forms of CD.

Most important findings

The most significant findings in this review underline the complexity of osteoporosis in CD, driven primarily by the inflammatory processes that increase bone resorption. Pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-17 play a key role in altering bone metabolism by activating the RANKL pathway, which leads to increased osteoclast activity and subsequent bone loss. Long-term corticosteroid use, which is common in CD treatment, further exacerbates osteoporosis by decreasing the effectiveness of bone formation and increasing bone resorption. Glucocorticoids also contribute to hormonal imbalances, particularly reducing the production of estrogen and androgen, which are essential for bone health.

The review also highlights malnutrition as a contributing factor, especially due to nutrient malabsorption in the intestines, resulting in deficiencies in calcium, vitamin D, and vitamin K, all of which are crucial for bone metabolism. A deficiency in these nutrients compromises bone density and contributes to osteoporosis in CD patients. Vitamin B12 and folate deficiencies further complicate this process by increasing homocysteine levels, which are associated with increased bone resorption.

Key implications

The review highlights the need for early and proactive management of osteoporosis in CD patients, particularly given its prevalence and potential for progression to severe complications, such as fractures. Screening for osteoporosis using DEXA scans should be integrated into routine care for patients with CD, particularly for those with risk factors like steroid use, malnutrition, or advanced disease. Clinicians should focus on implementing a multi-faceted treatment approach that combines medications to control CD symptoms with therapies to improve bone health. Steroid-sparing biologics like infliximab, along with the use of bisphosphonates and appropriate vitamin supplementation, can significantly mitigate the risks associated with osteoporosis in CD patients.

What was studied?

This original research employed bidirectional two-sample Mendelian randomization (MR) to test for causal relationships between Graves disease (GD) and inflammatory bowel disease (IBD). Genome-wide significant single-nucleotide polymorphisms (SNPs) for GD were taken from Biobank Japan (BBJ), while SNPs for IBD—including Crohn disease (CD) and ulcerative colitis (UC)—came from the International IBD Genetics Consortium. Multiple MR methods (inverse-variance weighted, MR-Egger, weighted median and MR-PRESSO) were applied to account for heterogeneity and pleiotropy, mimicking a randomized trial at the level of inherited genetic variation.

Who was studied?

The analysis drew on 2176 GD cases and 210 277 controls of East-Asian ancestry from BBJ, and 2824 IBD cases (1690 CD; 1134 UC) plus 3719 controls from East-Asian, Indian and Iranian cohorts within the IIBDGC panel. Mean age at GD diagnosis (not reported) typically peaks at 30-50 years, while mean CD and UC diagnosis ages were 27.6 ± 12.2 and 35.8 ± 13.7 years, respectively. Male representation was 27 % in GD versus 67 % in CD and 50 % in UC, ensuring sex-balanced causal inference.

Most important findings

*after exclusion of pleiotropic SNP rs1569723. Forest and leave-one-out plots on pages 4-6 visually confirm these asymmetric effects, with CD-associated SNPs clustering above the null line and UC-associated SNPs below.

Key implications

The asymmetric genetic links suggest shared immune-microbiome pathways between GD and CD, but distinct mechanisms in UC. CD-associated variants intersect with HLA-DRB1, JAK-STAT and PTPN22 loci—genes also tied to microbial sensing and T-helper 17 regulation—supporting the view that dysbiotic Crohn-type microbiota may precipitate thyroid autoimmunity. Conversely, UC-specific variants (e.g., epithelial barrier genes) may foster microbial communities that dampen GD risk. Clinically, heightened vigilance for thyroid dysfunction in CD patients, and consideration of microbiota-targeted or JAK inhibition strategies, could improve interdisciplinary care. The results also provide candidate microbial signatures (e.g., reduced Haemophilus abundance previously noted in CD) for inclusion in microbiome databases tracking autoimmune overlap.

What was studied?

This prospective study investigated the relationship between gut microbiota composition and the development of Graves’ disease (GD), with a particular focus on identifying distinct microbial signatures and their associations with immune dysregulation. Using 16S rRNA sequencing, the researchers profiled the gut microbiota in newly diagnosed GD patients both before and after antithyroid drug (ATD) therapy, compared to healthy controls. The study aimed to characterize alterations in gut microbial diversity and specific taxa, evaluate their associations with clinical and immune parameters (including cytokines such as IL-17), and assess the impact of standard GD treatment on restoring microbiome balance. Importantly, the study utilized machine learning (random forest analysis) to identify bacterial genera that could distinguish GD patients from healthy individuals with high accuracy, offering potential for diagnostic biomarker development and deeper insight into the gut-immune-thyroid axis.

Who was studied?

The study enrolled 65 newly diagnosed, untreated Graves’ disease patients (18 men, 47 women; median age 30) of Chinese Han ethnicity, treated at the Endocrinology Department of the First Affiliated Hospital of Nanchang University between October 2018 and September 2019. Thirty-seven of these patients completed a 3-month follow-up after receiving methimazole-based ATD therapy. The control group comprised 33 healthy volunteers (10 men, 23 women; median age 27) with no known diseases. All participants provided fecal and blood samples for microbiome and clinical parameter analyses. Strict inclusion and exclusion criteria were applied to avoid confounding factors such as recent antibiotic, probiotic, or prebiotic use, and comorbid autoimmune, gastrointestinal, hepatic, or endocrine diseases. The study also performed a subgroup analysis of GD patients with and without impaired liver function.

Most important findings

The gut microbiota of GD patients exhibited significantly lower richness and diversity compared to healthy controls, indicating marked dysbiosis. At baseline, notable microbial shifts included increased abundance of Bacilli (class), Lactobacillales (order), Streptococcaceae (family), and the genera Streptococcus, Veillonella, and Erysipelatoclostridium, all associated with pro-inflammatory states. In contrast, key short-chain fatty acid (SCFA)-producing and anti-inflammatory taxa—such as Peptostreptococcaceae, Christensenellaceae, Marinifilaceae, Rikenellaceae (families), and Roseburia, Romboutsia, Lachnospira, Eubacterium ventriosum (genera)—were significantly decreased in GD patients. After 3 months of ATD therapy, the microbiota composition of GD patients began to recover toward that of healthy controls, with partial restoration of SCFA-producing taxa and reduction of pro-inflammatory genera. IL-17, a cytokine associated with Th17-mediated immune response, decreased significantly post-treatment, and its levels correlated inversely with SCFA-producing bacteria such as Eubacterium hallii. Random forest analysis identified 12 bacterial genera—including Veillonella, Streptococcus, and Roseburia—that could collectively distinguish GD patients from controls with high diagnostic accuracy (AUC=0.90). Subgroup analysis revealed that reductions in Weissella and Leuconostocaceae were linked to impaired liver function in GD. Overall, the findings support a model where GD is associated with gut dysbiosis characterized by loss of beneficial, anti-inflammatory taxa and enrichment of pro-inflammatory bacteria, contributing to immune imbalance and disease pathogenesis.

Key implications

The study demonstrates that specific gut microbiome signatures are closely associated with Graves’ disease, highlighting dysbiosis as a potential contributor to immune dysregulation and disease progression. The partial recovery of microbiome composition and immune markers following antithyroid therapy suggests that gut microbiota may be both a biomarker and a therapeutic target in GD. The identification of 12 key bacterial genera that robustly differentiate GD from healthy states provides a foundation for future diagnostic tools, potentially enabling earlier detection or risk stratification. Moreover, associations between specific taxa and immune/inflammatory parameters (e.g., Th17/Treg balance, IL-17) lend support to the concept of microbiota-mediated modulation of autoimmune thyroid disease. These findings encourage further exploration of microbiome-targeted interventions—such as probiotics, prebiotics, or fecal microbiota transplantation—to restore microbial balance and improve clinical outcomes in GD. The study also underscores the need for longer-term and larger-scale research to validate and expand upon these results.

What was studied?

The paper discusses thromboembolic events (TEs) in patients with inflammatory bowel disease (IBD), specifically addressing the pathophysiology, epidemiology, and management of venous thromboembolism (VTE) and arterial thromboembolism (ATE). It explores how IBD, through chronic inflammation and altered immune responses, increases the risk of thromboembolism, particularly during disease flare-ups or post-surgery. The review further examines the underlying mechanisms that contribute to thromboembolic events in IBD patients, including the role of coagulation pathways, platelets, and various risk factors such as medication, hospitalizations, and comorbidities.

Who was studied?

The study focuses on patients with IBD, specifically those diagnosed with Crohn’s disease and ulcerative colitis. These patients were assessed in terms of their risk for developing thromboembolic events, both venous and arterial. Studies included patients from various geographical regions, including those undergoing hospitalizations and surgeries, and some specific subsets such as pregnant females and postoperative patients. The paper compares IBD patients with the general population to better understand the increased risks of VTE and ATE, focusing on demographics, disease activity, and the use of specific treatments like corticosteroids.

Most important findings

The most significant findings of this review indicate that patients with IBD are at a significantly increased risk for thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), with a 2–3 fold higher risk compared to the general population. The risk of developing thromboembolism is notably higher during disease flare-ups, hospitalization, and post-surgical periods. Patients with IBD who are treated with corticosteroids are particularly vulnerable due to the medication's pro-coagulant effects, which increase factors like VII, VIII, and IX in the blood, promoting thrombosis. Platelet activation is also observed in IBD patients, contributing to thromboembolic events, as evidenced by the presence of markers like CD40L and P-selectin on circulating platelets. Moreover, studies show that VTE in IBD patients tends to occur at a younger age compared to the general population, and those with IBD have a higher risk of recurrent thromboembolic events, particularly post-surgery.

Mesenteric ischemia, a rare but serious thromboembolic complication, has been linked to IBD, particularly in patients with active disease and a history of surgery. The inflammation in the intestines can lead to endothelial damage, which then activates the coagulation cascade, increasing the likelihood of thrombosis in both veins and arteries. This review also highlights the need for thromboprophylaxis, especially during hospital admissions and flare-ups of IBD, to reduce the incidence of thromboembolic complications.

Key implications

The review emphasizes the importance of recognizing the elevated risk of thromboembolic events in IBD patients and the need for tailored management strategies. Clinicians must be aware of the increased risk during flare-ups, surgeries, and with corticosteroid use, and should consider prophylactic anticoagulation therapies for hospitalized patients. This is particularly relevant in those with active disease or post-surgery. The findings also underscore the need for future research into the pathophysiology of thromboembolism in IBD, particularly to identify biomarkers that could help predict and assess thrombotic risks. The potential for platelet activation and altered coagulation in IBD calls for more targeted therapies that address both inflammation and thrombosis.

What was studied?

This study investigated serum calprotectin (S100A8/A9) as a potential biomarker for the diagnosis and follow-up of subacute thyroiditis, specifically subacute granulomatous (De Quervain) thyroiditis. The focus was on evaluating calprotectin's utility in differentiating the acute inflammatory phase from the recovery phase of the disease, and whether its levels can predict persistent hypothyroidism. Calprotectin, a cytosolic protein complex primarily produced by neutrophils and monocytes, is known to be elevated in various acute and chronic inflammatory states, but had not previously been evaluated in subacute thyroiditis. Patients were assessed using an array of standard laboratory parameters (e.g., free thyroxine [fT4], thyroid-stimulating hormone [TSH], C-reactive protein [CRP], erythrocyte sedimentation rate [ESR], white blood cell [WBC] count, absolute lymphocyte, and neutrophil counts) during both the acute and recovery phases, with persistent hypothyroidism determined at six months.

Who was studied?

The study included 36 adult patients (mean age 44.1 ± 8.8 years; 80.6% female) with a confirmed diagnosis of subacute granulomatous thyroiditis, presenting to a single tertiary center in Turkey between November 2018 and January 2020. Patients with confounding conditions (other infections, autoimmune or rheumatic disorders, recent steroid use, pregnant, major surgery, chronic hepatic/renal/cardiac diseases, or malignancies) were rigorously excluded to ensure specificity. Diagnosis was based on clinical presentation (fever, neck pain, thyrotoxic symptoms), elevated ESR and CRP, and supportive ultrasonographic findings. All patients provided informed consent, and local ethics approval was granted.

Most important findings

Serum calprotectin levels were significantly higher in the acute inflammatory phase than in the recovery phase (median 96.92 ng/mL [IQR: 24.47–130.37] vs. 37.98 ng/mL [IQR: 14.02–20.52]; p < 0.001). Similar trends were observed for other acute phase markers (ESR, CRP, WBC, ANC), all of which decreased upon resolution. However, calprotectin did not correlate with these classical inflammatory markers or with TSH and fT4 in either phase. Logistic regression revealed that neither calprotectin nor any traditional inflammatory marker predicted the development of permanent hypothyroidism at six months. The study concluded that, while calprotectin is a sensitive indicator of acute inflammation in subacute thyroiditis, it is not useful as a prognostic marker for long-term thyroid dysfunction. No significant correlations were identified between calprotectin and other inflammatory or thyroid parameters, pointing to its independence from other markers.

Key implications

The findings support serum calprotectin as a reliable and independent marker for the diagnosis and monitoring of the acute phase of subacute thyroiditis, enhancing clinical discrimination during active disease. However, its lack of association with persistent hypothyroidism restricts its use as a prognostic tool for long-term outcomes. The lack of correlation between calprotectin and classical markers implies mechanistic independence, potentially providing unique insight into innate immune activity in thyroid inflammation. Microbiome researchers and clinicians may consider including calprotectin as part of a broader signature for neutrophil-driven inflammatory processes. Further, larger, controlled studies are needed to clarify the predictive value of calprotectin for tissue-damaging sequelae and to explore therapeutic modulation (e.g., zinc supplementation) in subacute thyroiditis.

What was studied?

This original research article investigated the alterations in gut microbiota composition among patients with Graves’ disease (GD), a systemic autoimmune thyroid disorder characterized by hyperthyroidism. The study aimed to characterize and compare the gut microbial communities of GD patients and healthy controls using 16S rRNA gene sequencing. It sought to identify specific microbial taxa associated with GD and examine their relationship with clinical parameters of thyroid function, such as free thyroxine (FT4), thyrotropin (TSH), and thyroperoxidase antibody (TPOAb) status. The researchers also evaluated whether microbiome signatures could serve as potential biomarkers to distinguish GD patients from healthy individuals.

Who was studied?

The study population comprised 55 patients previously diagnosed with GD and 48 age-, sex-, and body mass index-matched healthy controls, all recruited from Chang Gung Memorial Hospital in Taiwan between October 2017 and March 2020. GD diagnosis was based on clinical features and laboratory criteria—including symptoms of thyrotoxicosis, diffuse goiter, ophthalmopathy, abnormal thyroid function tests, and positive TSH receptor autoantibodies. The healthy controls had normal thyroid function and no history of thyroid disease. Both groups were screened to exclude confounding conditions (e.g., recent antibiotic use, gastrointestinal disorders, other autoimmune diseases). Fecal samples were collected from all participants for microbiota analysis.

Most important findings

A total of 11.7 million sequencing reads were analyzed, yielding 684 operational taxonomic units (OTUs) in the GD group and 671 in controls, with similar richness and diversity between groups. However, principal coordinate and discriminant analyses revealed significant differences in overall community structure (ANOSIM p < 0.001). Key microbiome shifts in GD patients included a decreased relative abundance of Firmicutes and increased Bacteroidetes and Actinobacteria at the phylum level. Notably, families such as Prevotellaceae and Veillonellaceae and the genus Prevotella_9 were enriched in GD patients, whereas Lachnospiraceae, Ruminococcaceae, Faecalibacterium, and Lachnospira were more abundant in healthy controls. Metagenomic profiling identified 22 significantly altered bacterial taxa. Many GD-enriched taxa, including Prevotella_9, Parabacteroides, Collinsella, and Actinomyces_odontolyticus, showed strong positive correlations with TPOAb and FT4, and negative correlations with TSH. Conversely, taxa enriched in controls, such as Faecalibacterium and Lachnospiraceae NK4A136 group, showed the opposite pattern. A random forest model based on predominant taxa achieved an area under the curve (AUC) of 0.825, indicating these microbial features could effectively differentiate GD patients from controls.

Key implications

This study demonstrates that while overall gut microbial diversity remains unchanged, the taxonomic composition in GD patients is significantly altered, featuring a distinct microbial signature. The enrichment of pro-inflammatory taxa (such as Prevotella_9 and Veillonellaceae) and the reduction of anti-inflammatory butyrate producers (like Faecalibacterium and Lachnospiraceae) suggest a potential role of gut dysbiosis in GD pathogenesis. These findings highlight the gut microbiota as a possible contributor to, or biomarker of, autoimmune thyroid disease. The strong association between specific microbial taxa and thyroid-related clinical parameters underscores the potential for microbiome-based diagnostics or therapeutics in GD. However, causality cannot be established, and further longitudinal and functional studies are warranted to clarify the mechanistic links and clinical utility.

What was studied?

This original research article examined alterations in the gut microbiota composition of patients with Graves' disease (GD) compared to healthy controls using 16S rRNA gene sequencing. The primary aim was to characterize the gut microbial communities in GD, assess differences in bacterial diversity and abundance, and explore correlations between specific microbiota and clinical parameters of GD. The study also evaluated the potential of microbiome profiles to serve as discriminative biomarkers for distinguishing GD patients from healthy individuals, thereby contributing to a better understanding of the gut-thyroid axis in autoimmune thyroid disease.

Who was studied?

The study enrolled 55 patients with clinically diagnosed Graves’ disease and 48 age-, sex-, and BMI-matched healthy controls. All GD patients were recruited from the Division of Endocrinology and Metabolism at Chang Gung Memorial Hospital, Taiwan, and had been previously diagnosed and treated with anti-thyroid drugs (propylthiouracil, methimazole, or carbimazole), with an average follow-up of over 45 months. The control group was selected from a health screening center and had no history of thyroid disease, with normal thyroid-related laboratory values. Exclusion criteria included pregnancy, gastrointestinal disorders, concurrent autoimmune diseases, recent antibiotic or probiotic use, hormonal or herbal drug intake, gastrointestinal surgery, and strict vegetarianism. Fecal samples were collected from all participants for gut microbiota analysis.

Most important findings

The study found no statistically significant difference in overall gut microbial richness or diversity between GD patients and healthy controls, as measured by standard alpha diversity indices. However, beta diversity metrics—including principal coordinate analysis (PCoA) and partial least squares-discriminant analysis (PLS-DA)—demonstrated a clear separation in overall microbiota composition between the two groups (ANOSIM, p < 0.001). At the phylum level, GD patients exhibited a decreased abundance of Firmicutes and an increased abundance of Bacteroidetes and Actinobacteria compared to controls. Key microbial signatures in GD included increased levels of the families Prevotellaceae and Veillonellaceae, and the genera Prevotella_9, Parabacteroides, Collinsella, and Actinomyces_odontolyticus. In contrast, healthy controls had higher abundances of Lachnospiraceae, Ruminococcaceae, and the genera Faecalibacterium, Lachnospira, and Lachnospiraceae NK4A136. Notably, 22 bacterial taxa showed statistically significant differences between groups; 18 were increased and 4 decreased in GD patients. Several of these taxa, especially those enriched in GD, were positively correlated with GD-associated clinical parameters such as thyroperoxidase antibody (TPOAb) and free thyroxine (FT4) levels, and negatively correlated with thyroid-stimulating hormone (TSH). A machine learning model based on the top 15 discriminant taxa achieved an area under the ROC curve (AUC) of 0.825, indicating strong potential for microbiota-based discrimination of GD status.

Key implications

This study demonstrates that Graves’ disease is associated with a distinct gut microbiota signature, despite similar overall bacterial diversity compared to healthy controls. The shift towards increased Bacteroidetes and Actinobacteria and decreased Firmicutes, as well as the enrichment of specific pro-inflammatory and immunomodulatory taxa (such as Prevotella_9 and Veillonellaceae), supports the hypothesis that gut dysbiosis may contribute to GD pathogenesis via immune modulation. The strong correlation between key microbial taxa and clinical indicators of GD suggests that these bacteria may play a role in disease activity or progression. Moreover, the successful discrimination of GD patients based on gut microbiota profiles suggests potential for developing non-invasive microbial biomarkers for GD diagnosis or monitoring. However, as this was a cross-sectional, single-center study, causality remains undetermined, and larger multi-omics studies are needed to clarify mechanistic pathways and explore therapeutic interventions targeting the gut microbiome in GD.

What was studied?

This original research study investigated the composition of the gut microbiota in patients with Graves’ disease (GD), an autoimmune thyroid disorder characterized by hyperthyroidism. The focus keyphrase "gut microbiota in Graves’ disease" defines the core of this work, and the study aimed to determine whether there are distinct microbial signatures associated with GD compared to healthy controls. Researchers collected fecal samples from both groups and performed 16S rRNA gene sequencing to analyze the microbial communities present. The study also examined correlations between specific microbial taxa and clinical parameters relevant to GD, such as thyroid hormone levels and autoantibody status, seeking to identify potential microbial biomarkers that could distinguish GD patients from healthy individuals.

Who was studied?

The study population comprised 55 patients with previously diagnosed Graves' disease and 48 age-, sex-, and BMI-matched healthy controls recruited from a health screening center. All GD patients were under routine follow-up and had been treated with standard anti-thyroid drugs. Controls were screened to exclude thyroid disease and matched for relevant demographic and anthropometric factors. Exclusion criteria for both groups included recent antibiotic or probiotic use, presence of other autoimmune diseases, gastrointestinal disorders, recent gastrointestinal surgery, pregnancy, and strict vegetarianism. This careful selection ensured that observed differences in gut microbiota could be attributed primarily to GD status rather than other confounding factors.

Most important findings

The study found that while overall microbial richness and diversity were similar between GD patients and healthy controls, the global composition of the gut microbiota was significantly different, as demonstrated by principal coordinate analysis and partial least squares-discriminant analysis (ANOSIM p < 0.001). Notably, GD patients exhibited a decreased abundance of Firmicutes and an increased abundance of Bacteroidetes and Actinobacteria at the phylum level. At more refined taxonomic levels, GD patients had higher levels of Prevotellaceae, Veillonellaceae, Prevotella_9, Parabacteroides, Collinsella, and Actinomyces_odontolyticus, while healthy controls had higher levels of Lachnospiraceae, Ruminococcaceae, Faecalibacterium, and Lachnospira. Several of these taxa, particularly those enriched in GD, showed strong positive correlations with GD clinical parameters, including TPO antibodies and free T4, and negative correlations with TSH. A random forest classifier using the top 15 most discriminative taxa achieved an AUC of 0.825 for distinguishing GD patients from controls, highlighting the discriminative potential of these gut microbiome signatures.

Key implications

This study provides compelling evidence that the gut microbiota in Graves’ disease is characterized by distinct compositional alterations, despite similar overall diversity compared to healthy individuals. The identification of specific microbial taxa—particularly increased Prevotellaceae, Veillonellaceae, and Prevotella_9, alongside decreased Lachnospiraceae and Faecalibacterium—suggests possible microbial signatures relevant to GD pathogenesis or progression. These findings support the hypothesis that the gut microbiota may influence or reflect immune dysregulation in GD. Clinically, these microbial signatures could potentially serve as non-invasive biomarkers for GD diagnosis or monitoring, and may, in the future, guide the development of microbiota-targeted interventions. Further longitudinal and mechanistic studies are required to elucidate causality and functional consequences.

What was reviewed?

This narrative review synthesizes epidemiological and mechanistic literature linking Graves’ disease (GD) to depression. The authors searched PubMed/MEDLINE, Cochrane Library and Web of Science up to 22 March 2023, retrieving 11 human population studies (5 cohort, 3 cross‑sectional, 3 case‑control) and multiple basic‑science reports that collectively explore immune, hormonal and microbiome pathways connecting GD and mood disorders.

Who was reviewed?

The clinical evidence base spans >30 000 participants from Asia, Europe, Africa and North America. Cohorts ranged from large national databases (e.g., 20 975 Asian patients; 2 200 000 Swedes) to smaller hospital samples, covering adults, pregnant women and paediatric cases. Collectively, these studies consistently show higher depression risk in overt or sub‑clinical hyperthyroidism compared with euthyroid controls. Key mechanistic papers include rodent models of hyperthyroidism, human cytokine profiling, and microbiota analyses in 263 GD versus 239 healthy controls.

Most important findings

Graves’ disease‑related hyperthyroidism is increasingly recognised as a biological driver of depressive symptoms. The mechanisms converge on immune–neuroendocrine crosstalk and gut‑brain communication, each amplifying neuroinflammation and neurotransmitter dysregulation. The table below delineates the three core pathways and the epidemiological evidence base.

Key implications

Recognising GD as an independent driver of depression justifies routine mood screening in endocrine clinics and prompts integrative management. Potential interventions include early antithyroid therapy, β‑blockade, probiotics/synbiotics targeting SCFA restoration, and anti‑cytokine or HPA‑axis‑modulating strategies, though prospective trials remain scarce.

What was studied?

The systematic review and meta-analysis focused on the incidence and risk factors associated with paradoxical psoriasis or psoriasiform lesions in patients with inflammatory bowel disease (IBD) who were treated with anti-tumor necrosis factor (anti-TNF) therapy. Anti-TNF therapies, such as infliximab, adalimumab, and certolizumab, have been widely used in the treatment of IBD, including Crohn's disease (CD) and ulcerative colitis (UC). However, a paradoxical phenomenon has been observed where these therapies, which are also used to treat psoriasis, can induce psoriasis or psoriasiform skin lesions in some patients. This review aimed to quantify the pooled incidence of these skin lesions and identify the demographic and clinical risk factors that might contribute to their development.

Who was studied?

The study included a total of 30 articles comprising 24,547 IBD patients who were treated with anti-TNF agents. The studies were selected based on strict inclusion criteria, including observational cohort studies or case-control studies published in English, with full-text access. The patients included in the studies were diagnosed with IBD, either CD or UC, and had received anti-TNF therapy. The data focused on the incidence of psoriasis and psoriasiform lesions, with additional information on potential risk factors such as age, gender, smoking status, and the specific type of anti-TNF therapy used. These studies were conducted across a range of geographic locations, including Europe, North America, and Asia, offering insights into the global prevalence of anti-TNF-induced psoriasis in IBD patients.

Most important findings

The pooled incidence of psoriasis and/or psoriasiform lesions following anti-TNF therapy in IBD patients was 6.0%, with significant heterogeneity observed across studies. The incidence was higher for psoriasiform lesions compared to psoriasis. Meta-regression analysis identified several significant risk factors associated with the development of psoriasis or psoriasiform lesions. Female patients, younger age at the initiation of anti-TNF therapy, smoking status, and specific anti-TNF agents (adalimumab and certolizumab) were all found to be associated with an increased risk of developing these skin lesions. Additionally, ileocolonic Crohn's disease patients showed a higher risk compared to other IBD phenotypes. The study also found variations in risk depending on geographical region and population, suggesting that factors like environmental exposure and genetic predispositions might play a role in these outcomes.

Key implications

The findings from this study have several clinical implications. First, clinicians should be aware of the potential for paradoxical psoriasis or psoriasiform lesions when prescribing anti-TNF therapy for IBD, particularly for patients who are female, younger, or smokers. These patients may require closer monitoring for dermatological side effects. Moreover, the study suggests that the use of adalimumab or certolizumab might carry a higher risk of skin complications compared to infliximab, which may influence treatment decisions. The identification of these risk factors allows for more personalized approaches to IBD treatment, enabling clinicians to make more informed decisions regarding the use of anti-TNF therapies and the management of potential side effects. Understanding the mechanisms underlying these skin reactions could also lead to better preventive strategies or the development of therapies aimed at mitigating these adverse effects. Given the increasing use of anti-TNF therapies, further research is needed to explore the molecular mechanisms behind the paradoxical skin reactions and to identify additional risk factors.

What was studied?

The review article explores the relationship between microbial imbalances (dysbiosis) in the gut and the development of systemic autoimmune diseases. It highlights how dysbiosis in the gastrointestinal tract may trigger or exacerbate diseases such as type 1 diabetes (T1D), multiple sclerosis (MS), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE). The study examines how changes in the composition of the microbiome influence immune responses, leading to inflammation and autoimmunity. It emphasizes the role of microbial metabolites and the interaction between the gut microbiota and the host’s immune system in modulating immune functions, such as differentiation of T cells and the production of interleukins, which are critical in autoimmune disease pathogenesis.

Who was studied?

This review article synthesizes findings from a broad range of studies, including clinical and preclinical research, focusing on how microbial dysbiosis affects systemic autoimmune diseases. It discusses data from animal models (mice, rats) and human patients with autoimmune conditions. Specific emphasis is placed on the role of microbial species like Prevotella copri, Faecalibacterium prausnitzii, and Lactobacillus species, which influence immune responses either by promoting inflammation or exerting anti-inflammatory effects. The review incorporates findings on the relationship between gut microbial populations and the systemic immune response in diseases like T1D, MS, RA, and SLE.

Most important findings

The review underscores that microbial dysbiosis can drive systemic inflammation by affecting the integrity of the gut barrier, leading to the leakage of microbial metabolites like lipopolysaccharides (LPS) into the bloodstream. These metabolites contribute to immune system sensitization, promoting inflammatory responses. In autoimmune diseases such as T1D, MS, RA, and SLE, specific microbial taxa such as Bacteroides dorei and Prevotella copri have been associated with disease onset or progression. In contrast, beneficial microbes like Faecalibacterium prausnitzii can induce regulatory T cells and produce anti-inflammatory metabolites like butyrate. Furthermore, the review highlights the potential of microbiome-based therapies, including prebiotics, probiotics, and fecal transplants, to modulate immune responses and mitigate autoimmune disease symptoms.

Key implications

The article presents a compelling case for the gut microbiota as a modulator of systemic autoimmune diseases, suggesting that microbial dysbiosis could be a target for therapeutic interventions. Microbial modulation, through diet, lifestyle, or targeted microbiome-based therapies, holds potential for treating or preventing autoimmune diseases. This understanding opens up new avenues for clinical research into microbiome-based biomarkers and personalized treatment approaches for autoimmune conditions. The identification of specific microbial signatures associated with disease progression offers promise for early diagnosis and the development of microbiome-targeted interventions to prevent or manage autoimmune diseases effectively.

What was studied?

This study investigated the causal relationship between Graves’ disease (GD) and the gut microbiome using a bidirectional two-sample Mendelian randomization (MR) approach. Researchers utilized genome-wide association study (GWAS) summary statistics to examine whether changes in the gut microbiome contribute to the development of GD and whether GD, in turn, alters the gut microbiome. The study was grounded in the concept of the thyroid–gut axis (TGA), which posits bidirectional regulation between thyroid function and gut microbial composition. By leveraging MR methods, including inverse-variance weighting (IVW), weighted median, weighted mode, MR-Egger, and simple mode, the study aimed to infer causality while controlling for confounding and reverse causation.

Who was studied?

The analysis was conducted using GWAS data from two large cohorts. The gut microbiome dataset (n = 18,340) was derived from 24 international cohorts spanning European, Middle Eastern, East Asian, Hispanic/Latin American, and African American populations, as part of the MiBioGen consortium. The Graves’ disease dataset (n = 212,453; including 2,176 GD cases and 210,277 controls) came from BioBank Japan, representing individuals of Asian descent. Taxonomic profiling in the microbiome dataset used 16S rRNA sequencing, capturing 211 taxa after quality control and rarefaction.

Most important findings

The study identified several taxa with significant causal effects in both directions:

Gut Microbiome → GD:

GD → Gut Microbiome:

No evidence of heterogeneity, horizontal pleiotropy, or weak instrument bias was detected, strengthening the causal inference.

Key implications

This study provides robust evidence of a bidirectional causal relationship between Graves’ disease and specific gut microbial taxa, thereby supporting the existence of a thyroid–gut axis (TGA). The identification of microbiota such as Deltaproteobacteria and Anaerostipes as risk and protective factors, respectively, highlights candidate biomarkers and potential therapeutic targets. Moreover, the findings suggest that GD not only results from microbiome alterations but can itself induce compositional changes, potentially exacerbating autoimmune dysregulation. These results offer a strong foundation for incorporating Graves’ disease gut microbiome causality into both diagnostic algorithms and microbiome-targeted intervention (MBTI) frameworks.

What was studied?

This review focused on the dual roles of succinate in the pathogenesis and modulation of inflammatory bowel disease (IBD), particularly its involvement in immune regulation and metabolism. Succinate, a key metabolite produced by both host cells and gut microbiota, plays an essential role in the inflammation process by influencing immune cell signaling and modulating intestinal barrier functions. The review examines the metabolic and immune interactions between succinate and inflammatory pathways in IBD, along with the microbial factors that influence succinate levels.

Who was studied?

The study reviewed data from both clinical and experimental models of IBD, focusing particularly on patients with Crohn's disease (CD) and ulcerative colitis (UC). It highlights the dysregulation of succinate metabolism in these patients, noting increased succinate concentrations in the serum and feces, especially during active disease phases. It also explores the role of various gut microbiota, specifically those that produce succinate, and their influence on IBD severity.

Most important findings

The review identifies succinate as a central molecule linking metabolism, immune responses, and microbiota in IBD. Elevated succinate levels correlate with disease severity, particularly in IBD patients where microbial dysbiosis leads to increased succinate production. Succinate acts through the SUCNR1 receptor, initiating pro-inflammatory pathways, including NF-kB and MAPK signaling, which exacerbate intestinal inflammation. In contrast, at lower concentrations, succinate can promote tissue repair by enhancing epithelial cell function and supporting immune responses that repair intestinal barriers. The concentration-dependent effects of succinate, where low levels are protective and high levels induce inflammation, provide crucial insights into potential therapeutic strategies.

The review also emphasizes the importance of gut microbiota composition in regulating succinate levels. Specific bacteria such as Phascolarctobacterium and Dialister consume succinate, while Bacteroides and Prevotella contribute to its production, influencing the inflammatory environment in the gut. This dual role is further modulated by factors like diet, antibiotics, and microbial balance, underlining the complex relationship between microbiota and host metabolism in IBD.

Key implications

The findings suggest potential therapeutic strategies targeting succinate metabolism. By modulating microbial succinate production or altering the host’s succinate signaling pathways, it may be possible to attenuate the inflammatory responses in IBD. SUCNR1 antagonists, probiotics that consume succinate, or dietary interventions that optimize succinate production-consumption balance are promising approaches. Understanding the precise concentration thresholds for succinate’s protective and pathogenic roles could pave the way for more personalized and effective treatments, particularly in early-stage or flare-up IBD. Further research into the spatial dynamics of succinate signaling within the gut, coupled with microbiome-targeted therapies, offers new avenues for clinical interventions.

What was studied?

This review explores the metabolic influences of gut microbiota dysbiosis in inflammatory bowel disease (IBD), specifically examining how alterations in gut microbiota composition contribute to the progression of IBD. The authors investigate the role of microbial changes in metabolic pathways, highlighting how dysbiosis affects both immune response and metabolic functions in the colon.

Who was studied?

The review focuses on human patients diagnosed with IBD, particularly those with Crohn’s disease (CD) and ulcerative colitis (UC). The authors detail changes in the microbial composition of the gut in these patients compared to healthy individuals, highlighting key microbial species such as Escherichia coli, Firmicutes, and Bacteroidetes that are either depleted or enriched during the disease.

Most important findings

The review identifies several key findings in the relationship between gut microbiota dysbiosis and IBD. Notably, IBD patients exhibit reduced diversity in their gut microbiota, with a depletion of beneficial short-chain fatty acid (SCFA)-producing bacteria and an increase in proinflammatory microbes like adherent-invasive E. coli. These microbial shifts are linked to the disturbance of critical metabolic functions such as bile acid hydrolysis, SCFA production, and redox balance. The review also discusses the metabolic dysfunction of the host, including defective SCFA transport, impaired hydrogen sulfide detoxification, and disrupted immune signaling pathways, all of which contribute to chronic inflammation and disease progression.

Key implications

This review underscores the complex interaction between gut microbiota dysbiosis and host metabolism in IBD. The metabolic perturbations driven by microbial imbalances are critical to disease development, suggesting that targeting these microbial pathways could offer new therapeutic strategies. Approaches such as fecal microbiota transplantation (FMT) and probiotics, aimed at restoring microbiota balance, are highlighted as potential treatments. However, further research is needed to clarify the cause-effect relationship and to identify specific molecular mechanisms governing these interactions.

What was studied?

The study reviewed and analyzed the application of artificial intelligence (AI), specifically deep learning (DL), in capsule endoscopy for detecting lesions in patients with Crohn’s disease (CD). Capsule endoscopy is an effective diagnostic tool used for visualizing the gastrointestinal tract, particularly in cases like CD, where intestinal lesions are irregularly distributed and challenging to detect using traditional methods. The study synthesized data from various clinical trials to evaluate AI’s role in improving diagnostic accuracy and identifying mucosal lesions associated with Crohn’s disease. The research was motivated by the increasing reliance on AI in medical diagnostics and aimed to assess its efficiency in enhancing the detection of CD lesions through capsule endoscopy.

Who was studied?

The meta-analysis included eight studies that collectively analyzed a total of 444 patients, with 353 diagnosed with CD and 91 control participants. These studies involved AI-assisted image analysis of capsule endoscopy images, and the research primarily focused on the diagnostic accuracy of AI models in identifying lesions related to CD. The studies included a mix of retrospective and prospective designs, with participants ranging in number from 10 to 133 per study. These studies were conducted between 2020 and 2024, employing a variety of AI algorithms, including convolutional neural networks (CNNs) and other deep learning models, to assess their diagnostic performance.

Most important findings

The study found that AI-assisted capsule endoscopy demonstrated high diagnostic accuracy for detecting lesions in Crohn’s disease. Specifically, the pooled sensitivity of AI in identifying CD lesions was 94%, with a specificity of 97%. Other vital metrics included a favorable likelihood ratio (PLR) of 32.7, a negative likelihood ratio (NLR) of 6%, and a diagnostic odds ratio (DOR) of 576, all suggesting that AI can effectively distinguish CD lesions from other conditions. The area under the receiver operating characteristic curve (AUC) was found to be 0.99 , indicating excellent overall diagnostic performance. These findings suggest that AI models, profound learning algorithms, have substantial potential in assisting clinicians, especially less experienced ones, in detecting CD lesions during capsule endoscopy.

Key implications

The primary implication of this study is that AI, specifically deep learning and CNN algorithms, can significantly enhance the diagnostic process in Crohn’s disease, especially for clinicians who may have limited experience with capsule endoscopy. AI’s ability to automate lesion detection can reduce human error, shorten the time needed for image analysis, and improve the diagnostic yield of capsule endoscopy. However, the study also points out the need for further research, particularly large-scale, prospective studies with external validation, to confirm the robustness and generalizability of these AI systems. The current research is limited by small sample sizes and the lack of external validation, which raises concerns about the reliability and applicability of the findings in diverse clinical settings.

What was studied?

The study explores the genetic and epigenetic mechanisms underlying Inflammatory Bowel Disease (IBD), including both Crohn's Disease (CD) and Ulcerative Colitis (UC). The review analyzes various genetic factors and their relationship with IBD, highlighting how genetic predispositions interact with the microbiome and immune system. It also delves into pharmacogenetic aspects, explaining how genetic variations affect responses to treatment, and discusses the emerging role of epigenetic modifications, including DNA methylation and histone modifications, in disease pathogenesis.

Who was studied?

This review synthesizes data from numerous studies involving patients diagnosed with IBD. It includes research on genetic predispositions, epigenetic factors, and microbiome alterations in patients with both UC and CD. The review also references studies conducted on populations with varying genetic backgrounds, particularly focusing on how these genetic factors interact with environmental elements like diet, lifestyle, and microbial exposure, influencing disease onset and progression.

Most important findings

One of the key findings of the review is the identification of several genetic loci associated with IBD, including the NOD2 gene, which plays a crucial role in immune system activation and microbial recognition. Other genes, such as ATG16L1, CARD9, and CLEC7A, are also significantly implicated in the pathogenesis of IBD. These genes are associated with immune response regulation and the handling of gut microbiota, which is crucial in maintaining intestinal homeostasis. The review also highlights the role of epigenetic factors like DNA methylation in modifying the expression of genes related to inflammation and immune responses, influencing the severity of IBD. Furthermore, genetic and microbiome interactions were found to be pivotal in exacerbating the immune response, leading to the chronic inflammation characteristic of IBD.

Key implications

The review underscores the complexity of IBD, suggesting that both genetic and epigenetic factors are involved in the disease’s onset and progression. From a clinical perspective, understanding these genetic predispositions can enhance personalized treatment strategies, improving the effectiveness of drugs by aligning them with patients' genetic profiles. The microbiome's involvement also opens new avenues for therapy, including microbiota-based treatments such as fecal microbiota transplantation (FMT). The identification of genetic markers for disease severity and treatment response could pave the way for pharmacogenetic testing, helping clinicians to choose the most appropriate treatments based on a patient's genetic makeup.

What was studied?

This review article examines the relationship between nephrolithiasis (kidney stones) and Crohn's disease, a common form of inflammatory bowel disease (IBD). It focuses on the risk factors, pathophysiology, and management of nephrolithiasis in Crohn’s disease patients. The study also discusses preventative strategies for reducing kidney stone formation in these patients. It is well established that patients with Crohn's disease are at an increased risk for nephrolithiasis, and this review highlights the complex mechanisms, including altered gut flora, intestinal inflammation, and dietary habits, which contribute to stone formation in IBD. The article further investigates the role of dehydration, high protein diets, and bowel resections as significant contributors to kidney stone formation in Crohn’s disease patients.

Who was studied?

The review draws from various studies focusing on patients with Crohn's disease who have developed nephrolithiasis. This includes both adult and pediatric populations, with a particular focus on individuals who have undergone abdominal surgeries such as bowel resection or ileostomies, which are commonly performed in Crohn’s disease management. The article also incorporates data from large cohort studies and case series that provide a comprehensive view of the prevalence and risk factors associated with kidney stones in this patient group. Patients who have had surgery for Crohn’s disease are considered to be at higher risk for nephrolithiasis, particularly those who develop steatorrhea and malabsorption as a result of small bowel resections.

Most important findings

The review reveals that the incidence of nephrolithiasis in Crohn’s disease patients ranges from 7% to 28%, significantly higher than the general population's lifetime risk of 1-15%. The most common type of kidney stones in Crohn’s patients are calcium oxalate stones, which are often linked to increased urinary oxalate excretion and reduced levels of calcium and magnesium in the urine. The pathophysiology of nephrolithiasis in Crohn’s disease is multifactorial. Chronic diarrhea, malabsorption, and dehydration are major contributors to increased urinary oxalate levels, while small bowel resections can lead to fat malabsorption, which subsequently enhances oxalate absorption. Furthermore, Crohn’s disease patients are often at risk for altered intestinal microbiota, leading to reduced levels of oxalate-degrading bacteria, which further increases the risk of oxalate stone formation.

Additionally, the review emphasizes the role of diet in kidney stone formation. Patients with Crohn’s disease tend to have a high-protein, high-oxalate diet, which contributes to elevated urinary oxalate excretion. The reduction in urinary citrate due to small bowel disease or resections also promotes stone formation, as citrate is an inhibitor of calcium oxalate crystallization. Uric acid stones also occur in Crohn’s patients, particularly those with ileostomies, as they experience increased urine acidity due to bicarbonate losses. This combination of risk factors—dehydration, high dietary protein, and altered intestinal absorption—results in a higher incidence of nephrolithiasis in Crohn’s disease patients.

Key implications

The review stresses the importance of preventive measures to reduce the risk of nephrolithiasis in Crohn’s disease patients. Given the high prevalence of kidney stones in this population, clinicians should consider strategies such as increased fluid intake to produce at least 2.5 liters of urine per day, dietary modifications to reduce sodium and animal protein intake, and increasing the consumption of fruits and vegetables to improve citrate levels and reduce urinary supersaturation. For patients with a history of bowel resections or ileostomies, careful monitoring of kidney function and urine composition is crucial. Additionally, the review highlights the importance of early diagnosis and prompt treatment of nephrolithiasis to prevent complications like chronic kidney disease (CKD) or end-stage renal disease (ESRD). This includes the use of imaging techniques, such as ultrasound or CT scans, to detect kidney stones early in symptomatic patients.

What was studied?

This review article explored the advancements in immunomodulatory therapies for Inflammatory Bowel Disease (IBD), with a focus on their interaction with the gut-brain axis. The review synthesizes recent findings related to IBD pathogenesis, treatment efficacy, and new therapeutic strategies, particularly those targeting the gut-brain microbiota axis. It emphasizes how dysregulated immune responses in the gut, including inflammation and microbial imbalances, contribute to the disease progression and neuropsychiatric symptoms associated with IBD. The article also evaluates conventional and emerging treatments such as biological agents, stem cell therapies, probiotics, and fecal microbiota transplantation (FMT).

Who was studied?

The review summarizes findings from various research studies on IBD treatment, primarily targeting immunomodulatory therapies and their effects on the gut-brain axis. These studies include clinical trials, cohort studies, and meta-analyses involving IBD patients of varying ages and backgrounds. The study population in the review spans a broad spectrum of patients with Crohn’s disease (CD) and ulcerative colitis (UC), with a focus on those with severe or refractory disease forms. The review highlights the impact of these therapies on patient outcomes and their potential for alleviating both gastrointestinal and neuropsychiatric symptoms related to IBD.

Most important findings

The most significant findings of the study emphasize the role of the gut-brain axis in IBD pathophysiology and treatment efficacy. Biological agents like infliximab and vedolizumab have demonstrated remission rates of 40-69% in IBD patients, significantly improving outcomes. FMT emerged as a promising therapy, with clinical remission rates as high as 87.1% in ulcerative colitis patients, compared to 66.7% in the placebo group. The review also highlighted the role of probiotics and prebiotics in managing IBD and its associated neuropsychiatric conditions by modulating the gut microbiota and reducing inflammation. Moreover, stem cell therapies are gaining attention as they offer immune modulation and tissue repair benefits, although they are still in the experimental phase.

Key implications

The review suggests that targeting the gut-brain axis offers a novel therapeutic strategy for IBD management. This approach can address both the gastrointestinal and neuropsychiatric symptoms commonly associated with IBD. The use of immunomodulatory therapies, including biologics and stem cell treatments, has led to significant improvements in patient outcomes, though challenges remain with variability in response, long-term safety concerns, and accessibility. FMT shows considerable potential as an adjunct therapy, particularly in cases of ulcerative colitis, but further research is needed to standardize protocols and ensure long-term safety. Additionally, the integration of neuropsychological interventions, such as psychobiotics and cognitive-behavioral therapy, could enhance treatment outcomes by addressing the complex relationship between the gut and brain in IBD patients.

What was studied?

This study investigated alterations in the intestinal microbiota composition of patients with Graves' disease (GD) to explore possible microbiome signatures associated with the condition. The researchers used a combination of denaturing gradient gel electrophoresis (DGGE), real-time PCR, and high-throughput 16S rRNA gene sequencing (V3–V4 region) to compare microbial diversity, composition, and abundance in GD patients versus healthy controls. The study aimed to evaluate both qualitative and quantitative differences in gut microbiota and determine whether dysbiosis may be implicated in GD pathogenesis.

Who was studied?

The study analyzed fecal samples from 27 GD patients (10 males, 17 females, aged 35–50) and 11 healthy age- and sex-matched controls (4 males, 7 females). All GD patients had a disease duration of 1.5 years and were medication-free for at least six months before sampling. None of the participants had recent antibiotic, probiotic, or prebiotic use. Samples were collected at Xi'an Jiaotong University’s affiliated hospital and processed under strict ethical guidelines.

Most important findings

Graves' disease patients exhibited reduced gut microbial diversity, evidenced by significantly lower richness indices (Observed Species, Chao1, ACE, and Good’s coverage) compared to controls, although Shannon and Simpson indices were not statistically different. The most pronounced alterations were seen in specific taxa:

Real-time PCR confirmed significantly reduced copy numbers of Bifidobacterium and Lactobacillus in GD (P < 0.05), suggesting depletion of beneficial microbes. Meanwhile, Bacteroides vulgatus was slightly increased, and Clostridium leptum slightly reduced, although these changes did not reach significance by q-value correction.The dominant microbial phyla in GD were Bacteroidetes (57.6%) and Firmicutes (32.9%), with GD patients having a lower Firmicutes: Bacteroidetes ratio compared to controls.

Key implications

This study reveals that Graves' disease is associated with a distinct gut microbiota signature characterized by reduced microbial richness and altered abundances of both beneficial and potentially pathogenic taxa. The significant increase in Haemophilus parainfluenzae and Prevotella_9, along with the depletion of Faecalibacterium and Alistipes, suggests immune-related microbial imbalance. These taxa may serve as major microbial associations (MMAs) for GD and could be investigated as microbial targets for microbiome-based interventions. The depletion of Lactobacillus and Bifidobacterium also suggests potential for probiotic or prebiotic therapy. While causality remains unresolved, the findings reinforce the need to consider intestinal dysbiosis as a contributing factor in GD pathogenesis and therapy development.

What was studied?

This article provides an in-depth examination of the pathogenesis of ankylosing spondylitis (AS), focusing on recent developments in understanding the role of immune responses, particularly Type 17 immunity, in its development. It delves into the multifactorial aspects of AS pathogenesis, including genetic factors, immune cell involvement, and gut microbiome alterations. A significant part of the research highlights the involvement of the IL-23/IL-17 axis in driving inflammation and joint damage, particularly in the context of autoimmune responses. The review also presents the contribution of immunometabolism and local metabolic environments in the joints as important factors in disease progression. In addition, it explores therapeutic advancements targeting Type 17 immune responses, such as monoclonal antibodies and small molecules, and how these have provided insights into managing AS more effectively.

Who was studied?

The studies referenced in the article primarily focus on patients with ankylosing spondylitis (AS) and spondyloarthritis (SpA), as well as animal models. These include individuals diagnosed with AS, with some studies specifically comparing male and female patients due to observed gender differences in disease prevalence and progression. Genetic studies involving twins and first-degree relatives of AS patients suggest a strong hereditary component, with a significant association with the HLA-B27 gene. Additionally, the review references animal models, particularly HLA-B27 transgenic rats and mouse models of AS, which provide insights into the role of gut microbiota, immune system interactions, and metabolic changes in AS pathogenesis. The human studies also focus on biomarkers like IL-17 and IL-23, and immune cells, particularly T-helper cells, which are elevated in AS patients and play a crucial role in disease mechanisms.

Most important findings

The review identifies several key findings regarding the pathogenesis of AS. First, it reaffirms the importance of the IL-23/IL-17 immune axis, which has been implicated in the inflammation seen in AS. IL-23, a cytokine produced by myeloid cells, stimulates the differentiation of T-helper (TH17) cells, which in turn secrete pro-inflammatory cytokines such as IL-17, IL-22, and IL-17F. These cytokines are critical for the inflammation observed in the entheses (the sites where tendons or ligaments insert into the bone), a hallmark of AS. The article also discusses the importance of genetic factors, particularly the HLA-B27 allele, in increasing the susceptibility to AS. Moreover, the review highlights the growing evidence linking the gut microbiome to AS, with studies showing that patients with AS often exhibit dysbiosis, or microbial imbalance, in their gut. Changes in gut microbiota may influence immune responses, exacerbating inflammation and contributing to disease progression.

Another important finding from the article is the emerging role of the local metabolic environment in the joints in driving AS. The review discusses how metabolic factors, such as high salt diets and low pH, can influence T-cell responses, particularly TH17 cells, and how these factors might contribute to joint inflammation. Animal studies have demonstrated that a high-salt diet can exacerbate autoimmune responses, including those in the joints of AS models, further linking diet and metabolism to disease pathogenesis.

Key implications

The implications of these findings are significant for both understanding AS and developing more targeted therapies. The identification of the IL-23/IL-17 axis as central to AS pathogenesis supports the use of monoclonal antibodies targeting IL-17, such as secukinumab, in treating the disease. These therapies have shown promise in clinical trials, offering better control of disease activity and symptoms. Additionally, the potential role of gut microbiota in AS suggests that modifying the microbiome through dietary interventions, probiotics, or antibiotics might offer a novel approach to managing the disease. The connection between the local metabolic environment and immune responses opens new avenues for therapeutic strategies, such as targeting metabolic pathways in the joint and gut. Overall, the review suggests that AS treatment should be personalized, taking into account the genetic, immune, and metabolic factors involved in each patient’s disease.

What was studied?

This review explores the role of gut microbiota in pathogen colonization, immune responses, and its influence on inflammatory diseases, particularly Inflammatory Bowel Disease (IBD). It examines the complex relationship between gut microbes and the immune system, focusing on how the microbiota can influence immune regulation, prevent infections, and contribute to diseases like IBD. The study addresses the concept of dysbiosis, where an imbalance in the microbiota can promote disease and disrupt immune function, ultimately leading to inflammation.

Who was studied?

The review considers a broad range of studies involving both animal models and human patients. Animal models, especially germ-free mice, were used to study the role of the microbiota in immune responses and disease prevention. The review also discusses studies involving human patients with IBD, investigating how their gut microbiota composition correlates with disease progression. The research encompasses the interactions between specific microbial species in the gut and the immune system, along with how these interactions differ in individuals with conditions like IBD.

Most important findings

The review reveals the critical role of gut microbiota in maintaining immune homeostasis and preventing pathogen colonization. A healthy microbiota supports the immune system by promoting the production of immunoglobulins, such as IgA and IgG, which help defend against pathogens. It also supports immune cell activation and differentiation, such as the development of regulatory T cells (Tregs) that prevent excessive inflammation. On the flip side, dysbiosis—imbalance in microbial populations—has been linked to chronic diseases like IBD, where pathogenic bacteria such as Enterobacteriaceae can outgrow and exacerbate inflammation. The study further emphasizes that microbiota plays a significant role in modulating systemic immune responses, not just local gut immunity. The composition of the microbiota can also influence the body's ability to resist infections outside of the gut, which has broad implications for systemic immunity.

Key implications

The findings suggest that understanding how gut microbiota influences immune regulation could lead to new therapeutic approaches for inflammatory diseases like IBD. By manipulating the microbiota through interventions like probiotics, prebiotics, or diet, it may be possible to restore balance and prevent or treat conditions related to dysbiosis. Additionally, the review highlights the potential for microbiota-targeted therapies to improve immune system function and combat infections, both locally within the gut and systemically. A more nuanced understanding of the microbiota’s role in immune modulation could provide new avenues for clinical management of autoimmune and inflammatory conditions.

What was studied?

The paper reviews the incidence, pathophysiology, risk factors, and management of intestinal strictures in Crohn’s Disease (CD). Strictures, which involve the narrowing or constriction of the intestines, are a common complication of CD, and they often lead to significant morbidity. The study examines the mechanisms behind stricture formation, including chronic inflammation and fibrosis, as well as the role of genetic and environmental factors in influencing the likelihood of developing strictures. It also discusses various diagnostic techniques and management strategies, emphasizing the need for individualized treatment approaches to improve patient outcomes.

Who was studied?

This study synthesizes findings from a wide range of patient populations, particularly those with Crohn’s Disease who experience stricture formation. It includes data from various international studies that focus on patients with differing disease phenotypes, including those with small bowel and colonic strictures. Patients with CD who required surgical interventions due to complications like bowel obstruction or fistulas were particularly studied, with a focus on those undergoing long-term follow-ups. The paper also highlights genetic and environmental factors that predispose specific individuals to develop strictures.

Most important findings

The review emphasizes the complex mechanisms of fibrosis and inflammation that contribute to stricture formation in CD. Chronic inflammation leads to the thickening of the intestinal wall through the accumulation of extracellular matrix (ECM) and mesenchymal cell expansion. This process, driven by fibroblast activation and the secretion of pro-inflammatory cytokines such as TNF-α and IL-1β, leads to fibrosis and strictures.

Genetic factors, particularly mutations in the NOD2 and TNF-α genes, are associated with a higher risk of developing strictures. Patients with biallelic mutations in the CARD15 gene have a significantly higher risk of progressing to stricturing disease. Environmental factors like smoking, age of diagnosis, and the use of steroids are also major contributors to disease progression. Endoscopic findings, such as deep mucosal ulcerations, are predictive of stricture development.

In terms of diagnosis, imaging tools like transabdominal ultrasonography (TUS), CT, and MRI enterography are highlighted for their high sensitivity in detecting strictures. Endoscopy remains a gold standard, especially in assessing disease severity and the extent of mucosal damage. However, it is not always suitable for assessing deep small bowel lesions, and newer techniques like double-balloon enteroscopy (DBE) and capsule endoscopy have been introduced to overcome this limitation.

Key implications

The review underscores the importance of early diagnosis and personalized management strategies for patients with Crohn’s Disease and strictures. It highlights the role of non-invasive imaging techniques in identifying strictures early, which can potentially delay the need for surgery. The advancements in biological therapies, particularly anti-TNF-α treatments, offer hope for controlling inflammation and preventing the progression of fibrosis. However, while biologics are effective in inducing and maintaining remission, they may not always prevent stricture formation, and some patients may still require surgical interventions. Endoscopic dilation, strictureplasty, and surgery are presented as key therapeutic options for managing strictures when medical therapy fails.

What was studied?

This study focused on the relationship between the gut microbiota and bile acid composition in the ileal mucosa of patients with Crohn’s disease (CD). The researchers sought to investigate how microbial alterations (dysbiosis) in the small intestine correlate with changes in bile acid metabolism, which plays a crucial role in gut health and disease. The authors analyzed the microbial structure and bile acid composition in CD patients during clinical remission and compared them to non-CD controls. They also explored the link between specific gut microbiota taxa and the alterations in bile acid profiles.

Who was studied?

The study involved 38 CD patients in clinical remission and 12 non-CD controls. The participants were selected based on their clinical status, including disease activity indices (CDAI) for the CD group. The samples were collected using balloon-assisted enteroscopy (BAE) from the distal ileum, with samples categorized into active and inactive lesions based on endoscopic findings. The microbiota was analyzed from mucosal samples, while bile acid composition was analyzed from intestinal fluid.

Most important findings

The study found significant alterations in both the gut microbiota composition and bile acid profiles of CD patients. Specifically, the relative abundance of Escherichia was significantly higher in CD patients compared to non-CD controls, while Faecalibacterium and Roseburia (both butyrate-producing genera) were notably reduced. These findings align with previously reported dysbiosis in IBD, where an increase in facultative anaerobes like Escherichia was observed, particularly in active lesions. Furthermore, the study identified a shift in bile acid composition in CD patients, with a higher proportion of conjugated bile acids (such as glycocholic acid and taurocholic acid) and a reduction in the unconjugated bile acids like lithocholic acid (LCA). The composition of bile acids was linked to the microbial community, as higher levels of Escherichia and Lactobacillus were positively correlated with an increased proportion of conjugated bile acids, while Roseburia and Faecalibacterium were negatively correlated with conjugated bile acids.

Key implications

These findings highlight the interplay between the gut microbiota and bile acid metabolism in the pathophysiology of CD. The alteration of bile acid composition, particularly the increase in conjugated bile acids, may suggest malabsorption of bile acids in the ileum, possibly contributing to inflammation in CD. Moreover, the relationship between specific gut microbial taxa and bile acid metabolism could provide potential biomarkers for diagnosing and monitoring disease activity in IBD. Targeting microbiota profiles or manipulating bile acid metabolism could open up new therapeutic avenues for treating CD. Probiotic therapies or dietary interventions aimed at restoring beneficial microbiota and normalizing bile acid metabolism may offer additional strategies to manage or mitigate disease activity.

What was reviewed?

This narrative review collates epidemiological data, genetic predisposition, endogenous influences (e.g., oestrogen effects), environmental exposures and—most germane to microbiome‑focused clinicians—viral associations implicated in Graves’ disease (GD). It synthesises findings from population studies, molecular genetics and translational immunology to outline how host genetics (≈79 % of risk) interact with modifiable factors (≈21 %) to precipitate autoimmune hyperthyroidism.

Who was reviewed?

The authors analysed evidence drawn predominantly from adult cohorts in Europe, North America and East Asia, where GD incidence peaks between 30–60 years and exhibits a 5–10‑fold female preponderance. Additional data came from mechanistic studies using primary thyrocytes, B‑cell assays and interferon‑treated hepatitis C virus (HCV) cohorts, enabling integration of clinical and experimental perspectives.

Most important findings

Genomic studies confirm a polygenic architecture enriched for T‑cell regulatory loci (HLA‑DR3, CTLA‑4, PTPN22, CD40) that biases toward a Th1‑skewed response. Endogenous oestrogen signalling, skewed X‑chromosome inactivation and microchimerism further augment female risk. Environmentally, excess iodine, selenium, or vitamin D deficiency, smoking, halogenated pesticides, and dioxin (Agent Orange) exposure modulate disease penetrance. Crucially for microbiome signature databases, the review catalogues viral links: foamy viruses (inconclusive), parvovirus B19 (weak), Epstein–Barr virus (EBV reactivation expands TRAb‑positive B cells) and HCV. Large cohort and meta‑analytic data show that chronic HCV infection elevates thyroid autoantibody prevalence and hypothyroidism, while HCV‑related mixed cryoglobulinaemia markedly increases GD risk. HCV envelope protein E2 binds thyrocyte CD81, triggering IL‑8/CXCL10 production, thereby recruiting CXCR3⁺ Th1 cells and perpetuating autoimmunity. These microbe‑driven inflammatory signatures (CXCL9/10/11 axis) provide candidate biomarkers for a “thyroid‑autoimmunity virome” module within broader microbiome analytics.

Key implications

For clinicians, recognising viral and environmental co‑factors refines risk stratification and informs screening: (i) test thyroid function and antibodies in chronic HCV or EBV reactivation; (ii) counsel on iodine intake, smoking cessation, and micronutrient sufficiency; (iii) anticipate attenuated antithyroid‑drug requirements in interferon‑treated HCV patients. From a translational standpoint, integrating viral chemokine fingerprints into microbiome databases could uncover convergent immune pathways applicable to other organ‑specific autoimmunities and guide targeted immunomodulation.

What was studied?

This study explores the mechanisms that regulate intestinal homeostasis and inflammation, focusing on how the immune system interacts with the gut microbiota. The gut is home to a complex community of microbes, and the ability of the immune system to coexist with these microbes is essential for maintaining health. Disruptions to this delicate balance can lead to chronic diseases like inflammatory bowel disease (IBD).

Who was studied?

The research examines both human and animal models, including mice and zebrafish, to investigate the interactions between intestinal cells, the immune system, and the microbiota. Special focus is given to the function of various immune cells and the epithelial barrier in the gut, as well as how these interactions change under conditions of disease or stress.

Most important findings

The study found that the gut microbiota plays a crucial role in shaping immune responses, maintaining intestinal homeostasis, and preventing inflammation. Specifically, the gut microbiota instructs immune cells, guiding their proper development and function. Disruptions to the gut barrier and microbial imbalance, often seen in conditions like Crohn’s disease and ulcerative colitis, can trigger inappropriate immune responses, leading to chronic inflammation. Cells such as Paneth cells, which produce antimicrobial peptides, are key in regulating the microbial community in the gut, and mutations in genes like ATG16L1 can impair their function, exacerbating disease. The integrity of the intestinal epithelium, including tight junctions, is also vital for maintaining homeostasis, and disruptions to this barrier can result in disease.

Key implications

The findings highlight the importance of microbial interactions in regulating immune responses and maintaining gut health. Understanding how the microbiota influences immune function and epithelial integrity could lead to new approaches for treating chronic inflammatory diseases. Therapies targeting microbial populations or modulating immune responses could offer promising treatments for diseases like IBD, where inflammation is driven by immune system dysregulation.

What was studied?

This article investigates the long-term risk of developing inflammatory bowel disease (IBD) in patients with autoimmune hepatitis (AIH), focusing on a 20-year population-based study conducted using data from Clalit Health Services in Israel. The study aimed to explore the incidence, risk factors, and potential impact of IBD on liver-related outcomes in AIH patients. It also examined the temporal relationship between AIH and IBD, considering how both diseases coexist and whether IBD exacerbates liver complications in AIH patients.

Who was studied?

The study involved 1284 adult patients diagnosed with AIH between 2000 and 2024, using data from a large healthcare database in Israel. The cohort excluded patients with pre-existing cirrhosis, other chronic liver diseases, or IBD before their AIH diagnosis to ensure a more accurate assessment of the risk of developing IBD post-AIH. The study also considered various demographic factors, such as age, gender, socioeconomic status, and lifestyle factors like smoking, to identify potential risk factors for IBD development in this population.

Most important findings

The key finding of the study was that 9.81% of AIH patients developed IBD, most commonly Crohn’s disease (CD), during the follow-up period. The cumulative incidence of IBD increased progressively over time, with a notable rise in risk after 10 years. Smoking was identified as an independent risk factor for the development of IBD in AIH patients. The study also revealed that AIH patients with coexisting IBD had a higher prevalence of cirrhosis compared to those with AIH alone. Interestingly, while the presence of IBD was associated with greater liver fibrosis, it did not lead to an increased risk of severe liver-related complications like hepatocellular carcinoma (HCC), esophageal varices, or ascites.

The study further highlighted the absence of significant differences in the incidence of major liver-related complications between AIH patients with and without IBD, suggesting that while IBD may accelerate liver fibrosis, it may not directly influence the progression to end-stage liver disease in AIH patients. Furthermore, the findings underscore that CD, rather than ulcerative colitis (UC), is more commonly associated with AIH in this cohort, a trend that may reflect population-specific immune triggers.

Key implications

The findings of this study have significant clinical implications for the management of AIH patients, especially those at risk for developing IBD. The identification of smoking as a modifiable risk factor for IBD suggests that smoking cessation could be an important strategy in reducing the risk of developing IBD in AIH patients. The study also emphasizes the need for vigilant monitoring of AIH patients for the early signs of IBD, particularly Crohn’s disease, given its higher prevalence in this population.

Although the presence of IBD was associated with an increased prevalence of cirrhosis, the absence of an increased risk of severe liver-related complications suggests that IBD may not have a substantial effect on the progression of liver disease in AIH patients. However, these findings highlight the need for continued research to further understand the mechanisms linking IBD and AIH, particularly through shared immune pathways or genetic factors, which could provide insights for better clinical management and personalized treatment strategies.

What was studied?

The study explored siderophore-mediated iron acquisition in the gastrointestinal tract, focusing on its role in bacterial-host interactions. Siderophores are small molecules that bacteria secrete to scavenge iron from the host, a vital micronutrient. This review particularly looks at how siderophores influence bacterial growth, community dynamics, and host immune responses, with implications for both pathogen-driven diseases like infections and microbiota-driven diseases such as inflammatory bowel diseases (IBD) and colorectal cancer. The paper also emphasizes the competition for iron between resident microbiota and pathogens and the ways in which host mechanisms limit bacterial iron availability.

Who was studied?

The study primarily discusses how siderophore production and iron acquisition strategies are employed by different bacterial taxa within the intestinal microbiota, both in pathogenic bacteria and resident commensals. It includes data from rodent models, clinical studies, and experimental models using microbiota-transplanted mice to study how siderophore production by both beneficial and harmful bacteria impacts the intestinal environment. The review also covers the role of the host’s iron-binding proteins like lactoferrin and lipocalin-2 (Lcn2) in regulating microbial iron availability and their effects on the intestinal microbial community and inflammation.

Most important findings

The review identifies the key role of siderophores in regulating iron availability within the gut and modulating microbial communities. Specific bacteria, particularly from the Enterobacteriaceae family, produce siderophores such as enterobactin, salmochelin, and yersiniabactin, which enable them to outcompete other bacteria for iron. The competition for this limited resource can drive microbial community shifts in the gut, favoring siderophilic bacteria and potentially leading to dysbiosis, especially in the context of diseases like IBD and colorectal cancer.

Siderophore production also modulates the host’s immune system. For example, some siderophores can reduce the production of reactive oxygen species (ROS) by immune cells, offering a protective advantage to bacteria in inflamed environments. However, other siderophores, such as enterobactin, can activate inflammatory pathways by modulating iron homeostasis in host cells. This suggests that while siderophores can enhance microbial growth, they also influence host immune responses, sometimes exacerbating inflammation.

Moreover, host defenses, like Lcn2, can bind siderophores and restrict bacterial access to iron, illustrating the host’s nutritional immunity. The balance between bacterial iron acquisition and host immune response is crucial for maintaining a symbiotic relationship or fostering pathogenic conditions. The ability of some bacteria to resist these host defenses, through the production of Lcn2-resistant siderophores, provides them a competitive edge, particularly in the inflamed intestines of IBD patients.

Key implications

This review highlights the critical role of siderophore-mediated iron acquisition in both maintaining the gut microbiota and in the pathogenesis of diseases like IBD and colorectal cancer. The findings suggest that therapeutic interventions targeting siderophore systems could be an effective strategy for managing microbial dysbiosis and inflammation. For example, inhibitors of siderophore production or the development of synthetic sideromycins (antibiotics conjugated to siderophores) might help control pathogenic overgrowth while preserving beneficial microbiota. Additionally, understanding the precise role of siderophores in modulating host immune responses could lead to new therapeutic avenues for diseases involving chronic inflammation, such as IBD.

The review also underscores the need for further research to better understand the interaction between host iron regulation and microbial siderophore systems, particularly how these interactions influence immune responses and disease outcomes. Future studies could investigate the potential of siderophore-targeted therapies in treating infections, inflammation, and even cancer, particularly in microbiota-driven pathologies.

What was studied?

This original research investigated the gut microbiome in Graves disease hypothyroidism through an integrated analysis of fecal microbiota and metabolome profiles in patients with Graves' disease (GD) and hypothyroidism (HT) compared to healthy controls. Using 16S rRNA gene sequencing for microbial composition and untargeted liquid chromatography-mass spectrometry for metabolomics, the study aimed to identify distinct microbial and metabolic signatures, explore correlations between microbiota, metabolites, and clinical thyroid indicators (e.g., TSH, FT3, FT4, TRAb), and uncover potential pathways linking gut dysbiosis to thyroid dysfunction. Functional predictions via PICRUSt and pathway enrichment with KEGG highlighted microbial roles in metabolism, while OPLS-DA and Spearman correlations elucidated group differences and interactions.

Who was studied?

The study enrolled 90 participants from Shanghai Tenth People's Hospital, including 30 patients with newly diagnosed GD (mean age ~40 years, predominantly female), 30 with HT (similar demographics), and 30 age- and sex-matched healthy controls without thyroid disorders or recent antibiotic use. GD was diagnosed based on hyperthyroidism symptoms, elevated FT3/FT4, suppressed TSH, and positive TRAb; HT by hypothyroidism symptoms, reduced FT3/FT4, elevated TSH, and positive TPOAb/TgAb. Exclusion criteria included pregnancy, other autoimmune diseases, gastrointestinal disorders, or probiotic/antibiotic use within three months to minimize confounders affecting the microbiome.

Most important findings

The gut microbiome in Graves disease hypothyroidism showed reduced alpha diversity (Shannon index) in both GD and HT groups compared to controls, with beta diversity (Bray-Curtis) indicating distinct clustering. At the phylum level, Firmicutes dominated, but Bacteroidetes were depleted in disease groups; genus-level shifts included decreased Bacteroides and Prevotella in GD and HT, increased Enterococcus and Veillonella in GD, and elevated Ruminococcus in HT. These alterations suggest dysbiosis contributing to immune dysregulation, relevant for a microbiome signatures database where depleted Bacteroides (anti-inflammatory, SCFA producers) and enriched Enterococcus (potential pathogens) could serve as markers for GD, while Ruminococcus overabundance might signal HT. Metabolomics identified 120 differential metabolites, with GD showing enriched bile acids (e.g., cholic acid) and amino acids (e.g., L-tryptophan), HT displaying depleted fatty acids (e.g., oleic acid) and increased steroids. Correlations revealed Bacteroides positively linked to anti-inflammatory metabolites like indole-3-acetic acid, negatively to TRAb in GD; network analysis highlighted clusters where microbiota influenced thyroid hormones via metabolic pathways like tryptophan and bile acid metabolism.

Key implications

These findings imply that clinicians could use gut microbiome profiling as a non-invasive tool for early detection and monitoring of GD and HT, integrating fecal biomarkers like Bacteroides depletion or bile acid elevation into diagnostic panels to complement thyroid function tests. Therapeutically, targeting dysbiosis via probiotics (e.g., Bacteroides-enriched) or fecal microbiota transplantation might modulate immune responses and metabolic pathways, potentially alleviating symptoms or preventing progression. For clinical practice, this bridges microbiome research by suggesting personalized interventions based on signatures, such as tryptophan supplementation for GD to counteract indole pathway disruptions. Future longitudinal studies should validate causality, perhaps through Mendelian randomization, to refine microbiome-based therapies and expand databases for precision medicine in endocrinology.

What was studied?

This prospective study evaluated the relationship between gut microbiota (GM) composition and Graves’ disease (GD), an autoimmune thyroid disorder, in newly diagnosed patients. Using 16S rRNA gene sequencing of fecal samples, the researchers profiled and compared the GM of 65 untreated GD patients and 33 healthy controls. They assessed microbiota changes before and after three months of antithyroid drug (ATD) therapy. The investigation aimed to identify specific microbial signatures associated with GD, measure their correlation with clinical parameters, and observe whether GM dysbiosis recovers following treatment. Additionally, a subgroup analysis examined differences in microbiota among GD patients with or without impaired liver function.

Who was studied?

A total of 98 individuals of Chinese Han ethnicity participated: 65 were newly diagnosed, untreated GD patients (18 men, 47 women; median age 30 years), and 33 were healthy volunteers (10 men, 23 women; median age 27 years) recruited from the First Affiliated Hospital of Nanchang University. The GD group met stringent diagnostic criteria (clinical symptoms, thyroid hormone and antibody levels, and ultrasound findings). Exclusion criteria included recent antibiotic/probiotic use, previous ATD therapy, gastrointestinal or other autoimmune diseases, liver disease, or pregnancy. Of the 65 GD patients, 37 completed three months of follow-up on methimazole. A subgroup of GD patients with impaired liver function (GDH) was also analyzed separately from those with normal liver function (GDN).

Most important findings

The study demonstrated that the gut microbiota composition of GD patients is significantly distinct from healthy controls. GD patients exhibited reduced alpha diversity (richness and diversity) of their GM, while beta diversity analyses confirmed a clear separation between groups. Specifically, the GD group showed increased abundance of Bacilli (class), Lactobacillales (order), Streptococcaceae (family), and the genera Streptococcus, Veillonella, and Erysipelatoclostridium. Conversely, there were reductions in families such as Peptostreptococcaceae, Christensenellaceae, Marinifilaceae, and Rikenellaceae, and in genera including Roseburia, Romboutsia, Lachnospira, and Eubacterium ventriosum—all associated with production of short-chain fatty acids (SCFAs) and anti-inflammatory effects.

Using a random forest model, 12 genera were identified that could distinguish GD patients from controls with high accuracy (AUC = 0.9021), making them strong candidates for microbiome-based GD biomarkers. Correlations were observed between specific bacterial genera and clinical indicators: for instance, Veillonella abundance was positively correlated with thyroid hormone levels (FT3, FT4) and thyrotrophin receptor antibodies (TRAb), while several SCFA-producing genera showed negative correlations.

After three months of ATD therapy, the GM of GD patients showed partial recovery: the abundance of previously increased taxa (e.g., Streptococcus, Streptococcaceae) decreased, while the abundance of SCFA-producers (e.g., Romboutsia, Lachnospira, Eubacterium ventriosum) increased. However, diversity remained lower compared to controls, and some dysbiosis persisted, indicating incomplete restoration of the microbiome. IL-17 levels, a marker of Th17-mediated immune response, decreased significantly post-treatment and were negatively correlated with Eubacterium hallii group abundance.

In GD patients with impaired liver function, reductions in Weissella and Leuconostocaceae were associated with liver injury markers, supporting a possible gut-liver axis in GD pathophysiology.

Key implications

The study establishes a robust microbiome signature for Graves' disease, linking specific changes in gut microbial composition to disease presence and clinical parameters. The reduction in SCFA-producing, anti-inflammatory genera and the enrichment of pro-inflammatory bacteria suggest that GM dysbiosis may contribute to GD pathogenesis via immune modulation (e.g., Th17/Treg imbalance). Identification of 12 discriminatory genera provides a foundation for developing microbiome-based diagnostics or risk stratification tools for GD—potentially enabling earlier intervention before overt symptoms arise. The observed partial restoration of the GM following antithyroid therapy also suggests therapeutic modulation of the microbiome could complement GD management. The findings emphasize the importance of the gut-thyroid and gut-liver axes in autoimmune endocrine diseases, with implications for personalized medicine and the development of microbiome-targeted interventions.

What was studied?

This study aimed to identify biomarkers that predict non-response to infliximab treatment in Crohn’s Disease (CD) patients by exploring gut microbiome and metabolome interactions. Researchers sought to characterize how these microbiome-metabolome signatures influence the immune system and therapeutic efficacy, specifically in terms of M1 macrophage suppression and regulatory T cell (Treg) dominance.

Who was studied?

The study involved 100 CD patients who were starting infliximab therapy, as well as a control group of 49 healthy individuals. The patients were followed over time to evaluate their responses to infliximab, while their baseline microbiome and metabolome were analyzed to understand factors associated with primary non-response to the treatment.

Most important findings

The study found that certain microbiome signatures and metabolites were strongly associated with treatment response. Specifically, a reduction in beneficial bacteria like Bifidobacterium and Faecalibacterium at baseline was linked to infliximab failure. The gut microbiome of non-responders showed increased levels of pro-inflammatory genera such as Escherichia and Shigella, while beneficial species were significantly depleted. Metabolomic analysis also highlighted that non-responders had lower levels of taurochenodeoxycholic acid (TCDCA), which is associated with the regulation of immune cells, including Tregs. Fecal microbiota transplantation (FMT) experiments confirmed that microbiota from non-responders exacerbated inflammation in mice, supporting the role of specific gut microbial communities in treatment resistance. Additionally, a machine learning model based on microbiome data was able to predict treatment outcomes with an accuracy of 80.5%.

Key implications

These findings suggest that baseline microbiome and metabolome profiles could serve as predictive biomarkers for infliximab efficacy in CD patients. The research emphasizes the role of the gut microbiota in modulating immune responses and the importance of bile acid metabolism in treatment outcomes. This could lead to more personalized treatment strategies for CD, enabling clinicians to identify potential non-responders early and consider alternative therapeutic approaches. Additionally, restoring beneficial bacteria and specific metabolites could improve treatment outcomes in the future.

What was studied?

This paper reviews the role of phage therapy in targeting the intestinal bacterial microbiota for the treatment of liver diseases. It highlights the growing interest in using phages as a therapeutic strategy to manipulate the microbiota and address liver conditions associated with microbial imbalances, such as non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, and cirrhosis. The review also discusses phage therapy's ability to precisely target harmful bacterial populations without causing extensive disruption to the overall gut microbiome.

Who was studied?

The studies referenced in the review predominantly focus on animal models, particularly mice, and clinical case studies involving human patients with liver diseases. The populations studied range from those with liver conditions such as NAFLD, alcoholic liver disease, primary sclerosing cholangitis, and cirrhosis, to patients undergoing phage therapy for various bacterial infections. The paper also references clinical trials that assess the effectiveness and safety of phage treatments, as well as preclinical studies exploring phages' potential in microbiome manipulation.

Most important findings

The review presents several key findings regarding the potential of phage therapy in liver diseases. It identifies specific bacterial genera in the gut microbiota, such as Bacteroides, Blautia, Dorea, and Prevotella, that are more abundant in patients with liver conditions, suggesting they could be potential targets for phage therapy. The paper also discusses how phages can selectively reduce the abundance of these pathobionts, helping to restore a balanced microbiota. Moreover, phages' role in reducing inflammation and alleviating liver disease symptoms is emphasized, with studies showing that phages targeting Enterococcus faecalis or Klebsiella pneumoniae can improve liver function in animal models of alcohol-induced liver injury and cirrhosis.

Another important finding is that the use of engineered or synthetic phages, which are designed to broaden the host range and reduce resistance, offers a promising way to overcome challenges associated with natural phages. The paper also mentions that synthetic biology platforms can create phages tailored to target specific bacterial strains, enhancing the precision of phage therapy.

Key implications

Phage therapy's potential for liver disease treatment highlights its ability to target specific gut bacteria linked to the progression of liver conditions. This targeted approach could offer a more effective and less disruptive alternative to broad-spectrum antibiotics, which can exacerbate dysbiosis. Phage therapy also holds promise for combating antimicrobial-resistant infections, a growing concern in clinical settings. However, the review emphasizes that clinical trials are still necessary to validate the safety and efficacy of phage therapy for liver diseases. Further research should focus on identifying the most suitable bacterial targets, optimizing phage cocktails, and ensuring that phage treatment does not induce significant resistance or cause off-target effects.

What was studied?

This review article focuses on the effects of iron therapy on oxidative stress and intestinal microbiota in individuals with inflammatory bowel disease (IBD). Specifically, it investigates the relationship between iron supplementation, redox status, and the gut microbiota, examining how iron deficiency and therapy can influence disease outcomes in IBD patients. The article also highlights the clinical implications of these findings and the potential consequences of both iron deficiency and excess on the gastrointestinal system.

Who was studied?

The review synthesizes evidence from various studies, primarily involving patients with IBD, including both Crohn's disease (CD) and ulcerative colitis (UC). These patients are often affected by iron deficiency anemia (IDA) or non-anemic iron deficiency (NAID), conditions common in IBD due to factors like chronic inflammation, malabsorption, and blood loss. The review also references studies in healthy volunteers to compare the effects of iron therapy and oxidative stress.

Most important findings

The review emphasizes that iron deficiency and iron supplementation both significantly influence oxidative stress and intestinal microbiota in IBD. Iron deficiency is associated with increased oxidative stress, while iron supplementation—especially intravenous iron—has been shown to increase oxidative stress markers and alter the microbiota. The studies reveal conflicting results on the impact of oral versus intravenous iron therapy, with oral iron generally showing less impact on oxidative stress than intravenous formulations. Notably, intravenous iron therapy is linked with increased reactive oxygen species (ROS), which could potentially exacerbate inflammation and alter the gut microbial environment. Furthermore, iron therapy, whether oral or intravenous, alters the intestinal microbiota, potentially influencing the gut's inflammatory status. Some iron formulations may exacerbate dysbiosis, while others, such as Lactobacillus plantarum, may aid in iron absorption without significantly harming the microbiota.

Key implications

The review suggests that while iron therapy is necessary to address iron deficiency in IBD patients, its administration must be managed carefully to avoid exacerbating oxidative stress or disturbing the intestinal microbiota. Clinicians should consider low-dose or intermittent oral iron therapy in quiescent IBD and reserve intravenous iron for more severe cases. Given the observed changes in the microbiota, it's important to further study the long-term clinical significance of these alterations and their potential effects on disease activity and patient outcomes. A personalized approach to iron therapy is recommended, factoring in the patient’s specific IBD condition, disease activity, and iron status.

What was studied?

This study explores the dual roles of copper in infectious diseases, highlighting its essential function in both host immune defense and pathogen survival. Copper acts as a toxic substance to pathogens but is also a vital micronutrient necessary for cellular processes, including redox reactions and electron transfer. The research delves into how pathogens utilize copper to thrive within the host while also examining the ways in which the host manipulates copper to combat infections. The study provides a comprehensive understanding of copper's multifaceted role at the host-pathogen interface.

Who was studied?

The research focuses on the interaction between various pathogens, including bacteria, fungi, and viruses, and the host immune system. It emphasizes how copper is both a weapon for the host and a challenge for pathogens. The study examines how different pathogens, particularly bacterial pathogens, adapt to the toxic effects of copper through mechanisms like copper export and sequestration, enabling them to survive inside host cells. It also investigates the host's strategies for manipulating copper levels to either enhance its toxic effects against pathogens or limit microbial access to copper to prevent infection.

Most important findings

The study reveals that copper’s role in infection is complex and dual-faceted. On one hand, copper is essential for the host’s immune system, enabling the activation of copper-dependent enzymes that defend against pathogens and regulate oxidative stress. On the other hand, pathogens have developed various mechanisms to counteract copper toxicity, such as copper export systems and the production of metal-binding proteins. These adaptive strategies allow pathogens to survive in environments where copper levels are high, such as within the host during infection. The research highlights how the host also exploits copper’s toxic effects to kill pathogens, particularly through the actions of immune cells like macrophages. Moreover, the study suggests that the manipulation of copper levels, either by enhancing its toxic effects on pathogens or limiting its availability, could provide new therapeutic strategies for managing infections.

Key implications

These findings underscore copper's essential and paradoxical role in infectious disease. While copper is toxic to many pathogens, its dual role as both a nutrient and a weapon makes it a valuable tool in the host’s immune response. The study's insights into how pathogens manage copper stress can inform the development of novel therapies, such as copper-based antimicrobial agents, to combat infections. Additionally, understanding how the host manipulates copper to regulate immune responses suggests new approaches for enhancing the immune system during infection. Therapeutic interventions targeting the mechanisms of copper acquisition and resistance in pathogens, as well as strategies to modulate copper levels in the host, could offer new avenues for treating a range of infections.

What was studied?

The study explores the clinical characteristics of intra-abdominal abscesses (IA) and intestinal free-wall perforations (IP) in Korean patients with Crohn’s disease (CD). These complications, which often arise from deep transmural inflammation, can severely affect patient outcomes. The research examines the differences in clinical features, risk factors, and associated complications between IA and IP, highlighting how the progression of CD influences the development of these conditions. The study aimed to investigate these differences to improve treatment strategies and patient prognosis.

Who was studied?

The study involved patients diagnosed with Crohn’s disease across 32 hospitals in Korea, focusing on those who developed complications such as IA and IP. The cohort included 1286 patients, with 147 (11.4%) diagnosed with IA and 83 (6.5%) with IP. The study explored various factors like age, disease behavior, intestinal stricture, and perianal fistulas, comparing these features in patients with IA, IP, and those without such complications. Data were collected from retrospective medical records spanning multiple years, providing a broad view of the disease progression and complications.

Most important findings

The study revealed several key findings that enhance the understanding of IA and IP in the context of Crohn’s disease. Firstly, the average age of patients with IA was lower than that of patients with IP, suggesting that IA may develop earlier in the disease course. Additionally, patients with IA were more likely to have perianal fistulas and intestinal strictures, which were significantly more prevalent compared to the control group. The development of intestinal stricture after diagnosis was strongly associated with both IA and IP, with patients showing a markedly higher risk for these complications if strictures were present. Disease behavior also played a role: patients with IP had a higher frequency of stricturing and penetrating disease (B2 and B3) compared to those with IA, indicating that more aggressive forms of Crohn’s disease were linked to IP.

Interestingly, both IA and IP patients had higher rates of disease progression during follow-up, though IA was more likely to develop later in the disease course. The study also pointed out the importance of timely diagnosis, as delays could worsen the severity of these complications.

Key implications

This study underscores the importance of identifying patients at high risk for developing IA and IP based on their disease phenotype, presence of strictures, and perianal fistulas. Early diagnosis and timely intervention could significantly reduce the risk of these severe complications. The findings suggest that while the mechanisms behind IA and IP may be similar, their clinical features differ enough to warrant distinct management strategies. Treatment options such as antibiotic therapy, drainage, and selective surgical resection may be necessary, particularly when these complications are not managed early. The study calls for further investigation into the underlying genetic and environmental factors that influence the development of IA and IP, as well as the potential role of biologics in preventing these complications.

What was studied?

This meta-analysis explored the prevalence and bidirectional association between autoimmune liver diseases (AILD) and inflammatory bowel disease (IBD). The study aimed to quantify how frequently IBD occurs among patients with AILD and vice versa. AILDs, including primary sclerosing cholangitis (PSC), autoimmune hepatitis (AIH), and primary biliary cirrhosis (PBC), are immune-mediated liver diseases. The research also investigated potential common mechanisms, such as the role of the gut-liver axis, which could contribute to the development of both conditions. By synthesizing data from 172 observational studies, the research sought to improve understanding of how these diseases influence each other and inform clinical management strategies.

Who was studied?

The study encompassed data from 172 observational studies, including a total of 1,550,966 participants. These participants were diagnosed with either IBD, AILD, or both. The data was collected from a wide range of geographic regions, and the studies involved patients from different demographic backgrounds, including various age groups and ethnicities. Specific focus was given to patients with Crohn’s disease (CD) and ulcerative colitis (UC), the two main types of IBD, as well as patients with different kinds of AILD, namely PSC, AIH, and PBC. The study examined how these diseases coexisted in patients, focusing on their prevalence in various groups.

Most important findings

The meta-analysis revealed a notable prevalence of IBD in AILD patients, with the highest rate observed in PSC patients. Approximately 32% of patients with AILD had IBD, with PSC being the most strongly associated with IBD, particularly UC. The prevalence of IBD in PSC patients was found to be significantly higher compared to other forms of AILD, suggesting that PSC might serve as a strong marker for IBD risk. Conversely, the study found that about 2.28% of patients with IBD also had AILD. Among IBD patients, PSC was the most common form of AILD, followed by autoimmune hepatitis and primary biliary cirrhosis, though these conditions were less prevalent. This bidirectional relationship suggests a complex interplay between the two conditions, with gut-liver interactions potentially driving the association. The study also found variations in these associations across different regions and demographics.

Key implications

The findings from this meta-analysis suggest that clinicians should be vigilant in monitoring patients with IBD for signs of AILD, particularly PSC, as it is highly prevalent among this group. The shared pathophysiological mechanisms between IBD and AILD, such as immune system dysregulation and microbial factors, warrant further exploration. For IBD patients, especially those with UC or extensive disease, regular liver function tests and screening for AILD should be part of routine care to enable early detection and improve management. Similarly, patients with AILD, particularly those with PSC, should undergo screening for IBD, as early detection can help prevent the progression of both conditions. The bidirectional nature of the relationship between these diseases calls for a multidisciplinary approach to treatment, with collaboration between gastroenterologists and hepatologists to optimize patient care.

What was studied?

This study aimed to explore the prevalence of iron deficiency anemia (IDA) among patients with Crohn’s disease (CD), using a large, USA-based cohort. The researchers investigated the association between IDA and various hospitalization outcomes, including length of stay, total charges, need for blood transfusions, and rates of readmission. By analyzing data from the Nationwide Readmissions Database (NRD), they sought to determine the burden of IDA in CD patients and its impact on disease management.

Who was studied?

The study analyzed 72,076 hospitalized CD patients aged 18 and older. Of these, 8.1% had a comorbid diagnosis of IDA, and the remaining patients were used as a comparison group. The patients included in the study had varying disease activity, and the data was adjusted to control for factors such as age, sex, disease complications, and comorbid conditions. The study also excluded patients with anemia of chronic disease (ACD), focusing on IDA as the key factor.

Most important findings

The study found that 8.1% of CD patients had IDA, a condition that was linked to worse hospitalization outcomes. Patients with IDA had a significantly longer length of stay (median of 4 days vs. 3 days in non-IDA patients), higher median hospitalization costs, and were more likely to require blood transfusions. Additionally, CD patients with IDA had increased rates of non-elective readmissions, both within 30 days and 90 days after discharge. The study also highlighted that IDA in CD patients was associated with a higher prevalence of gastrointestinal bleeding, fistulas, and abscesses, which are common complications of CD. However, IDA was not significantly associated with inpatient mortality after controlling for other variables. Multivariate regression analysis revealed that IDA increased the odds of readmission by 25% within 30 days and by 39% within 90 days.

Key implications

This study underscores the significant burden of IDA in patients with Crohn’s disease and its association with worse clinical outcomes, such as longer hospital stays, higher costs, and higher readmission rates. It emphasizes the need for early recognition and management of IDA in this patient population to improve hospitalization outcomes. The findings suggest that IDA is an underappreciated complication in CD, and routine screening for anemia should be integrated into clinical practice, particularly given its impact on quality of life and the increased risk of comorbid conditions such as gastrointestinal bleeding and fistula formation. Future research should focus on refining diagnostic approaches to differentiate IDA from anemia of chronic disease (ACD) in CD patients and on developing optimal management strategies, including more widespread use of parenteral iron supplementation.

What was studied?

This review investigates the association between pyoderma gangrenosum (PG) and inflammatory bowel disease (IBD), a rare but significant extraintestinal manifestation. The study covers epidemiology, clinical features, risk factors, and treatment responses of PG in patients with IBD. The article synthesizes data from 115 published case reports and series, focusing on the epidemiological features of PG in both adult and pediatric populations. It also evaluates therapeutic approaches, highlighting the growing use of biologics and the complex nature of treatment, which varies depending on the severity and individual patient response.

Who was studied?

The reviewed articles cover a range of patients with PG and IBD, with a focus on both adults and children. In adult populations, PG is often diagnosed in middle-aged patients, predominantly affecting females. The relationship between PG and IBD has been thoroughly investigated in cohort studies and case series. For children, IBD remains the most common comorbidity with PG, although reports suggest varying presentations based on comorbid conditions and the presence of other immune disorders. This review highlights the diversity in clinical manifestations of PG, with patients presenting at various stages of IBD, sometimes before, during, or after IBD diagnosis.

Most important findings

Recent large cohort studies reveal that the prevalence of PG is significantly higher in IBD patients compared to the general population. The review includes findings from diverse datasets, with IBD being diagnosed in 34% of PG patients. It highlights that PG is more common in patients with Crohn's disease (CD) than ulcerative colitis (UC). The clinical manifestations of PG are highly variable, but they most commonly involve ulcerative lesions that appear on the extremities, particularly below the knee. Treatment outcomes also show considerable variation, with most patients requiring systemic therapies like corticosteroids, immunosuppressants, or biologics. The review underscores the evolving therapeutic strategies, especially the increasing use of TNF-α inhibitors, reflecting efforts to target overlapping inflammatory pathways between PG and IBD.

Key implications

The study emphasizes the importance of recognizing PG as a significant clinical challenge in managing IBD patients, particularly due to its complex and varied clinical presentation. While biologics have become central to the treatment of PG, the individualized nature of therapy suggests that current approaches are still not standardized. The findings call for better diagnostic criteria and more controlled studies to establish definitive treatment protocols and to understand the underlying pathophysiological mechanisms linking PG to IBD. There is a critical need for multi-center, prospective studies that can overcome the limitations of the available data, such as reporting bias and small sample sizes, to help refine treatment strategies and improve patient outcomes.

What was studied?

This review explores the complex and dual roles of succinate in inflammatory bowel disease (IBD), emphasizing its involvement in the microbiota-metabolism-immune axis. Succinate, a metabolite produced both by host cells and gut microbiota, plays a significant role in IBD by influencing immune responses and metabolic pathways that drive disease progression or promote tissue repair. The review focuses on how succinate's effects are modulated by its concentration, which can either exacerbate inflammation or support healing processes in the gut.

Who was studied?

The review integrates findings from human clinical studies and preclinical models, including mice and pigs, to explore succinate's role in IBD. The focus is on the gut microbiota's influence on succinate production, the effect of succinate on immune cells such as macrophages and T cells, and how succinate's accumulation in the intestinal lumen correlates with disease activity in IBD patients. This research highlights the specific bacteria involved in succinate metabolism and the subsequent immune responses within the gut, particularly during active disease phases.

Most important findings

Succinate’s role in IBD is context-dependent, with evidence pointing to both pro-inflammatory and anti-inflammatory effects. Elevated succinate levels in IBD patients correlate with more severe disease, as succinate activates immune pathways that exacerbate inflammation. Succinate acts through its receptor, SUCNR1, triggering pro-inflammatory signaling pathways like Wnt/β-catenin and NF-κB, which contribute to intestinal barrier dysfunction, increased fibrosis, and immune cell activation. In contrast, at physiological concentrations, succinate supports tissue repair by promoting anti-inflammatory responses and enhancing epithelial barrier function. The review highlights how the balance between succinate-producing and succinate-consuming bacteria in the gut influences these outcomes. Dysbiosis in IBD patients, particularly the overgrowth of succinate-producing bacteria, contributes to increased succinate levels, exacerbating the disease.

Key implications

The findings suggest that succinate could be a target for therapeutic intervention in IBD. By regulating succinate levels or its signaling pathways, it may be possible to manage the immune responses that drive IBD. Therapies could involve targeting the gut microbiota to balance succinate production and consumption or developing SUCNR1 antagonists to block succinate’s pro-inflammatory effects. Additionally, monitoring succinate levels in patients could provide valuable diagnostic information, allowing for personalized treatment strategies that align with the specific metabolic and immune environment of each patient.

What was studied?

This article delves into the complex relationship between the NOD2 gene and its contribution to the pathogenesis of Crohn's disease (CD). The NOD2 gene, a crucial part of the immune response, has been extensively studied since its identification in 2001 as a major factor in CD. The review highlights how NOD2’s dysfunction leads to the disease through impaired bacterial clearance, resulting in chronic inflammation, altered immune responses, and fibrosis. Recent advances in genetic studies, including genome-wide association studies (GWAS) and next-generation sequencing (NGS), have provided deeper insights into the specific variations of NOD2 and their impacts on disease phenotypes, particularly the fibrostenotic subtype of CD.

Who was studied?

The review synthesizes findings from a wide range of patient populations across different geographical regions, including pediatric and adult patients with CD. Notably, studies involving genetic sequencing from cohorts in Europe, North America, and other diverse regions have been analyzed. The article also discusses studies on specific NOD2 mutations like R702W, G908R, and L1007fs, which are frequently studied in relation to CD. Additionally, the authors explore how these mutations contribute to the stricturing phenotype and disease complications such as fibrosis. This study also includes analyses of the genetic and phenotypic correlations observed in individuals with rare and common variants of NOD2.

Most important findings

The most critical finding of this review is the significant role of NOD2 in Crohn’s disease pathogenesis, particularly in its contribution to the stricturing phenotype. Variants of NOD2, such as R702W, G908R, and L1007fs, have been found to impair immune responses, particularly the response to bacterial stimuli. This leads to defective bacterial clearance, triggering inflammatory pathways that drive the disease. The article underscores that despite extensive research, many questions remain about how rare variants within the NOD2 gene contribute to disease. The review also addresses the challenges of associating rare variants with CD due to their low frequency and lack of functional testing. Additionally, the research emphasizes that while NOD2’s role in CD is well established, further investigation into how these variants interact with the microbiome is needed.

Key implications

The review highlights the potential for NOD2 to serve as a clinical tool for personalized medicine in CD. The identification of specific NOD2 mutations can aid in early disease prediction and stratification, particularly for patients at high risk of developing fibrosis. The possibility of using NOD2 as a biomarker for disease progression opens new avenues for targeted therapies aimed at preventing complications, such as stricturing and the need for surgery. However, the review also emphasizes the need for further research into the genetic heterogeneity of NOD2 and its interaction with the microbiome. Understanding how different NOD2 variants influence the immune system could lead to more precise treatments tailored to individual genetic profiles, enhancing clinical outcomes.

What was studied?

This review focuses on the environmental risk factors associated with the development of inflammatory bowel disease (IBD), specifically Crohn’s disease (CD) and ulcerative colitis (UC). It explores the complex interplay between environmental exposures, microbiome alterations, and immune responses that contribute to the onset and progression of IBD. The review synthesizes findings from various meta-analyses, highlighting modifiable risk factors such as smoking, diet, and early-life antibiotic use, while also discussing protective factors like breastfeeding and Mediterranean diets. It aims to provide a strategy for reducing IBD risk through environmental modifications and guides healthcare providers on preventing IBD through lifestyle changes.

Who was studied?

This review does not focus on a specific patient group but instead synthesizes data from multiple studies involving a wide range of populations across different age groups and ethnic backgrounds. It includes studies from both high-prevalence and newly industrialized regions, focusing on individuals who have been exposed to various environmental factors and assessing how these exposures influence the likelihood of developing CD and UC. The review also examines preclinical cohorts, including those at high genetic risk for IBD, to identify potential biomarkers and environmental factors that may trigger disease onset.

Most important findings

The review identifies several environmental factors that contribute to the pathogenesis of IBD. Smoking is a significant risk factor, especially for Crohn’s disease, and has been shown to worsen disease progression. In contrast, a Mediterranean diet rich in fiber, fruits, vegetables, and fish has a protective effect, potentially reducing inflammation and modulating the gut microbiome. Early life exposures, such as antibiotic use and breastfeeding, play crucial roles in shaping the gut microbiota, with breastfeeding being protective against IBD. The review highlights the Hygiene Hypothesis, which suggests that a lack of early exposure to microbes in sterile environments increases the risk of immune-mediated diseases like IBD. Lifestyle factors such as physical activity, stress management, and maintaining a healthy weight are associated with a lower risk of IBD.

Key implications

The findings suggest that modifiable environmental factors present an opportunity for preventive health strategies aimed at reducing the incidence of IBD. Healthcare providers can play a pivotal role in advising patients on lifestyle and dietary changes that can mitigate the risk of developing IBD. The review also stresses the importance of future research to develop high-quality interventional studies that can more definitively assess the effectiveness of environmental modifications in preventing IBD. Identifying biomarkers associated with ecological exposures will further help in targeting high-risk individuals for early interventions. In particular, the review calls for more comprehensive studies involving diverse populations to understand the varying effects of environmental factors on IBD risk across different regions and demographics.

What was studied?

The study investigates the prevalence of zinc deficiency in patients with Crohn's disease (CD), a form of inflammatory bowel disease (IBD). Zinc is an essential trace element involved in various physiological processes, including immune function and intestinal health. The study aimed to evaluate serum zinc levels in CD patients and compare them with healthy controls, considering factors like age, sex, and site of inflammation in relation to zinc deficiency. Given the importance of zinc in immune function and gut barrier integrity, the study also explored its potential role in the pathogenesis and exacerbation of CD.

Who was studied?

The study included 65 patients with confirmed CD, recruited from a cohort of patients attending clinics in Iran. These patients were compared with 65 healthy controls who had no gastrointestinal diseases, no recent use of dietary supplements, and no gastrointestinal symptoms such as diarrhea or vomiting. Both groups were matched for age and sex to ensure comparability, and their serum zinc levels were measured and analyzed. Data was collected on the patients' demographic factors, site of inflammation, and the presence of other comorbidities.

Most important findings

The study found that while the average serum zinc level in CD patients (88.1 ng/dL) was not significantly different from the control group (86.2 ng/dL), zinc deficiency was significantly more prevalent in CD patients. Specifically, 21.5% of CD patients had zinc deficiency compared to 7.7% in the control group (P=0.025). However, the difference in serum zinc levels between males and females, or across different age groups, was not statistically significant. The site of inflammation within the gastrointestinal tract (e.g., ileitis, colitis, ileocolitis) did not appear to affect zinc levels or deficiency rates. These findings suggest that while serum zinc levels were relatively similar between CD patients and healthy controls, CD patients exhibited a higher rate of zinc deficiency.

Key implications

The study's findings indicate that zinc deficiency is more common in CD patients than in healthy controls, highlighting the need for routine screening of zinc levels in this population. Zinc plays a crucial role in immune function and maintaining the intestinal barrier, and its deficiency could potentially contribute to disease exacerbation, malnutrition, and impaired immune responses in CD patients. Given the higher prevalence of zinc deficiency in CD, clinicians should consider zinc supplementation for patients with low serum zinc levels, especially since zinc deficiency can worsen IBD symptoms, delay recovery, and increase susceptibility to infections. Further studies are needed to better understand the long-term effects of zinc deficiency in CD and to explore whether zinc supplementation can improve disease outcomes.

What was studied?

This case–control observational study investigated the associations between peripheral blood cytokine profiles and gut microbiota composition in patients with Graves' disease (GD), the most common autoimmune thyroid disorder. The study aimed to elucidate the interplay between immune dysregulation—specifically changes in cytokines such as interleukin-10 (IL-10), transforming growth factor β (TGF-β), and interleukin-17A (IL-17A)—and alterations in gut microbial communities, potentially contributing to GD pathogenesis. These gut microbiome cytokine associations are pivotal to understanding Graves' disease better. The researchers performed comprehensive profiling using high-resolution 16S rRNA gene sequencing for fecal microbiota and multiplex cytokine arrays for serum immune markers, alongside standard thyroid function testing. The study also included in silico functional prediction of microbial metabolic pathways. Statistical analyses (including alpha and beta diversity, correlation, and discriminant analyses) were employed to identify microbial signatures associated with immune and thyroid dysfunction in GD.

Who was studied?

The study enrolled 30 consecutive, untreated Graves’ disease patients (primarily female, as per GD epidemiology) admitted to the Department of Endocrinology at the Third Affiliated Hospital of Qiqihar Medical University (China) between January and July 2023. Thirty age- and sex-matched healthy controls (HC) were recruited from individuals undergoing routine physical examination in the same period. Exclusion criteria included alternative causes of thyrotoxicosis, autoimmune comorbidities, recent antibiotic/probiotic or immunosuppressive use, pregnancy/lactation, and acute infections, ensuring a focused comparison of GD-specific changes. Both groups were matched for demographic variables, and comprehensive baseline data (age, sex, BMI) were collected.

Most important findings

The study revealed significant gut microbial dysbiosis in Graves’ disease, with lower overall microbial diversity and richness compared to healthy controls. At the phylum level, GD patients exhibited reduced Firmicutes and increased Bacteroidetes. Discriminative analysis identified 19 taxa with altered abundance, most notably: decreased Bifidobacterium and Veillonella (commensals) and increased Prevotella_9 and Megamonas (potential pathobionts). Importantly, cytokine-microbiota correlations showed that anti-inflammatory cytokines (IL-10, TGF-β) were positively associated with Bifidobacterium and Parasutterella, but negatively with Prevotella_9 and Megamonas.

Conversely, the pro-inflammatory cytokine IL-17A was positively correlated with Prevotella_9 and Megamonas and negatively with Bifidobacterium and Veillonella. Key thyroid function indices (TSH, FT3, FT4, TRAb) were also linked to specific bacterial genera, underscoring a multi-layered gut-immune-thyroid axis. Functional predictions indicated upregulation of energy and immune-related pathways in the GD microbiome, alongside downregulation of amino acid metabolism, membrane transport, and xenobiotic degradation.

Key implications

This study provides robust evidence that Graves’ disease is characterized by gut microbial dysbiosis, which is closely intertwined with immune imbalance and thyroid dysfunction. The identification of specific bacterial genera, such as increased Prevotella_9 and Megamonas (linked to pro-inflammatory cytokines and hyperthyroidism), and decreased Bifidobacterium and Veillonella (linked to anti-inflammatory cytokines and thyroid regulation), offers potential microbial biomarkers for GD diagnosis and monitoring. These findings suggest that modulating the gut microbiome or targeting the cytokine-microbiota axis could represent novel therapeutic strategies for GD. Additionally, the study highlights the need for further mechanistic and interventional research to clarify causality and therapeutic potential, as well as validation in larger and more diverse populations.

What was reviewed?

This narrative review collates pre‑clinical and clinical data on Graves’ disease (GD) pathogenesis and evaluates emerging “precision” therapeutics that intervene at discrete immune‑molecular checkpoints—CD20, CD40/CD40L, BAFF, neonatal Fc‑receptor, HLA‑DRβ1‑Arg74—or directly antagonise the thyrotropin receptor (TSHR) via monoclonal antibodies, small‑molecule inverse agonists or CAR‑T strategies. It also summarises complementary insights from genetics, epigenetics and the gut microbiome that refine present pathogenic models and inform candidate drug targets.

Who was reviewed?

The authors executed a PubMed search (no end‑date; English language only) for mechanistic and interventional studies, excluding case reports, letters and abstracts. Included material spans animal models, phase I–II trials, population genetics and multi‑centre microbiome consortia (e.g., INDIGO). Clinical data predominantly involve adult GD patients (with or without orbitopathy), whereas immunobiology derives from both human biospecimens and murine thyroiditis/GD models. Overall, the synthesis integrates evidence from several hundred individuals across Europe and Asia plus complementary in‑vivo platforms.

Most important findings

Immune escape hinges on TSHR‑stimulating antibodies driven by aberrant T‑ and B‑cell costimulation (CD40/CD40L) and BAFF‑mediated survival of autoreactive B cells. Genome‑wide and epigenetic studies highlight HLA‑DR, CTLA‑4, PTPN22 and FOXP3 variants, while single‑cell RNA‑seq reveals expanded memory B‑cell and CD16⁺ NK‑cell compartments. Importantly for microbiome signature databases, GD exhibits a reproducible dysbiosis: reduced α‑diversity and phylum‑level shifts summarised below.

Therapeutically, anti‑CD20 (rituximab) and anti‑CD40 (iscalimab) achieve biochemical remission in 40‑50 % of early GD, especially when baseline TRAb < 20 IU/L. FcRn blockade (batoclimab) rapidly de‑tiers TRAbs; TSHR‑blocking mAb K1‑70 and small molecules (ANTAG‑3, VA‑K‑14, S37) normalise thyroid hormones in murine models. Peptide apitope ATX‑GD‑59 restores tolerance in 50 % of mild GD, and TSHR‑CAR‑T selectively deletes TRAb‑producing B cells in vivo.

Key implications

Targeted immunomodulators promise durable euthyroidism without ablation or life‑long levothyroxine, and microbiome data suggest adjunctive avenues such as microbial metabolite supplementation or dysbiosis‑directed probiotics. Integration of host genetics, microbiota and antigen‑specific therapy could enable precision stratification, minimising exposure to broad immunosuppression and its respective risks.

Citation

Viola N, Colleo A, Casula M, Mura C, Boi F, Lanzolla G. Graves’ Disease: Is It Time for Targeted Therapy? A Narrative Review. Medicina. 2025; 61(3):500. https://doi.org/10.3390/medicina61030500

What was studied?

The review focuses on how gut microbiota influences intestinal inflammation, particularly in the context of diet and extrinsic stressors. The paper explores the interaction between microbiota dysbiosis and intestinal diseases such as inflammatory bowel disease (IBD). The authors examine the role of diet, antibiotics, sleep disturbance, physical activity, and environmental stressors like heat, cold, and pollutants in altering the gut microbiome, which could contribute to intestinal inflammation. Specifically, they address the microbial shifts that occur with these stressors and their potential to either promote or prevent inflammation in the gut.

Who was studied?

The paper highlights studies conducted in both animal models and human populations, providing insights into how changes in the gut microbiome are linked to diseases such as IBD. The studies primarily explore changes in the microbiota composition in response to dietary habits, extrinsic environmental factors, and physical or psychological stress. These factors were observed to influence the abundance of certain bacterial families and genera, such as Lactobacillus, Bifidobacterium, and Faecalibacterium, all of which play crucial roles in maintaining intestinal health. The findings offer valuable insights for clinicians working with IBD patients or those affected by dysbiosis due to external factors.

Most important findings

One of the most critical findings is the relationship between gut microbiota alterations and intestinal inflammation. The review reports that environmental and dietary stressors like high-fat diets and environmental pollutants can significantly alter the gut microbiota, promoting the growth of pro-inflammatory bacteria such as Enterobacteriaceae. The paper highlights the reduction in beneficial microbes like Lactobacillus and Faecalibacterium, which are known to produce anti-inflammatory metabolites like short-chain fatty acids (SCFAs). Furthermore, psychological stress was shown to exacerbate inflammation by reducing the proportion of beneficial bacteria and increasing the abundance of harmful microbes, which are associated with intestinal barrier dysfunction.

The paper discusses the beneficial effects of certain diets, such as the Mediterranean diet, on the gut microbiota composition. High fiber and prebiotic-rich foods were found to support the growth of beneficial bacteria, enhancing gut health and reducing inflammation. Conversely, western-style diets, rich in fats and sugars, were linked to higher levels of inflammatory bacteria, contributing to conditions like IBD.

Key implications

The findings underline the importance of addressing diet and extrinsic stressors when managing patients with intestinal inflammation or IBD. Clinicians should consider dietary interventions, such as increasing fiber intake and incorporating probiotic-rich foods, to help modulate the gut microbiota in favor of reducing inflammation. The review also suggests that managing stress and reducing exposure to harmful environmental factors, such as pollutants, can play a role in improving gut health. Probiotic treatments might also be a promising strategy to restore gut balance and prevent the progression of IBD. Further studies are necessary to fully understand the direct mechanisms linking stress, diet, and microbiota alterations to inflammation, especially in clinical settings.

What was studied?

This review article explores the extraintestinal manifestations (EIMs) associated with inflammatory bowel disease (IBD), particularly focusing on Crohn's disease (CD) and ulcerative colitis (UC). It discusses the prevalence, pathophysiology, and various manifestations that affect organs and systems outside the gastrointestinal tract, such as dermatological, ophthalmological, musculoskeletal, hepatobiliary, and other organ systems. It also touches on potential causal mechanisms and associations with IBD treatments.

Who was studied?

The study primarily focuses on a wide range of patients with IBD, drawing data from both adult and pediatric populations. The article highlights findings from pediatric centers where IBD's extraintestinal manifestations are reported to be more prevalent compared to general adult populations. Additionally, it emphasizes the associations of EIMs with underlying IBD disease, genetic factors (such as HLA phenotypes), and the treatments used, such as immunosuppressive and biologic therapies.

Most important findings

The article reveals that EIMs of IBD can involve nearly every organ system, with the skin, eyes, joints, and hepatobiliary system being among the most commonly affected. Dermatological manifestations such as erythema nodosum and pyoderma gangrenosum are particularly prevalent in patients with CD. These skin conditions often correlate with the activity of the underlying disease, indicating a shared immune-mediated pathophysiology. Musculoskeletal issues, particularly peripheral arthritis and axial arthropathy (ankylosing spondylitis and sacroiliitis), are also common and significantly impact the quality of life of IBD patients. Additionally, hepatobiliary manifestations like primary sclerosing cholangitis (PSC) are more frequently observed in patients with UC, while non-alcoholic fatty liver disease (NAFLD) and other liver-related complications are common in CD.

The pathogenesis of these manifestations is complex and involves immune system dysregulation, bacterial factors, genetic predispositions, and the impact of IBD treatments. Recent studies in animal models highlight the importance of gut microbiota in the expression of EIMs, particularly in genetically predisposed individuals. Moreover, the role of medications, especially corticosteroids and immunosuppressants, in triggering or exacerbating EIMs has been observed in some patients.

Key implications

Understanding the broad spectrum of extraintestinal manifestations in IBD is crucial for clinicians, as EIMs often present before the onset of gastrointestinal symptoms, complicating the diagnosis. Recognizing these manifestations early can lead to more timely interventions and prevent long-term complications. For pediatric patients, the prevalence of EIMs is notably higher, emphasizing the need for careful monitoring across different age groups. Additionally, since some manifestations, like pyoderma gangrenosum and uveitis, can occur independent of IBD activity, they may require separate therapeutic strategies, which could include immunosuppressive or biologic treatments.

What was studied?

This study examined how a low-nickel diet influences persistent gastrointestinal and extraintestinal symptoms in celiac patients who remain symptomatic despite full serologic and histologic remission on a gluten-free diet. Because a gluten-free diet often increases dietary nickel exposure—especially from foods like corn—the investigators explored whether nickel allergic contact mucositis (ACM) contributes to symptom relapse in patients who would otherwise be considered to have non-responsive celiac disease. Nickel sensitivity was evaluated using an oral mucosa patch test, and symptom changes were assessed through a modified Gastrointestinal Symptom Rating Scale.

Who was studied?

A total of 102 adults with celiac disease adhering to a strict gluten-free diet for at least 12 months were screened. After excluding individuals with lactose intolerance, Helicobacter pylori infection, inflammatory bowel disease, cancer, or insufficient symptom severity, 20 women aged 23–65 completed the study. All participants were in confirmed serologic and histologic remission yet reported relapsing gastrointestinal or systemic symptoms. Each underwent nickel oral mucosa patch testing and subsequently followed a low-nickel diet for three months in addition to their gluten-free diet.

Most important findings

The study revealed consistent nickel sensitivity among the final cohort: all 20 participants exhibited positive findings on the oral mucosa patch test, indicating nickel ACM. Symptomatic patterns showed three distinct phases. Symptoms initially improved with gluten withdrawal but then recurred during prolonged gluten-free eating, suggesting increasing dietary nickel load from nickel-rich gluten-free staples. After initiation of the low-nickel regimen, patients experienced marked improvement across both gastrointestinal and systemic symptoms. The trend was evident in symptom trajectory graphs, where nickel-related symptoms such as bloating, loose stools, dermatitis, headache, and fatigue demonstrated a clear rise during prolonged gluten-free eating and an equally clear drop after nickel restriction. Table 1 summarizes symptom directionality, showing more than 80% of symptoms improving after the diet change.

Key implications

This study highlights nickel ACM as an underrecognized contributor to persistent symptoms in celiac patients on long-term gluten-free diets. Since many gluten-free foods are naturally high in nickel, dietary nickel exposure becomes a potential trigger for IBS-like and systemic manifestations. The findings support incorporating nickel sensitivity evaluation into the workup for non-responsive celiac disease once gluten exposure and villous damage are excluded. Clinically, a structured low-nickel diet may reduce symptoms substantially and prevent misclassification of nickel sensitivity as refractory celiac disease or unexplained IBS-like relapse. The work also underscores broader dietary-microbial interactions: nickel-sensitive mucosal inflammation likely alters microbial ecology, contributing to symptom generation and emphasizing the relevance of nickel-associated microbial signatures in clinical microbiome frameworks.

Citation

Borghini R, De Amicis N, Bella A, Greco N, Donato G, Picarelli A. Beneficial effects of a low-nickel diet on relapsing IBS-like and extraintestinal symptoms of celiac patients during a proper gluten-free diet: Nickel allergic contact mucositis in suspected non-responsive celiac disease. Nutrients. 2020;12(8):2277. nutrients-12-02277

What was studied?

This paper focuses on nutritional status and its detection in patients with inflammatory bowel diseases (IBD), specifically Crohn’s disease (CD) and ulcerative colitis (UC). It explores the mechanisms leading to malnutrition in IBD, including altered digestion, malabsorption, and drug-nutrient interactions. The study also evaluates various screening tools used to assess the nutritional risk in these patients.

Who was studied?

The study involved patients diagnosed with IBD, including both those with active disease and those in remission. These patients face a higher risk of malnutrition, often due to disease-related complications like malabsorption, diarrhea, and changes in appetite. The review also looks into the impact of disease activity on nutritional status, with a focus on IBD-related nutrient deficiencies, including deficiencies in vitamins like B12 and D, as well as minerals such as iron, zinc, and magnesium.

Most important findings

The review highlights several crucial findings regarding malnutrition in IBD patients. It emphasizes the importance of regular nutritional screening, particularly using tools like the Saskatchewan Inflammatory Bowel Disease–Nutrition Risk Tool (SaskIBD-NR Tool) and the IBD-specific Nutritional Screening Tool (IBD-NST). These tools are useful for identifying nutritional risk before the onset of severe malnutrition. Nutrient deficiencies, particularly in vitamin B12, folate, iron, and zinc, were found to be prevalent in IBD patients, with CD patients being more vulnerable to deficiencies like vitamin B12 due to the common ileocecal location of the disease. Additionally, the use of anti-TNFα therapy, such as infliximab, was shown to improve nutritional status in IBD patients, with better outcomes observed when nutritional status was optimized before therapy.

Key implications

The findings of this study have important implications for both clinical practice and research. For clinicians, this paper underscores the need for routine and specific nutritional screenings in IBD patients to identify those at risk of malnutrition early, allowing for timely interventions. It also points out the significance of dietary and pharmacological interventions, such as the use of anti-TNFα therapy, in improving nutritional outcomes. For researchers, the study calls for further validation of IBD-specific nutritional screening tools and the exploration of the relationship between nutritional status and disease outcomes, particularly in the context of surgery and long-term disease management.

What was reviewed?

This narrative literature review comprehensively examines the roles of trace elements—including iron (Fe), copper (Cu), cobalt (Co), iodine (I), manganese (Mn), zinc (Zn), silver (Ag), cadmium (Cd), mercury (Hg), lead (Pb), and selenium (Se)—in thyroid physiology, hormone synthesis, and the pathogenesis of thyroid diseases. The review details the molecular mechanisms by which these elements affect thyroid hormone biosynthesis, metabolism, immune function, and oxidative stress within the thyroid gland. It further explores how imbalances in these elements contribute to the development and progression of various thyroid disorders, including Graves’ disease, Hashimoto’s thyroiditis, hypothyroidism, autoimmune thyroiditis, thyroid nodules, thyroid cancer, and postpartum thyroiditis. Special attention is given to the dual role of certain elements as both essential micronutrients and potential endocrine disruptors, and to their emerging roles as therapeutic targets or biomarkers.

Who was reviewed?

This review synthesizes findings from a wide range of studies involving diverse populations—adults and children, both healthy and with thyroid disease, from various geographic regions (including iodine-deficient and iodine-sufficient areas). It includes research on different subgroups such as pregnant women, patients with autoimmune thyroid diseases, those exposed to occupational or environmental heavy metals, and individuals undergoing specific thyroid treatments. Evidence is drawn from human epidemiological studies, clinical trials, animal experiments, and cellular/molecular investigations.

Most important findings

The review highlights that optimal concentrations of Fe, I, Cu, Zn, and Se are critical for healthy thyroid hormone synthesis and metabolism. Deficiencies in Fe, Zn, Se, or I, or toxic exposures to Cd, Hg, and Pb, disrupt thyroid hormone production, immune tolerance, and redox balance, predisposing individuals to hypothyroidism, autoimmune thyroiditis, and thyroid cancer. For example, Fe is essential for thyroperoxidase activity; Cu and Zn are components of antioxidant enzymes; Se is vital for deiodinase function; while both deficiency and excess I impact hormone synthesis through mechanisms such as the Wolff–Chaikoff effect. Heavy metals (Cd, Hg, Pb) promote oxidative stress, immune dysregulation, and oncogenic transformation. The review also notes gender-specific and age-dependent differences in trace element effects, and complex interactions between environmental exposure, genetic susceptibility, and thyroid disease risk. Recent research into ferroptosis and cuproptosis (forms of metal-dependent cell death) suggests potential for novel biomarkers and therapeutic strategies in thyroid cancers.

Key microbial and microbiome associations:

While the review centers on trace elements, it references the gut microbiome’s role in thyroid autoimmunity, especially its impact on trace element absorption (notably Fe and Se) and immune modulation. Dysbiosis may impair micronutrient status, influencing the risk and severity of autoimmune thyroid diseases. This emerging connection between trace element metabolism, the gut microbiome, and thyroid autoimmunity is a promising area for further investigation and may be relevant for microbiome signature databases.

Key implications

Clinical management of thyroid disorders should consider patients’ trace element status, exposure to environmental toxins, and dietary habits. Screening and correcting micronutrient deficiencies (Fe, Zn, Se, I) can help prevent or ameliorate thyroid dysfunction, while minimizing exposure to toxic metals (Cd, Hg, Pb) is crucial for thyroid health. Personalized approaches, considering genetic and microbiome influences, may optimize prevention and treatment. Some trace elements (Se, Fe, Cu) and related molecular pathways (ferroptosis, cuproptosis) hold promise as therapeutic targets or diagnostic/prognostic biomarkers in thyroid cancer and autoimmunity. Integration of trace element assessment into clinical and public health practice, alongside continued research into their interplay with the microbiome, could significantly improve thyroid disease outcomes.

What was studied?

This study examines the relationship between zinc (Zn) and copper (Cu) concentrations, particularly the Cu/Zn ratio, and markers of disease activity in patients with inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). Zinc and copper are trace elements essential for immune function and antioxidant processes. The study explores how these elements, along with the Cu/Zn ratio, correlate with clinical markers of inflammation, such as C-reactive protein (CRP) and fecal calprotectin (FC), in patients with active IBD. This correlation could provide insights into the potential role of these trace elements in disease progression and activity.

Who was studied?

The study involved 154 IBD patients (98 with CD and 56 with UC), who were recruited from a gastroenterology department in Basel, Switzerland. Participants were in various stages of disease activity, with a majority of CD patients in clinical remission. Disease activity was assessed using the Harvey–Bradshaw Index (HBI) for CD and the Modified Truelove and Witts Severity Index (MTWSI) for UC. The patients' zinc and copper levels were measured alongside inflammatory markers (CRP and FC), and their relationship was analyzed through multiple linear regression models, adjusting for confounding factors like age and gender.

Most important findings

The study found that zinc insufficiency was present in 11.2% of CD patients and 14.3% of UC patients. Copper insufficiency was observed in 20.4% of CD patients and 7.1% of UC patients. Zinc deficiency in IBD patients was associated with anemia, hypoalbuminemia, and elevated levels of both CRP and FC, indicating an active inflammatory state. On the other hand, copper deficiency was linked to lower CRP values and a trend toward lower FC in both CD and UC patients. The key finding was that the Cu/Zn ratio correlated significantly with disease activity markers: the Cu/Zn ratio was positively associated with CRP levels in both CD and UC patients, and with FC levels specifically in UC patients. The study also found that adjusting for serum albumin did not significantly affect the correlation between Cu/Zn ratio and CRP, suggesting that the Cu/Zn ratio could be a reliable marker for systemic inflammation in IBD patients.

Key implications

These findings suggest that the Cu/Zn ratio may serve as a novel biomarker for assessing disease activity in IBD patients. The significant correlation between the Cu/Zn ratio and inflammatory markers like CRP and FC points to the potential utility of this ratio in clinical settings, offering a non-invasive way to monitor disease progression. Given the elevated Cu/Zn ratio observed in active disease states, monitoring these trace elements could improve the management of IBD, allowing for better-informed treatment decisions, particularly in cases where traditional markers of inflammation may not provide a full picture. Additionally, the study highlights the importance of addressing micronutrient deficiencies in IBD patients, as deficiencies in zinc and copper may contribute to disease severity and complications. Further prospective studies are needed to validate the Cu/Zn ratio as a diagnostic and prognostic tool in IBD, and to explore the potential benefits of zinc and copper supplementation as part of IBD management.

What was studied?

The study explores the use of hyperbaric oxygen therapy (HBOT) as an adjunctive treatment for perianal fistulas in patients with Crohn’s disease (CD). The primary objective was to assess the efficacy of HBOT combined with conventional therapies in reducing fistula activity, as well as to evaluate its impact on disease activity indices and biomarkers. The effects were assessed through various parameters, including the Crohn’s Disease Activity Index (CDAI), Simple Endoscopic Score for Crohn’s Disease (SES-CD), Perianal Crohn’s Disease Activity Index (PDAI), and laboratory tests like faecal calprotectin and CRP levels.

Who was studied?

The study enrolled 11 patients diagnosed with Crohn’s disease and active perianal fistulas. These patients had a minimum disease duration of three years and had a history of recurrent disease episodes and fistula activity. All participants underwent conventional therapies, including immunosuppressive treatments, biological drugs (in some cases), and surgery for fistula management. Hyperbaric oxygen therapy was introduced as a supplementary treatment, with participants receiving 30 sessions over six weeks. The cohort consisted of a small group of patients, aged around 30 years, with a mix of male and female participants.

Most important findings

The study found that HBOT, when combined with conventional therapies, resulted in substantial clinical improvements. The CDAI scores showed an 81.8% improvement in disease activity. Fistula healing, as assessed by the PDAI, showed a 54.5% remission rate, with patients showing marked reduction in fistula activity. The clinical effects were sustained over a 9-month follow-up period, with significant improvements in endoscopic scores (SES-CD) and faecal calprotectin levels. These findings suggest that HBOT contributes not only to reducing fistula activity but also to overall disease management in Crohn’s disease patients.

Key implications

This study highlights the potential of HBOT as a therapeutic adjunct for patients with Crohn’s disease complicated by perianal fistulas. The findings suggest that HBOT may offer a new treatment option, especially for those with recurrent fistula activity unresponsive to conventional treatments. Moreover, the combination of HBOT with biologic therapies may enhance therapeutic outcomes, though larger studies are needed to confirm these results and establish optimal treatment regimens. The significant improvements in disease markers such as faecal calprotectin and CRP suggest that HBOT may also play a role in modulating inflammation and supporting mucosal healing.

What was studied?

This study investigated the alterations in gut microbiota composition and function in patients with Graves’ disease (GD) and Hashimoto’s thyroiditis (HT), the two most common forms of autoimmune thyroid disease (AITD). The authors collected fecal samples from patients with GD, HT, and healthy controls, analyzing the gut microbial communities through 16S rRNA sequencing. Thyroid function and autoantibody levels were measured to confirm disease status. Furthermore, the study employed advanced bioinformatics analyses, including LEfSe (Linear Discriminant Analysis Effect Size), random forest modeling, and functional pathway predictions using KEGG (Kyoto Encyclopedia of Genes and Genomes) and COG (Clusters of Orthologous Groups) databases. The primary aim was to identify specific microbial taxa and metabolic pathways associated with GD and HT, and to explore whether common microbial or metabolic signatures could differentiate patients from healthy individuals. The authors also sought to uncover functional shifts in gut microbial metabolism potentially relevant to AITD pathogenesis.

Who was studied?

The study enrolled 70 Han Chinese adults from northeast China: 27 patients with GD, 27 patients with HT, and 16 healthy controls. All patients were newly diagnosed, had not received anti-thyroid or hormone replacement therapy, and were free from other autoimmune diseases, recent antibiotic or probiotic use, metabolic disorders, and significant surgeries affecting the gastrointestinal tract. The control group had normal thyroid function and negative thyroid antibodies. All participants underwent standardized clinical, laboratory, and microbiological assessments. The strict inclusion and exclusion criteria ensured minimal confounding from comorbidities or medication use, and the cohort represents a relatively homogenous ethnic and geographic background, enhancing internal validity though potentially limiting generalizability.

Most important findings

The study revealed that although the overall abundance and diversity of gut microbiota were similar between GD, HT, and healthy controls, the structure and composition of the microbial communities were markedly different in patients with autoimmune thyroid disease. Notably, HT patients had the highest levels of Proteobacteria and Actinobacteria, with these phyla also elevated in GD compared to controls. Both GD and HT groups exhibited increased levels of Erysipelotrichia, Cyanobacteria, and Ruminococcus_2, while Bacillaceae and Megamonas were depleted relative to controls. At the genus level, Prevotella_9, Ruminococcus_2, and Lachnospiraceae_NK4A136_group were elevated in GD, and Enterococcus was elevated in HT, while Megamonas was more abundant in healthy individuals. Random forest analysis identified Bacillus, Blautia, and Ornithinimicrobium as potential biomarkers for distinguishing GD and HT from healthy controls, with high discriminative accuracy (AUC up to 1). Functional prediction analyses indicated that the “ABC transporter” metabolic pathway—a key system for ATP-dependent substrate transport—was enriched in both disease groups, suggesting its involvement in disease pathogenesis. GD and HT patients also showed greater microbial enrichment in carbohydrate transport/metabolism and a reduction in amino acid transport/metabolism. Furthermore, unique and shared bacterial taxa were linked to metabolic pathways such as glutathione, arachidonic acid, purine, and pyrimidine metabolism, implicating these pathways in the autoimmune process.

Key implications

This study provides evidence that patients with GD and HT share a common dysbiotic gut microbiome signature and functional metabolic alterations, particularly involving the ABC transporter pathway and several key bacterial taxa. These findings suggest that gut microbiome changes may contribute to the pathogenesis of AITD through disruption of specific microbial communities and metabolic pathways. Identification of Bacillus, Blautia, and Ornithinimicrobium as potential diagnostic biomarkers could facilitate early detection or risk stratification of AITD based on stool microbiome analysis. The enrichment of the ABC transporter pathway points to potential mechanistic links between gut microbiota metabolism and thyroid autoimmunity and may offer new therapeutic targets. The results support the concept of a “thyroid-gut axis,” where microbial and metabolic profiles are intimately associated with thyroid autoimmunity. However, the study’s limitations, including its single-center design and ethnically/geographically homogenous cohort, highlight the need for larger, diverse, and mechanistic studies to confirm and expand upon these findings.

What was studied?

The study explored the environmental influences on the onset and clinical course of Crohn’s disease (CD), focusing on factors such as childhood hygiene, lifestyle choices, diet, air pollution, smoking, breastfeeding, and seasonal variation. The authors provided a comprehensive overview of how these environmental factors may either exacerbate or contribute to the onset of CD. In particular, they highlighted that changes in childhood hygiene, such as urban upbringing and access to sanitary conditions, might play a role in disease development. At the same time, smoking and diet were identified as significant environmental risk factors. The study also aimed to establish the link between early life factors, such as breastfeeding and appendectomy, and the risk of developing CD.

Who was studied?

The study reviewed a wide range of epidemiological data and prior studies on the environmental factors contributing to the development and course of Crohn’s disease. It focused on populations from various geographic locations, highlighting the rising incidence of CD in industrialized countries and examining childhood hygiene, air pollution, and lifestyle factors such as smoking and diet. The review also explored the impact of breastfeeding, air pollution, and appendectomy, looking at both retrospective and prospective data from case-control and cohort studies. It did not focus on specific patient groups but instead aggregated findings from multiple studies to determine common environmental risk factors.

Most important findings

The following table summarizes the key findings related to the environmental risk factors for Crohn’s disease:

Key implications

The findings suggest that environmental factors, particularly smoking, diet, and potentially air pollution, play a significant role in both the onset and clinical course of Crohn’s disease. The review emphasized that smoking cessation should be a priority for patients with CD to reduce relapses and complications. Additionally, while dietary interventions could be beneficial, more research is needed to establish firm dietary recommendations. The role of breastfeeding in preventing CD requires further investigation, as the protective effects observed in some studies were not consistent. Overall, understanding these environmental risk factors can help clinicians provide more personalized care and interventions, particularly in preventing disease onset and managing disease flares.

What was studied?

This review article investigates the links between psoriasis and inflammatory bowel disease (IBD), including the genetic, immunological, and environmental factors that contribute to the co-occurrence of these conditions. It highlights shared risk factors, including genetic susceptibility loci, immune dysregulation, and microbiota alterations, that drive the pathogenesis of both diseases. Furthermore, the review provides a comprehensive look at the similarities in the immune mechanisms underlying psoriasis and IBD, especially focusing on the IL-23/Th17 immune pathway, which is central to the inflammatory process in both diseases. The study also explores the pharmacological treatments commonly used to manage psoriasis and IBD, discussing the overlap and specificities of treatment regimens.

Who was studied?

The article synthesizes research from various studies on individuals with psoriasis and IBD. It incorporates findings from both human studies and animal models. Patients with psoriasis and those with Crohn’s disease (CD) and ulcerative colitis (UC), the two primary forms of IBD, are the central focus. The review discusses the genetic overlap between these diseases, emphasizing the role of specific genetic loci (e.g., PSORS1 for psoriasis and IL-23R for IBD) that predispose individuals to both conditions. The article also examines the role of the gut microbiome and immune system, with particular attention to inflammatory mediators, immune cells such as T-cells, macrophages, and dendritic cells, and their involvement in the pathogenesis of both psoriasis and IBD.

Most important findings

One of the most important findings from this review is the genetic overlap between psoriasis and IBD, particularly the shared susceptibility loci, such as the PSORS1 locus for psoriasis and IL-23R for IBD. The presence of these shared genetic markers suggests a common genetic pathway that predisposes individuals to both conditions. The review also highlights the significant role of the immune system, particularly the IL-23/Th17 axis, in driving inflammation in both psoriasis and IBD. This immune pathway leads to the activation of T-cells and the production of proinflammatory cytokines, such as IL-17, which contribute to the inflammatory processes in both diseases.

Additionally, the article points out that microbiota dysbiosis plays a crucial role in the pathogenesis of both psoriasis and IBD. In both conditions, there is a shift in the microbial composition, with a reduction in anti-inflammatory bacteria and an increase in proinflammatory microbes. This imbalance exacerbates the inflammatory response and further contributes to disease progression. In terms of treatment, the review reveals that therapies targeting IL-17, such as secukinumab, have shown efficacy in psoriasis but are less effective in IBD, suggesting disease-specific differences in immune responses despite shared pathways.

Key implications

The implications of these findings are significant for both the management and treatment of psoriasis and IBD. Understanding the shared genetic and immune pathways between the two diseases opens the door for more targeted, personalized therapies that address both skin and gut inflammation simultaneously. The identification of the IL-23/Th17 axis as a central player in disease progression suggests that immunomodulatory treatments targeting this pathway could be beneficial in treating both psoriasis and IBD, though the differential response of these diseases to certain treatments, such as anti-IL-17 therapy, requires consideration of disease-specific factors.

What was reviewed?

This narrative review synthesises more than three decades of genetic investigations into Graves’ disease (GD), spanning early candidate‑gene work through contemporary genome‑wide association studies (GWAS). It catalogues >80 susceptibility loci, detailing how immune‑regulatory (e.g., HLA‑DRB1, CTLA4, PTPN22) and thyroid‑specific (TSHR, TG) variants contribute to disease risk and phenotypic diversity. The authors chronologically trace methodological advances—from linkage analyses to large, multi‑ethnic GWAS—highlighting how each step refined our understanding of GD heritability (estimated at 60–80%) and polygenic architecture.

Who was reviewed?

The review aggregates evidence from over 30 000 individuals of European ancestry (Icelandic/UK) and nearly 10 000 East‑Asian participants (Chinese, Japanese, Korean), in addition to smaller Indonesian, Turkish and other cohorts. It contrasts allele frequencies, effect sizes and population‑specific signals (e.g., PTPN22*620W absent in Asians), thereby underscoring genetic heterogeneity and the importance of ancestry‑tailored risk models.

Most important findings

Across populations, the largest effects arise from HLA class II, CTLA4, TSHR and PTPN22, yet most variants confer modest odds ratios (~1.1). Notably, low‑frequency variants in FLT3 and ADCY7 exhibit larger effects (~1.5) and elevate circulating FLT3‑ligand, linking haematopoietic signalling to autoimmunity. The bubble plot on page 4 visually ranks the top 10 loci by odds ratio versus allele frequency, illustrating the inverse relationship between variant rarity and statistical power. Clinically oriented sections dissect genotype–phenotype links: specific CTLA4, HLA and TSHR alleles predict younger onset, larger goitres and higher thyroid‑stimulating antibody titres, while HLA‑B38:02/DRB108:03 mark risk for antithyroid‑drug‑induced agranulocytosis. Although the paper does not directly explore the thyroid microbiome, it foregrounds immune pathways (e.g., T‑cell co‑stimulation, B‑cell activation) that also mediate host–microbe cross‑talk, making these loci prime candidates for future microbiome–genome interaction studies and inclusion in microbiome signature databases.

Key implications

Elucidation of GD’s complex genetic landscape advances precision endocrinology: incorporating genotypes into the “GREAT+” score refines relapse prediction after antithyroid therapy, and CD40/HLA haplotypes may stratify responders to emerging biologics. Integrating genetic risk with environmental modifiers (stress, iodine, smoking) and, prospectively, thyroid‑resident microbiota could enable holistic risk stratification, personalised monitoring and targeted immunomodulation.

What was studied?

This study investigates the relationship between fecal bile acid composition and inflammatory bowel disease (IBD), particularly focusing on ulcerative colitis (UC) and Crohn’s disease (CD). Researchers sought to identify specific bile acid species that are altered in active disease and whether these alterations correlate with markers of disease severity such as fecal calprotectin and C-reactive protein (CRP). The aim was to explore if bile acid profiles could serve as potential biomarkers for distinguishing between IBD subtypes and assessing disease activity.

Who was studied?

The study included 62 patients with IBD (38 with CD and 24 with UC) and 17 healthy controls. The IBD patients were assessed based on clinical diagnosis and disease activity, with markers such as fecal calprotectin and CRP used to measure inflammation. Stool samples were collected from all participants, and the bile acid composition was analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Most important findings

The study found that IBD patients exhibited significant alterations in fecal bile acid composition compared to healthy controls. Notably, UC patients had lower levels of secondary bile acids, such as deoxycholic acid (DCA) and lithocholic acid (LCA), and a higher proportion of primary bile acids like cholic acid (CA) and chenodeoxycholic acid (CDCA). In contrast, CD patients showed increased levels of secondary bile acids. Specifically, UC patients had a decreased ratio of secondary to primary bile acids compared to controls, suggesting impaired bile acid metabolism. In UC, a negative correlation was observed between the levels of certain bile acids (such as hyodeoxycholic acid and glycolithocholic acid) and fecal calprotectin, a marker of mucosal inflammation. However, in CD patients, bile acid levels did not correlate with inflammation markers. The study also identified that bile acid composition could potentially distinguish between UC and CD, with specific bile acids like GHDCA and GCDCA showing diagnostic potential for UC.

Key implications

The altered fecal bile acid composition in IBD patients, particularly UC, offers insight into the underlying metabolic disturbances associated with disease activity. This finding highlights the potential of bile acids as non-invasive biomarkers for IBD, specifically for distinguishing between UC and CD. The correlation between bile acid levels and disease markers like fecal calprotectin suggests that bile acid profiles could also serve to monitor disease activity and assess treatment responses, particularly in UC. Further studies are needed to confirm the clinical validity of these biomarkers and to explore their therapeutic potential, such as modulating bile acid metabolism to improve disease outcomes. Additionally, these findings could contribute to the development of personalized treatment strategies based on bile acid profiles.

What was studied?

This original research article conducted a comparative assessment of the gut microbial composition and predicted metabolic function in patients with Graves’ disease (GD) and Graves’ orbitopathy (GO), as well as healthy controls. Using 16S rRNA gene sequencing, the authors aimed to identify specific intestinal bacterial taxa and functional signatures associated with GD and GO, in order to better understand the microbiome-related differences between these two clinical phenotypes. The study also explored whether gut microbial features could provide markers to distinguish GO from GD in clinical practice, and how these microbial alterations might relate to disease pathophysiology, particularly autoimmunity.

Who was studied?

The study population consisted of 30 patients with Graves’ disease (GD) without orbitopathy, 33 patients with Graves’ orbitopathy (GO), and 32 healthy control subjects, all recruited from the outpatient department of Beijing Tongren Hospital, Capital Medical University. The three groups were matched for age and sex, and strict inclusion and exclusion criteria were applied, such as age (18-65 years), no recent use of antibiotics, probiotics, hormonal medications, or Chinese herbal medicine, and absence of chronic gastrointestinal disorders, systemic diseases, or other autoimmune conditions. Both GD and GO patients had normalized thyroid hormone levels at the time of sampling, minimizing confounding effects of thyroid dysfunction. GO was diagnosed according to EUGOGO guidelines, and all participants provided informed consent.

Most important findings

The gut microbiota of GD and GO patients showed significant alterations in comparison to healthy controls, with notable differences between the GD and GO groups themselves. Alpha diversity (Shannon index) was significantly reduced in both GD and GO patients relative to controls, indicating lower microbial diversity. At the phylum level, GO patients had a significant decrease in Deinococcus-Thermus and Chloroflexi compared to GD patients. Genus-level analysis revealed that Subdoligranulum and Bilophila were increased, while Blautia, Anaerostipes, Dorea, Butyricicoccus, Romboutsia, Fusicatenibacter, unidentified_Lachnospiraceae, unidentified_Clostridiales, Collinsella, Intestinibacter, and Phascolarctobacterium were decreased in GO relative to GD. Additionally, Prevotella copri was enriched in both GD and GO groups compared to controls.

Random forest modeling identified Deinococcus-Thermus, Cyanobacteria, and Chloroflexi as among the top taxa distinguishing between the groups. Importantly, several microbial taxa—including Subdoligranulum and Lachnospiraceae—showed strong associations with serum thyrotropin receptor antibody (TRAb) levels, a key marker of thyroid autoimmunity, even after adjusting for age and sex. Functional predictions (via KEGG pathways) indicated enhanced nucleotide metabolism, energy metabolism, and enzyme family pathways in GD and GO, with viral protein family enrichment specifically in GD.

Key implications

These findings underscore that distinct gut microbiome signatures characterize GD and GO, supporting the hypothesis that gut dysbiosis may contribute to the development and progression of Graves’ orbitopathy in GD patients. The microbial taxa identified—especially the reduction of butyrate-producing and anti-inflammatory bacteria such as Lachnospiraceae and Blautia in GO—suggest mechanisms linking the microbiome to immune activation and orbital inflammation. The robust association of specific microbes with TRAb levels further highlights the potential of gut microbial markers as adjuncts in diagnosis, risk stratification, or even as therapeutic targets for GO. Functional pathway enrichment, notably in nucleotide and energy metabolism, hints at altered host-microbe metabolic interactions in these autoimmune thyroid conditions. However, larger multicenter studies and mechanistic investigations are needed to confirm causality and clinical utility.

What was studied?

This original research article investigated the differences in gut microbial composition and predicted microbial metabolic functions between patients with Graves’ disease (GD), those with Graves’ orbitopathy (GO), and healthy controls. Using 16S rRNA gene sequencing, the study sought to identify specific gut microbiota signatures and metabolic pathway alterations associated with each disease state, with the focus keyphrase "gut microbiota in Graves’ disease and Graves’ orbitopathy." The study aimed to enhance understanding of the relationship between the gut microbiome and the pathophysiology of GD and GO, and to explore whether distinct microbial and metabolic profiles could help distinguish GD from GO in clinical practice.

Who was studied?

The study population consisted of 30 patients with GD (without GO), 33 patients with GO, and 32 healthy controls, all recruited from the Department of Endocrinology at Beijing Tongren Hospital, Capital Medical University, China, between 2017 and 2019. Participants were matched for age and sex where possible. Inclusion criteria for GD and GO were based on established clinical guidelines, with GO diagnosed according to the EUGOGO criteria. Participants with recent probiotic or antibiotic use, hormonal medication, gastrointestinal disease, major systemic illness, pregnancy, or substance abuse were excluded. All GD and GO patients were on antithyroid medications and had normal FT3 and FT4 levels at enrollment. The selected cohorts were designed to minimize confounding factors and ensure differences in gut microbiota were attributable to disease status.

Most important findings

The study revealed that both GD and GO patients exhibited significantly reduced gut microbial diversity compared to healthy controls, as shown by the Shannon index, indicating dysbiosis in disease states. Beta-diversity analysis demonstrated distinct clustering of microbial communities among the three groups. At the phylum level, GO patients had a significant decrease in Deinococcus-Thermus and Chloroflexi compared to GD patients, while GO patients also showed increased Bacteroidetes and decreased Firmicutes relative to controls. At the genus level, GO patients exhibited higher levels of Subdoligranulum and Bilophila and lower levels of Blautia, Anaerostipes, Dorea, Butyricicoccus, Romboutsia, Fusicatenibacter, unidentified Lachnospiraceae and Clostridiales, Collinsella, Intestinibacter, and Phascolarctobacterium compared to GD. Several taxa, particularly Subdoligranulum and unidentified Lachnospiraceae, showed strong associations with TRAb levels (thyrotrophin receptor antibody) in both GD and GO, suggesting a potential link between specific gut bacteria and disease immunopathology. Random forest analysis identified Deinococcus-Thermus, Cyanobacteria, and Chloroflexi as top taxa for distinguishing between groups. Functionally, predicted KEGG pathway analysis indicated that both GD and GO patients’ gut microbiota were enriched for nucleotide metabolism, energy metabolism, and enzyme family pathways compared to controls. A unique enrichment of viral protein family pathways was observed in GD compared to GO, aligning with hypotheses about viral triggers in autoimmunity.

Key implications

This study provides robust evidence that the gut microbiota in Graves’ disease and Graves’ orbitopathy is altered in both composition and predicted metabolic function, with distinct microbial signatures for each condition. The identification of specific taxa (e.g., Deinococcus-Thermus, Chloroflexi, Subdoligranulum, and Lachnospiraceae) that differentiate GD from GO and their association with TRAb levels may offer new biomarkers for disease stratification and risk assessment. The functional enrichment of nucleotide and energy metabolism pathways and the unique viral protein family pathway in GD suggest that the gut microbiome may contribute to disease mechanisms and progression. These findings support the potential for microbiome-based diagnostic tools and therapeutic strategies targeting gut microbial modulation in the management of Graves’ disease and its extrathyroidal manifestations.

What was studied?

The study investigated the associations between gut microbiota composition and thyroidal function status in Chinese patients with Graves’ disease (GD), focusing on how gut microbial profiles relate to clinical characteristics and thyroid autoantibody levels, particularly thyrotropin receptor antibody (TRAb). Using 16S rDNA high-throughput sequencing, the researchers compared the gut microbiota of untreated primary GD patients with healthy controls and further analyzed changes in microbiota after anti-thyroid drug therapy (Methimazole). The study aimed to identify specific microbial signatures linked to GD and the restoration of thyroid function following treatment, and to explore correlations between gut microbial taxa and thyroid autoimmunity markers.

Who was studied?

The study enrolled 15 adult patients (7 males, 8 females) with newly diagnosed, untreated primary GD from Jinling Hospital, Southeast University, Nanjing, China. Fourteen healthy adult volunteers (6 males, 8 females) served as controls. All participants were between 18 and 65 years old, from the same geographic region (Jiangsu Province), and had similar dietary backgrounds. Exclusion criteria included a history of autoimmune, metabolic, gastrointestinal, or genetic diseases, recent antibiotic/probiotic use, special diets, pregnancy, or major organ dysfunction. For the treatment group analysis, 13 GD patients were re-sampled after 3–5 months of Methimazole treatment, once their thyroid function had largely normalized.

Most important findings

The study found that patients with untreated GD exhibited significantly reduced gut microbiota alpha diversity (lower observed OTUs, Shannon, and Simpson indices) compared to healthy controls. The most notable microbial shifts at the genus level included significant increases in Lactobacillus, Veillonella, and Streptococcus in GD patients, with Blautia and Ruminococcus also elevated. Conversely, beneficial genera such as Phascolarctobacterium and Synergistetes were depleted in GD patients. After Methimazole treatment and restoration of thyroid function, gut microbial diversity improved, and the abundance of Blautia, Corynebacterium, Ruminococcus, and Streptococcus decreased, while Phascolarctobacterium increased.

Correlational analysis revealed that TRAb levels were positively associated with the abundance of Lactobacillus and Ruminococcus, and negatively associated with Synergistetes and Phascolarctobacterium. Synergistetes abundance was also negatively correlated with other thyroid autoantibodies (TGAb, TPOAb), suggesting a possibly protective role. Notably, changes in Ruminococcus and Phascolarctobacterium closely tracked changes in TRAb levels before and after treatment. The findings suggest that Ruminococcus and Lactobacillus may serve as novel microbial biomarkers for GD, while Synergistetes and Phascolarctobacterium may exert protective effects against thyroid autoimmunity.

Key implications

This study underscores a strong association between GD and gut microbiota dysbiosis, with specific microbial signatures correlating with disease activity and immune status. The depletion of potentially protective genera (Synergistetes, Phascolarctobacterium) and enrichment of taxa like Ruminococcus and Lactobacillus in GD patients are particularly relevant for microbiome signature databases. Importantly, restoration of euthyroid status partially normalizes the gut microbiota, implying that thyroid function and the gut microbiome are dynamically linked. These findings highlight the potential of targeting the gut microbiota for novel GD biomarkers or therapeutic interventions, though causality remains to be established. Further research with larger cohorts and mechanistic studies is warranted to clarify the role of gut microbes in GD pathogenesis and management.

What was studied?

This study investigated the genome sequences of six Enterococcus faecalis strains that were isolated from copper-fed pigs in Denmark. The strains were selected based on their copper resistance or sensitivity, providing insight into the molecular mechanisms underlying copper resistance in E. faecalis. Enterococcus faecalis, a Gram-positive bacterium commonly found in the gastrointestinal tracts of both humans and animals, has been known for its role as a pathogen. The study also examined how copper resistance genes in these strains could potentially co-exist with antibiotic resistance genes, providing valuable insights into the growing concern of multi-drug-resistant pathogens. Comparative genomic analysis was used to assess the differences between copper-resistant and copper-sensitive strains and to identify potential co-transfer of resistance determinants.

Who was studied?

The study involved six E. faecalis strains (S1, S12, S17, S18, S19, and S32), which were isolated from healthy pigs that were fed copper-supplemented diets. These strains were compared in terms of their copper resistance capabilities and their genomic features. Three of the strains (S1, S18, and S32) were identified as copper-resistant, while the other three (S12, S17, and S19) were copper-sensitive. The researchers used whole-genome sequencing and comparative genome analysis to study the genetic makeup of these strains, with a particular focus on genes related to copper and antibiotic resistance.

Most important findings

The genomic analysis revealed significant differences between copper-resistant and copper-sensitive E. faecalis strains. Notably, the copper-resistant strains (S1, S18, and S32) contained genes encoding copper resistance, including the copYABZ operon, which was absent in the copper-sensitive strains. The copA, copB, and copZ genes involved in copper efflux and homeostasis were present in all the strains but were more prominent in the copper-resistant strains. Additionally, a tcrYAZB operon, responsible for high-level copper resistance, was found in the copper-resistant strains, as well as a cueO gene encoding a multicopper oxidase that helps detoxify copper by converting Cu(I) to Cu(II).

The study also identified that the copper-resistant strains contained additional genes related to antibiotic resistance, such as tetM (tetracycline resistance) and vanA (vancomycin resistance). The presence of these genes in the same strains suggests a potential co-transfer mechanism between copper and antibiotic resistance. Furthermore, mobile genetic elements, such as transposases, were found near the copper resistance genes, indicating that copper resistance could be transferred to other bacteria in the environment.

Key implications

The findings highlight the complex relationship between copper resistance and antibiotic resistance in E. faecalis, suggesting that copper supplementation in livestock feed could inadvertently contribute to the development of multidrug-resistant strains. The identification of genetic elements responsible for copper resistance and their co-location with antibiotic resistance genes raises concerns about the spread of resistance through horizontal gene transfer, especially in environments where both copper and antibiotics are used, such as in agriculture.

This study emphasizes the need for careful management of copper use in animal feed, as it may not only contribute to copper resistance in bacteria but also to the emergence of multidrug-resistant pathogens. The genomic insights into E. faecalis resistance mechanisms offer a better understanding of how resistance determinants are transferred and could inform strategies to reduce the spread of resistance in both agricultural and clinical settings. Further research into the environmental impact of copper use in agriculture, and the role of E. faecalis as a reservoir for resistance genes, could help mitigate the risks associated with copper supplementation in livestock.

What was studied?

The study investigates the role of Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn’s disease (CD), considering its historical context, detection in patients, and potential pathogenesis. The researchers explore the similarities between Crohn’s disease and Johne’s disease in ruminants, both of which share clinical features, including chronic intestinal inflammation. The research focuses on MAP's presence in patients with CD and examines whether it is a causative factor or merely a bystander.

Who was studied?

The research primarily addresses studies conducted on patients diagnosed with Crohn's disease, comparing the prevalence of MAP in these individuals with that in healthy controls. This includes a series of clinical studies examining MAP's presence through molecular and immunological testing methods such as PCR, ELISA, and interferon release assays. The studies also assess the impact of anti-MAP therapies on patients, considering the disease’s progression and treatment response.

Most important findings

The study highlights the significant presence of MAP in patients with Crohn's disease compared to non-CD patients, though its causal role remains unclear. Several studies have demonstrated higher rates of MAP positivity in CD patients, with one study reporting a prevalence of 92% in CD patients compared to 26% in controls. However, while MAP is more prevalent in CD patients, the relationship between its presence and disease progression is still debated. The research also shows that MAP may trigger an immune response in CD patients, but this evidence remains inconclusive. Furthermore, anti-MAP therapies, including antibiotics like rifabutin and clofazimine, have shown mixed results, with some studies reporting improvement in clinical symptoms while others find no significant long-term benefit.

Key implications

The findings suggest that MAP could play a role in the pathogenesis of Crohn’s disease, but more research is needed to determine whether it is a causative agent or simply a bystander. The presence of MAP in a significant proportion of CD patients warrants further investigation into whether anti-MAP therapies could become part of standard treatment protocols. The study underscores the need for randomized controlled trials that confirm MAP’s role in CD and assess the efficacy of targeted therapies. Future studies should focus on whether MAP eradication correlates with clinical improvement and explore the potential for personalized treatment strategies based on MAP status.

What was studied?

This cross-sectional original research article investigated the composition and metabolic functions of the gut microbiota in patients with Graves’ disease (GD) compared to healthy controls. Using high-throughput 16S rRNA gene sequencing of fecal samples, the study aimed to profile differences in microbial diversity, identify specific taxonomic shifts, and examine associations between gut microbiota and thyroid function, autoimmunity, and metabolism. The research further explored whether certain microbial signatures could serve as noninvasive diagnostic biomarkers for GD, and assessed the potential mechanistic links between gut microbiota alterations and the pathogenesis of autoimmune thyroid disease.

Who was studied?

The study population comprised 45 untreated GD patients (12 males, 33 females; ages 16–65, median age 37) and 59 healthy control volunteers (22 males, 37 females; ages 22–71, median age 43). Controls were matched for age and sex, and all participants were recruited from the same hospital in Shanghai, China. Inclusion criteria for GD were based on ATA guidelines and included elevated thyroid hormone levels, decreased TSH, diffuse thyroid enlargement by ultrasonography, and positive TRAB antibodies. All subjects were free from malignancy, gastrointestinal, or other endocrine diseases, and had not used antibiotics, probiotics, or prebiotics for at least one month prior to sampling. Fecal samples were collected after overnight fasting, and comprehensive thyroid function and antibody profiles were measured for all participants.

Most important findings

The most notable microbiome-related findings were a significant reduction in alpha diversity and abundance of specific gut microbiota in GD patients compared to controls. At the phylum level, GD patients exhibited a lower proportion of Firmicutes and a higher proportion of Bacteroidetes. At the genus level, GD patients had increased Bacteroides and Lactobacillus but decreased abundances of Blautia, [Eubacterium]_hallii_group, Anaerostipes, Collinsella, Dorea, unclassified_f_Peptostreptococcaceae, and [Ruminococcus]_torques_group. Subgroup analyses indicated that Lactobacillus may play a key role in the pathogenesis of autoimmune thyroid disease, with higher levels observed in GD patients with concurrent Hashimoto’s thyroiditis. Correlation analyses revealed that Blautia levels positively correlated with TPOAB and TMAB levels, suggesting a possible anti-inflammatory, regulatory function; conversely, Bacteroides levels negatively correlated with these antibodies, and Dorea showed a negative correlation with TPOAB. Functional predictions showed that Blautia was strongly associated with multiple metabolic pathways, implicating its role in energy and immune regulation. A diagnostic model using the top nine discriminative genera achieved an AUC of 0.81, indicating strong potential for microbial biomarkers in GD diagnosis.

Key implications

These findings suggest that gut microbiota dysbiosis—characterized by decreased Firmicutes and butyrate-producers, and increased Bacteroides and Lactobacillus—may contribute to the pathogenesis of Graves’ disease through impaired intestinal barrier function, altered immune regulation, and disrupted metabolic signaling. The identified microbial shifts, particularly the reduction of butyrate-producing bacteria such as Blautia and [Eubacterium]_hallii_group, may diminish regulatory T cell differentiation and promote chronic inflammation and autoimmunity. The strong diagnostic potential of a nine-genera microbiome signature offers a promising, noninvasive approach for distinguishing GD patients from healthy individuals. Clinically, the study highlights the potential for microbiome-based diagnostics and therapeutics in GD, but also underscores the need for further mechanistic and longitudinal research to validate causality and therapeutic targets.

What was studied?

This original research article investigated the gut microbiota composition and its metabolic functions in patients with Graves’ disease (GD), an autoimmune thyroid disorder. The study aimed to uncover specific microbial signatures associated with GD, explore correlations between gut microbiota and thyroid function, and evaluate the potential of microbiome profiles as non-invasive diagnostic tools for GD. Using high-throughput 16S rRNA sequencing of fecal samples, the authors compared the microbial diversity, abundance, and structure between untreated GD patients and matched healthy controls. They further analyzed the relationships between specific bacterial genera, thyroid autoantibody levels, and predicted metabolic pathway involvement, with an emphasis on the identification of microbiome-based biomarkers for GD. The focus keyphrase "gut microbiota in Graves’ disease" is central to this investigation, as the study provides new insights into how gut microbial alterations may contribute to the pathogenesis and potential diagnosis of GD.

Who was studied?

The study cohort comprised 45 untreated patients with Graves’ disease (12 males, 33 females; median age 37, range 16–65 years) and 59 healthy controls (22 males, 37 females; median age 43, range 22–71 years), all recruited from the Shanghai Tenth People's Hospital. Controls were matched for age and sex, confirmed to be free of thyroid disease by clinical and laboratory assessment, and none had received antibiotics, probiotics, or prebiotics for at least one month prior to sampling. Subjects with malignancies, gastrointestinal, or other endocrine diseases were excluded. Fecal samples, collected after an overnight fast, were stored at -80°C until analysis. Detailed clinical data, including thyroid function tests (FT3, FT4, TT3, TT4, TSH) and thyroid autoantibodies (TGAB, TPOAB, TMAB, TRAB), were obtained for all participants to facilitate correlation analyses between microbiota and disease phenotypes.

Most important findings

The study revealed a marked reduction in alpha diversity (species richness and evenness) of the gut microbiome in GD patients compared with healthy controls, indicating a less robust and potentially dysbiotic microbial community. At the phylum level, GD patients exhibited significantly lower Firmicutes and higher Bacteroidetes proportions. Notably, at the genus level, GD patients had elevated levels of Bacteroides and Lactobacillus, while beneficial butyrate-producing genera such as Blautia, [Eubacterium]_hallii_group, Anaerostipes, Collinsella, Dorea, unclassified Peptostreptococcaceae, and [Ruminococcus]_torques_group were significantly depleted. Lactobacillus levels were particularly increased in GD patients with concurrent Hashimoto’s thyroiditis, suggesting a role in broader autoimmune thyroid disease (AITD) pathogenesis.

Correlation analyses demonstrated that Blautia levels positively correlated with thyroid autoantibodies (TPOAB, TMAB), while Bacteroides showed inverse associations, and Dorea was negatively correlated with TPOAB. Functional predictions implicated Blautia in key metabolic pathways (lipid, amino acid, and carbohydrate metabolism), hinting that its depletion may disrupt intestinal homeostasis and immune regulation. A diagnostic model using nine genera distinguished GD patients from controls with high accuracy (AUC=0.81). Collectively, the findings support a model where microbial dysbiosis—characterized by loss of butyrate producers and expansion of potentially pathogenic taxa—may impair intestinal barrier integrity, promote systemic inflammation, and trigger or exacerbate thyroid autoimmunity.

Key implications

This study underscores the significant role of gut microbiota in the pathogenesis and potential non-invasive diagnosis of Graves’ disease. The identified microbial signatures—particularly the depletion of butyrate-producing genera and enrichment of Bacteroides and Lactobacillus—may contribute to immune dysregulation and thyroid dysfunction through alterations in intestinal permeability and pro-inflammatory signaling. The strong association between specific genera and thyroid autoantibody levels suggests that microbiota-driven immune mechanisms could be central to GD onset and progression. The diagnostic model based on microbial markers offers a promising, non-invasive adjunct for GD detection. These results open avenues for microbiome-based therapeutic interventions and precision diagnostics in AITD, but further studies are necessary to clarify causality, elucidate underlying mechanisms, and validate these biomarkers in larger, diverse populations.

What was studied?

This study investigates the role of Mycobacterium avium subspecies paratuberculosis (MAP) as a potential causative agent for Crohn’s disease (CD). MAP is a known pathogen causing Johne’s disease in ruminants and is often found in the intestines of CD patients. The paper discusses the various lines of evidence suggesting a link between MAP and CD, including molecular, serological, and microbiological approaches. However, the article also addresses the controversies surrounding this hypothesis, particularly in light of failed attempts to treat CD with antimycobacterial therapy. The research delves into the difficulties in conclusively proving that MAP is the causative agent of CD, despite its frequent detection in patients.

Who was studied?

The article surveys the work of various researchers who have examined MAP's role in CD. It reviews studies that focus on the detection of MAP DNA in the intestines and blood of CD patients, serological reactivity to MAP antigens, and the effects of antimicrobial treatment. It also mentions a series of experimental studies, which include attempts to culture MAP from CD patients and tests for genetic susceptibility that might predispose individuals to MAP infection. Importantly, the authors highlight the failure of some large-scale studies to demonstrate definitive therapeutic benefits from antimycobacterial treatment, even though MAP is frequently detected in CD patients.

Most important findings

The study reveals multiple points of contention in the debate about whether MAP plays a causal role in CD. The article identifies that while MAP has been frequently isolated from the intestinal tissues and blood of CD patients, it has not been consistently proven to be the direct cause of disease. Additionally, attempts to treat CD patients with antimycobacterial drugs have yielded inconclusive results, suggesting that MAP may not be a primary causative agent. Despite this, MAP’s ability to infect macrophages and survive within granulomas, similar to other mycobacteria, is highlighted as a key feature that warrants further investigation. The study also addresses the challenges in detecting MAP, given its slow growth and the issues with traditional culture methods. The evidence from various studies suggests that while MAP is often present in CD patients, its exact role remains elusive, and it may be one of several contributing factors to disease progression.

Key implications

The failure to prove MAP as a causative factor in CD despite its frequent detection underscores the complexity of inflammatory bowel diseases (IBD). The inability to produce consistent results with antimycobacterial therapy challenges the hypothesis that MAP is the primary cause of CD. However, the research suggests that MAP may still play a role in the disease's pathogenesis, potentially in conjunction with other factors such as host immune response, genetics, and microbial dysbiosis. These findings point to the need for further research on the interplay between MAP and other microbial or environmental factors in the development of CD. The article also emphasizes the importance of improving detection methods and treatment strategies to better understand the role of MAP and other microbes in IBD.

What was studied?

This article reviews the environmental risk factors and migration patterns related to the increasing incidence of inflammatory bowel diseases (IBD), specifically Crohn's disease (CD) and ulcerative colitis (UC). The study primarily focuses on epidemiological data, drawing attention to migration patterns that help identify environmental influences contributing to the onset and clinical progression of IBD. It assesses migration cohorts, with particular emphasis on first and second-generation migrants moving from regions with low IBD incidence to areas with higher prevalence, in order to study the environmental triggers involved.

Who was studied?

The study investigates populations from various ethnic backgrounds, especially focusing on first- and second-generation migrants. These cohorts were chosen due to their transition from areas with low IBD incidence to areas with high IBD prevalence, thus providing an excellent opportunity to explore the effects of environmental changes on disease manifestation. The study highlights the epidemiology of IBD in migrant populations from the Middle East, including immigrants to Australia, as a prime example of how migration studies can offer insight into the contribution of environmental factors. Furthermore, the review discusses the differences in disease characteristics between migrants and native populations and between different generations of migrants.

Most important findings

The article presents a comprehensive review of several epidemiological studies that have identified various environmental factors associated with IBD. It found that migration from low-incidence regions to high-incidence regions leads to an increased risk of IBD, especially among second-generation migrants. Studies from countries like the UK, Sweden, and Israel showed a rise in the incidence of IBD among first- and second-generation migrants from regions with historically low IBD rates. Notably, migrants from Middle Eastern countries to developed countries such as Australia were identified as an emerging cohort for further research into IBD's environmental triggers. Smoking, oral contraceptive use, and childhood infections were identified as significant but controversial environmental factors. Additionally, a shift towards Westernized diets and lifestyles in migrant populations was implicated in the increasing prevalence of IBD, supporting the hygiene hypothesis, which posits that improved hygiene and decreased exposure to infections may increase susceptibility to autoimmune diseases like IBD.

Key implications

The primary implication of this study is the identification of migrant groups, especially those from regions with historically low IBD incidence, as ideal candidates for future epidemiological research. These populations offer a unique opportunity to study the environmental risk factors influencing IBD onset in developed countries. Furthermore, the review underscores the need for studies that compare first- and second-generation migrants to understand how lifestyle and environmental changes influence the development and progression of IBD. This approach could lead to a better understanding of IBD's pathogenesis and provide insights into how modern lifestyles, including diet and hygiene, contribute to disease manifestation. Additionally, future research should focus on disentangling the genetic and environmental factors involved in IBD to help develop targeted prevention and treatment strategies for at-risk populations.

What was studied?

This review focuses on the genetic and environmental factors influencing Crohn's disease (CD), examining how both genetic susceptibility and environmental exposures contribute to the onset and progression of the disease. It discusses key genetic variants like NOD2, which plays a crucial role in immune regulation, and the environmental factors such as smoking, diet, and vitamin D deficiency. The review aims to clarify the interaction between immune dysregulation, gut microbiome changes, and environmental exposures, with a particular focus on how these factors influence disease pathogenesis and therapeutic outcomes.

Who was studied?

The review incorporates data from studies involving patients with Crohn's disease, encompassing both adult and pediatric populations. It particularly looks at patients with a genetic predisposition to CD, including those with known mutations in genes like NOD2 and IL23R. Additionally, it examines how lifestyle factors such as smoking and diet, as well as environmental factors like vitamin D levels, impact the development and severity of Crohn’s disease. The study also considers how these factors interact with the gut microbiome, influencing disease activity and response to treatment.

Most important findings

The review highlights that mutations in the NOD2 gene significantly increase the risk of developing Crohn’s disease by impairing immune regulation, leading to heightened inflammation in the intestines. Smoking is another major risk factor, exacerbating the disease by altering gut microbiota and increasing inflammation. Diet also plays a critical role; high-fat and low-fiber diets contribute to increased inflammation and microbial imbalance, while omega-3 fatty acids and fiber can have protective effects. Vitamin D deficiency is commonly found in CD patients and is linked to worse disease outcomes, emphasizing the importance of maintaining adequate vitamin D levels to support immune regulation and intestinal health.

Key implications

The findings suggest that personalized management strategies are crucial for Crohn’s disease patients, considering both their genetic predispositions and environmental factors. Smoking cessation and dietary interventions should be prioritized as part of a comprehensive treatment plan, especially as smoking is linked to disease exacerbation. The review also recommends monitoring vitamin D levels in CD patients, as supplementation may help reduce inflammation and improve disease outcomes. Given the interplay between the microbiome and these factors, future research into microbiome-based therapies could offer promising treatments, further improving disease management.

What was studied?

This study focuses on the epidemiological factors contributing to the development and progression of Crohn's disease (CD). It reviews both the environmental and genetic influences that contribute to the onset and clinical course of the disease, examining the role of diet, stress, infections, and genetics, as well as the impact of microbial exposure. The review systematically examines how these external risk factors influence the disease's development, relapse, and long-term management.

Who was studied?

The review encompasses a wide range of studies focusing on different populations globally, from industrialized countries to developing nations. It highlights various age groups and how these factors contribute differently to the disease’s incidence and progression. Additionally, the study includes references to the rising incidence of CD, particularly in developing countries, and the higher prevalence among individuals in their 20s to 50s. Both male and female populations are represented, with additional focus on the environmental exposures in these regions.

Most important findings

The review identifies several key environmental and genetic factors that influence the development of CD. Smoking is a significant risk factor, as it exacerbates disease progression. Infections, particularly Clostridium difficile, are linked to disease relapse. Dietary factors, such as a low-fiber diet, are shown to play a critical role in disease exacerbation. Genetic predispositions, especially mutations in genes like NOD2, are closely associated with earlier disease onset and familial occurrences. The study also emphasizes that environmental changes, particularly in industrialized countries, contribute to an increasing incidence of CD, highlighting the importance of understanding the complex interplay between genetics, diet, and microbial exposure in managing the disease.

Key implications

Understanding the environmental and genetic risk factors for Crohn's disease has profound implications for both diagnosis and treatment. Clinicians can utilize this information to improve patient management by focusing on modifiable risk factors such as diet, smoking cessation, and infection prevention. Early diagnosis and personalized treatment strategies based on these external factors, combined with genetic testing, may help prevent disease progression and improve patient outcomes. Furthermore, the findings support the need for global surveillance to monitor the rising incidence of CD, particularly in regions where the disease is becoming more prevalent.

What was studied?

This study examined whether a common gut microbiota dysbiosis exists across multiple immune-mediated inflammatory diseases (IMIDs), specifically Crohn’s disease (CD), ulcerative colitis (UC), multiple sclerosis (MS), and rheumatoid arthritis (RA). Researchers employed 16S rRNA gene sequencing of stool samples and machine learning techniques to identify both disease-specific and shared microbial signatures. This pilot investigation also explored the potential of taxonomic features to classify disease states using random forest classifiers.

Who was studied?

The study included 99 participants: 20 with CD, 19 with UC, 19 with MS, 21 with RA, and 23 healthy controls (HC). Patients were recruited from clinical centers in Winnipeg, Canada, and met disease-specific diagnostic criteria. Inclusion criteria mandated age above 18 and no antibiotic use in the preceding 8 weeks. Biological replicates were collected approximately two months apart to assess microbial stability over time.

What were the most important findings?

The study identified a shared gut microbiota dysbiosis signature across IMIDs, marked by reduced diversity and distinct taxonomic shifts compared to healthy controls. Alpha diversity was significantly lower in IMID groups, especially in CD. Key genera enriched across all disease groups included Actinomyces, Eggerthella, Clostridium III, Faecalicoccus, and Streptococcus—potential Major Microbial Associations (MMAs) due to their pro-inflammatory profiles and consistent presence in IMID cohorts. In contrast, Gemmiger, Lachnospira, and Roseburia were significantly depleted in IMIDs and are known to produce anti-inflammatory metabolites like butyrate. Machine learning classifiers distinguished disease from HC with high accuracy (AUC up to 0.95 for CD), confirming the reliability of these microbial features as diagnostic indicators. Disease-specific signatures were also detected: Bifidobacterium was elevated in UC, Intestinibacter in CD, and unclassified Erysipelotrichaceae in MS.

What are the greatest implications of this study?

This study provides compelling evidence for a partially conserved gut microbiota dysbiosis pattern in IMIDs, despite their diverse clinical presentations. The findings suggest that microbial taxa such as Streptococcus and Eggerthella may contribute to shared pathogenic mechanisms via modulation of host immunity, while depletion of butyrate-producing genera like Roseburia may reflect a breakdown in mucosal tolerance. These MMAs highlight targets for microbiome-modulating interventions and support their integration into risk stratification and personalized treatment strategies. Furthermore, the study underscores the diagnostic potential of microbiota-based machine learning tools, offering a route to non-invasive, microbiome-informed screening across inflammatory conditions.

What Was Studied?

This study systematically investigated alterations in the gut microbiota composition in patients with Hashimoto’s thyroiditis (HT), an organ-specific autoimmune disease, compared to healthy controls. The researchers used 16S rRNA sequencing to profile and compare the gut microbiota of 50 HT patients and 27 matched healthy controls. The study aimed to identify microbial biomarkers associated with HT and their correlations with clinical parameters, such as thyroid peroxidase antibody (TPO-Ab) and thyroglobulin antibody (TG-Ab) levels.

Who Was Studied?

The study involved two cohorts: an exploration cohort of 28 HT patients and 16 healthy controls, and a validation cohort of 22 HT patients and 11 healthy controls. All participants were of Han Chinese ethnicity, aged between 18 and 65 years, and matched for age, sex, and BMI. Patients included were euthyroid and free from confounding conditions or recent medications that could affect the gut microbiota.

Key Findings

The study revealed significant differences in the gut microbiota composition between HT patients and healthy controls, though overall bacterial diversity and richness were similar. HT patients exhibited a marked increase in Firmicutes and a reduction in Bacteroidetes, with a significantly higher Firmicutes-to-Bacteroidetes (F/B) ratio. At the genus level, the abundances of Blautia, Roseburia, Ruminococcus_torques_group, and Eubacterium_hallii_group were significantly increased in HT patients. In contrast, beneficial genera like Bacteroides, Fecalibacterium, and Prevotella_9 were significantly decreased.

The researchers identified 27 genera with significant differences between HT patients and controls using linear discriminant analysis effect size (LEfSe). Ten genera, including Bacteroides and Fecalibacterium, were highlighted as potential biomarkers, achieving high diagnostic accuracy with AUC values of 0.91 and 0.88 in the exploration and validation cohorts, respectively.

Microbiota changes were correlated with clinical parameters. For instance, increased levels of Blautia and Dorea were positively associated with TPO-Ab and TG-Ab, while reduced levels of Fecalibacterium and Bacteroides correlated inversely with these antibodies.

Greatest Implications

The findings highlight the potential role of gut dysbiosis in the pathogenesis of HT. The observed microbial shifts suggest a loss of anti-inflammatory and barrier-supporting taxa, such as Fecalibacterium, and an increase in pro-inflammatory or mucin-degrading taxa, such as Ruminococcus_torques_group. This dysbiosis may contribute to immune activation and thyroid autoimmunity through mechanisms like increased intestinal permeability and molecular mimicry. Additionally, the identified microbial biomarkers could serve as non-invasive tools for HT diagnosis and disease monitoring. However, longitudinal studies and experimental validation are needed to confirm causality and explore therapeutic interventions targeting the gut microbiota.

What was studied?

This study investigated the subgingival microbiome in Chinese patients with rheumatoid arthritis (RA), periodontitis (PD), and healthy controls, aiming to explore potential microbial links between RA and PD. Using 16S rRNA Illumina MiSeq sequencing, the authors characterized bacterial composition and diversity in subgingival plaque, identifying differentially abundant taxa and evaluating whether oral microbiota might play a contributory role in RA pathogenesis via periodontal inflammation.

Who was studied?

A total of 143 participants were enrolled, comprising 54 RA patients, 45 PD patients, and 44 healthy controls, all recruited from Sichuan Provincial People’s Hospital. Inclusion criteria excluded individuals with systemic diseases other than RA or PD, and participants had not used antibiotics or immunosuppressive therapies in the preceding three months. Subgingival plaque samples were collected from six standardized index teeth for uniformity across groups.

What were the most important findings?

Although microbial richness (as measured by alpha diversity indices like Chao and Simpson) did not differ significantly among the RA, PD, and control groups, key compositional shifts were observed. Most notably, the phylum Spirochaetes—and its lineage down to the genus Treponema—was significantly enriched in RA patients at all taxonomic levels (P < 0.008). These results were specific to RA; while PD patients showed a similar trend, the differences did not reach statistical significance.

Additionally, RA samples showed higher relative abundances of Porphyromonas, Prevotella, and Veillonella, which are consistent with previous literature identifying these as periodontopathogenic taxa. Conversely, Streptococcus and Gemella, both associated with a healthy oral microbiome, were significantly depleted in RA. Interestingly, Tannerella, another "red complex" pathogen, was also elevated in RA (P = 0.010), supporting a dysbiotic profile that overlaps with PD yet remains distinct.

From a microbiome signatures perspective, Treponema and Porphyromonas gingivalis are reaffirmed as Major Microbial Associations (MMAs) due to their consistent elevation and mechanistic links to citrullination and RA immunopathology. The study also reinforces the microbial overlap and divergence between RA and PD, highlighting subgingival niches as potential sources of systemic immune modulation.

What are the greatest implications of this study?

This study adds to a growing body of evidence implicating the oral microbiome—specifically the subgingival community—in the pathogenesis of rheumatoid arthritis. The consistent enrichment of Treponema across all taxonomic levels in RA patients suggests it may play a previously underappreciated role in RA, warranting mechanistic exploration, especially in relation to periodontal-immune crosstalk. The differential regulation of classic periodontal pathogens between RA and PD patients also underscores that, while these diseases share microbial risk factors, their oral dysbiosis patterns are not identical.

For clinical application, the identification of Treponema and Porphyromonas as MMAs provides potential microbial biomarkers for RA risk screening. Furthermore, the observation that RA patients without clinically diagnosed PD still harbor elevated pathobiont levels suggests that subclinical periodontal dysbiosis may be a risk modifier in RA development. This has implications for early intervention strategies and supports the integration of dental and rheumatologic care. For the Microbiome Signatures Database, this study strongly validates subgingival Treponema spp. as a population-specific MMA for RA and supports the prioritization of oral-microbiome-focused MBTIs.

What was studied?
The study assessed thyroid function and oxidative stress in foundry workers occupationally exposed to lead (Pb) dust and fumes. It investigated the correlation between blood lead levels (BLL) and thyroid hormones, as well as markers of oxidative stress.

Who was studied?
The study involved 59 adult male foundry workers exposed to lead and a control group of 28 male subjects with no history of lead exposure or thyroid abnormalities.

What were the most important findings?

Foundry workers had significantly higher blood lead levels (16.5±1.74 µg/dl) compared to the control group (12.8±1.16 µg/dl).

The exposed group exhibited significantly increased levels of free triiodothyronine (FT3) and free thyroxine (FT4), and decreased levels of thyroid stimulating hormone (TSH).

Markers of oxidative stress showed a significant increase in malondialdehyde (MDA) and a significant decrease in glutathione (GSH) among exposed workers.

A significant positive correlation was found between BLL and duration of employment, while a negative correlation existed between BLL and both TSH and GSH levels.

Elevated thyroid hormones were observed in 32.76% of the occupationally exposed workers.

There was a significant positive relationship between GSH and TSH, and between MDA and FT3 and FT4 among exposed workers.

What are the greatest implications of this study?
The study suggests that occupational exposure to lead dust and fumes can stimulate thyroid function, resulting in increased thyroid hormone levels, which may contribute to an oxidative-antioxidant imbalance. This imbalance, indicated by increased MDA and decreased GSH levels, underscores the potential health risks associated with prolonged exposure to lead, highlighting the need for improved protective measures and monitoring in industrial settings.

What was studied?

This study investigated the taxonomic and functional gut microbiota profiles of euthyroid individuals with and without thyroid peroxidase antibodies (TPOAb), a marker for autoimmune thyroid diseases such as Hashimoto’s thyroiditis. The goal was to assess whether gut microbiota composition differs in individuals with TPOAb before the clinical onset of autoimmune thyroid disease and to evaluate ethnic variations in thyroid biomarkers.

Who was studied?

The study examined 1,468 euthyroid participants aged 35 years and older from the multiethnic HELIUS cohort, including European Dutch, Moroccan, and Turkish individuals. Of these, 159 participants were TPOAb-positive, and 1,309 were TPOAb-negative. Fecal microbiota composition was analyzed using 16S rRNA sequencing.

What were the most important findings?

The study revealed no significant differences in global gut microbiota diversity (alpha or beta diversity) between TPOAb-positive and TPOAb-negative individuals. However, 138 microbial taxa were nominally associated with TPOAb presence, with 13 taxa consistently significant across multiple statistical methods. Among the most notable taxa, members of the Desulfovibrionaceae family were positively associated with TPOAb presence, while certain taxa from the Clostridiales vadin BB60 group were negatively associated. Functional pathway analysis indicated reduced abundance of pathways related to D-glucarate degradation, glycolysis, and adenosylcobalamin biosynthesis in TPOAb-positive participants, although none of these associations were statistically significant after correction for multiple testing. Ethnicity emerged as a more significant factor in microbiota variation than TPOAb status, with no ethnic differences in thyroid biomarker levels found.

What are the greatest implications of this study?

This study underscores the role of gut microbiota in the early stages of autoimmune thyroid disease, suggesting that microbial alterations may not be the primary driver of TPOAb seroconversion. However, the associations between specific taxa and TPOAb presence warrant further investigation to elucidate their potential involvement in disease progression. The lack of robust differences in microbiota composition between groups highlights the need for longitudinal studies to determine causal relationships between gut dysbiosis and autoimmune thyroiditis. Moreover, the findings emphasize the importance of considering ethnic diversity in microbiome research to ensure accurate interpretation of results.

What Was Studied?

This study, conducted by Mori-Yamanaka et al. and published in Tohoku J. Exp. Med. in 2023, definitively explored serum lactoferrin (LTF) and anti-lactoferrin antibody (aLF) levels in patients with endometriosis. Endometriosis, a chronic inflammatory condition marked by ectopic endometrial-like tissue, remains poorly understood in terms of its underlying mechanisms. The researchers aimed to determine whether LTF, an iron-binding glycoprotein with antimicrobial and anti-inflammatory properties, and aLF, an autoantibody tied to immune dysregulation, play roles in the disease’s pathology. By measuring these markers in the blood of endometriosis patients compared to controls and assessing changes after surgical intervention, the study sought to uncover potential links to inflammation and autoimmunity. Although the study did not directly investigate microbiome signatures, LTF’s known role in modulating microbial environments suggests a possible indirect connection to gut or pelvic microbiome alterations in endometriosis.

Who Was Studied?

The research focused on 68 Japanese women undergoing surgery at Shiga University of Medical Science Hospital between November 2020 and May 2022. Of these, 51 had surgically and histopathologically confirmed endometriosis, spanning all stages (I-IV) per the revised American Society for Reproductive Medicine classification. The remaining 17 women, who underwent surgery for other gynecological issues like uterine myomas or benign ovarian tumors, served as controls without endometriosis. This cohort provided a robust sample to compare LTF and aLF levels across disease states and post-treatment outcomes, offering clinicians a clear demographic context for interpreting the findings.

What Were the Most Important Findings?

The study conclusively demonstrated that serum LTF and aLF levels are significantly elevated in endometriosis patients compared to controls, with p-values of 0.016 and 0.028, respectively. These elevations were particularly striking in advanced stages (III and IV), showing stronger statistical significance (LTF: p = 0.024; aLF: p = 0.016) compared to controls. Following surgery in 21 patients, aLF levels dropped markedly (p < 0.001), while LTF levels showed no significant change (p = 0.102). Notably, 43% of endometriosis patients exhibited aLF levels above the reference range, a prevalence akin to autoimmune conditions. Although microbiome data wasn’t directly assessed, LTF’s antimicrobial properties hint at potential microbial associations, possibly involving dysbiosis in the pelvic or gut microbiome, which could exacerbate inflammation in endometriosis. These findings position LTF and aLF as key players in the disease’s inflammatory and possibly autoimmune landscape.

What Are the Greatest Implications of This Study?

This study’s implications are profound for clinicians managing endometriosis. The elevated aLF levels, mirroring patterns in autoimmune diseases, strongly suggest that endometriosis involves an autoimmune component, potentially driven by immune responses to microbial or endogenous triggers. This insight could shift treatment paradigms toward immune-modulating therapies. Moreover, the significant post-surgical decline in aLF levels establishes it as a promising biomarker for monitoring disease activity and treatment success, offering a practical tool for clinical decision-making. While LTF’s role remains less clear, its persistence post-surgery and antimicrobial function imply a complex interplay with inflammation and possibly the microbiome, warranting further investigation into microbial signatures like those of Lactobacillus or Prevotella, known to influence pelvic health. Despite the study’s limitations—its small sample and surgical focus—these findings pave the way for innovative diagnostics and therapies, urging clinicians to consider immune and microbial factors in endometriosis care.

What was studied?

This study investigated the bidirectional causal relationship between Graves’ Disease (GD) and the gut microbiome. Utilizing Mendelian randomization (MR), it examined how alterations in the gut microbiome might influence GD and vice versa, supporting the thyroid–gut axis (TGA) concept. Genome-wide association study (GWAS) summary datasets, which analyze millions of genetic variants across diverse populations to identify associations between genetic markers and specific traits, were sourced from international consortiums to evaluate these interactions.

Who was studied?

The study involved two large datasets. Gut microbiome data included 18,340 samples spanning diverse ethnic groups (European, Middle Eastern, East Asian, Hispanic/Latin American, and African American), while GD data included 212,453 samples of Asian ethnicity, sourced from Biobank Japan. These comprehensive datasets were analyzed to identify instrumental variables linking genetic variants to gut microbiome composition and GD susceptibility.

What were the most important findings?

The study established a bidirectional causal relationship between Graves’ disease (GD) and the gut microbiome, identifying key microbial associations that act as either risk or protective factors. Risk factors for GD included the classes Deltaproteobacteria (odds ratio [OR] = 3.603) and Mollicutes, as well as the genera Ruminococcus torques group, Oxalobacter, and Ruminococcaceae UCG 011. Protective associations were observed for the family Peptococcaceae and the genus Anaerostipes (OR = 0.489). Furthermore, GD was found to alter gut microbiome composition, increasing the abundance of genera like Anaerofilum (OR = 1.584) and reducing taxa such as the Clostridium innocuum group (OR = 0.918) and Sutterella (OR = 0.953). These findings highlight the regulatory activity of the thyroid–gut axis (TGA) and provide strong evidence for its involvement in GD pathogenesis.

What are the greatest implications of this study?

The findings underscore the critical role of the gut microbiome in GD pathogenesis and its reciprocal interaction with thyroid health. Identifying specific microbial taxa as risk or protective factors offers actionable insights for microbiome-targeted interventions (MBTIs), such as probiotics or dietary modifications, tailored to mitigate GD risk or progression. The bidirectional relationship between GD and the gut microbiome highlights the need for integrated approaches addressing both thyroid and gut health. These results could guide the development of precision medicine strategies, leveraging the gut microbiome to modulate immune responses and improve clinical outcomes for patients with GD. This research also establishes a foundational understanding of major microbial associations (MMAs) within the TGA, paving the way for future therapeutic innovations. Further, this study establishes a methodological precedent for using Mendelian Randomization to discern causal effects in microbiome-related research.

What was studied?

This study explored the gut microbiota of children diagnosed with early-onset pediatric multiple sclerosis (MS) and compared it to controls of similar age and sex. The researchers aimed to identify gut microbial community differences, including taxonomic and functional perturbations, and examined the influence of immunomodulatory drug (IMD) exposure. This study also predicted functional metabolic pathways based on microbial profiles.

Who was studied?

The study involved 18 children with relapsing-remitting multiple sclerosis (RRMS) and 17 healthy controls. The participants, aged 4 to 18 years, were enrolled from a University of California, San Francisco pediatric clinic. MS cases were within two years of symptom onset, with half being IMD-naïve. Both groups were matched by age and sex, with controls lacking autoimmune conditions or recent antibiotic exposure.

What were the most important findings?

The study revealed significant microbial differences between pediatric MS cases and controls. MS cases exhibited an enrichment in pro-inflammatory taxa, including Desulfovibrionaceae (e.g., Bilophila, Desulfovibrio) and Christensenellaceae, and a depletion of anti-inflammatory taxa such as Lachnospiraceae and Ruminococcaceae. Additionally, metabolic pathways related to glutathione metabolism were enriched in MS cases, regardless of IMD exposure. Notably, IMD exposure correlated with reduced beta diversity variations, suggesting partial modulation of the microbiome toward a more control-like composition. Furthermore, the study observed shifts in microbial genes involved in lipopolysaccharide biosynthesis and immune modulation, linking gut dysbiosis with potential mechanisms of neuroinflammation and neurodegeneration.

What are the greatest implications of this study?

This study highlights the potential role of gut microbiota in the early pathogenesis of pediatric MS. The observed microbial dysbiosis aligns with a pro-inflammatory milieu that may contribute to immune dysregulation in MS. The findings underscore the importance of gut-targeted interventions, such as dietary modifications or probiotics, as potential therapeutic strategies. The results also emphasize the need for longitudinal studies to elucidate causative versus consequential relationships between gut dysbiosis and MS development.

What Was Studied?

Integrative analysis reveals novel gut microbiota-transcriptome signatures for Hashimoto's thyroiditis, aiding early diagnosis and treatment.This study explored the molecular signatures of Hashimoto’s thyroiditis (HT) through an integrative analysis of gut microbiome and host transcriptome (miRNA/mRNA). It aimed to identify novel molecular markers and elucidate the gut-thyroid axis, using data from 31 early HT patients and 30 healthy controls across discovery and validation cohorts. The study sought to uncover interactions between the gut microbiota and host gene expression, providing insights into HT pathogenesis.

Who Was Studied?

Participants included 31 early HT patients and 30 healthy individuals aged 18–65. HT cases were defined by elevated thyroid antibodies (TPOAb/TGAb) and morphological abnormalities while maintaining normal thyroid function. Exclusions included antibiotic or probiotic use, significant dietary changes, or comorbid conditions. Blood and fecal samples were collected for transcriptomic and metagenomic sequencing.

What Were the Most Important Findings?

The study identified subtle but significant gut microbiota alterations in early HT patients. While alpha diversity was unchanged, beta diversity analysis revealed compositional shifts, including increased Bacillota_A and Spirochaetota at the phylum level and significant differences in 24 genera and 67 species. Beneficial microbes like Barnesiella intestinihominis were reduced, while opportunistic pathogens like Peptostreptococcus were enriched. Host transcriptome analysis identified 1975 downregulated and 1821 upregulated mRNAs, alongside 27 miRNAs. Immune and inflammation-related pathways were enriched, with hsa-miR-548aq-3p and hsa-miR-374a-5p playing key roles. Key molecular signatures included three bacterial species (Salaquimonas_sp002400845, Clostridium_AI_sp002297865, Enterocloster_citroniae) and six RNAs (e.g., GADD45A, IRS2, SMAD6). These integrated signatures demonstrated strong diagnostic potential (AUC=0.95) in distinguishing HT patients from healthy controls.

What Are the Greatest Implications?

This research advances understanding of the gut-thyroid axis and provides a robust framework for early HT diagnosis and treatment. Molecular signatures identified offer potential for targeted therapies, including microbiome modulation. For example, restoring beneficial microbes such as Barnesiella intestinihominis or targeting specific pathogenic species may offer therapeutic benefits. Integration of gut microbiota and transcriptome data sets a precedent for multidimensional biomarker development in autoimmune conditions.

What was studied?

This observational study examined the relationship between hypersensitivity to metals—specifically mercury and nickel—and the prevalence of chronic fatigue and autoimmune disorders. The research utilized the MELISA® (Memory Lymphocyte ImmunoStimulation Assay) to assess in vitro lymphocyte reactivity to various metals among patients with autoimmune thyroiditis, fatigue without endocrinopathy, and occupational exposure to dental metals. The central goal was to evaluate whether metal hypersensitivity constitutes a risk factor for fatigue and autoimmunity and whether removal of metal exposures (e.g., dental amalgam) could reverse symptoms.

Who was studied?

The study analyzed 72 fatigued patients divided into three primary groups: (1) 22 patients with autoimmune thyroiditis, including some with autoimmune polyglandular syndrome (APS); (2) 28 fatigued individuals without endocrinopathies, many of whom experienced local or systemic symptoms linked to dental alloys; and (3) 22 fatigued professionals with long-term occupational metal exposure, including dentists and technicians. A control group of 13 healthy, fatigue-free individuals without autoimmunity was also included. Lymphocyte reactivity to 17 metals was measured using the MELISA® test. Additionally, two patients underwent dental amalgam replacement and were followed for symptom changes and immune reactivity post-intervention.

What were the most important findings?

Lymphocyte stimulation indices revealed that reactivity to inorganic mercury and nickel was significantly elevated in all fatigued patient groups compared to healthy controls. Specifically, 72.7% of autoimmune thyroiditis patients and 61.1% reacted to mercury and nickel, respectively, with similar trends in the other fatigued cohorts. This pattern was not seen with most other metals, suggesting a specific immunologic sensitivity to mercury and nickel in this population. Notably, healthy controls exhibited no reactivity to nickel and minimal reactivity to mercury. Two representative case studies illustrated that removal of metal-containing dental restorations significantly reduced both symptom burden and lymphocyte reactivity in follow-up MELISA® tests. One patient, initially disabled due to fatigue and autoimmune comorbidities, returned to work and experienced sustained health improvements after amalgam replacement.

These findings imply a mechanistic link between metal-driven immune activation and chronic fatigue, potentially via inflammatory disruption of the hypothalamic-pituitary-adrenal (HPA) axis. Nickel exposure, often underestimated, appeared especially important, with sensitization possibly enhanced by environmental and occupational exposures (e.g., stainless steel, dental alloys, cigarette smoke). The results further underscore the inadequacy of patch testing alone in detecting systemic hypersensitivity and support the utility of MELISA® as a diagnostic adjunct.

What are the greatest implications of this study?

This paper provides early, compelling evidence that hypersensitivity to mercury and nickel may play a causative role in the symptomatology of fatigue, autoimmune disorders, and related syndromes like chronic fatigue syndrome (CFS). It introduces the concept that these metals can induce systemic immune activation, not merely local contact dermatitis, thereby contributing to dysregulation of the HPA axis and the development or exacerbation of autoimmunity. Clinically, the study supports consideration of metal sensitization in patients with unexplained fatigue or autoimmune disease, and it opens the door to therapeutic strategies involving metal detoxification or elimination—particularly amalgam removal. Furthermore, the study highlights MELISA® testing as a superior method for detecting metal sensitization compared to standard patch tests, particularly in systemic presentations. This work is foundational in drawing attention to metallomic contributors to chronic inflammatory and autoimmune conditions.

What was studied?
The study investigated the gut microbial composition in patients with Graves’ disease (GD) compared to healthy controls.

Who was studied?
The study involved 27 GD patients and 11 healthy controls, with fecal samples collected for analysis.

What were the most important findings?

The association between gut microbiota and host homeostasis is pivotal for understanding various diseases, including autoimmune disorders like Graves’ disease (GD), characterized by hyperthyroidism and ophthalmopathy. This study hypothesized that gut bacteria play a significant role in GD pathogenicity. To investigate this, the intestinal bacterial composition of 27 GD patients and 11 healthy controls was analyzed using PCR-DGGE of the 16S rRNA gene targeting the V3 region and Real-time PCR for specific bacterial groups. High-throughput sequencing of the 16S rRNA gene (V3+V4 regions) was performed on randomly selected samples using the Hiseq2500 platform.

The results revealed a lower diversity of intestinal bacteria in GD patients compared to controls. Statistical analyses indicated significant alterations in bacterial phyla, with a higher relative abundance of Prevotellaceae and Pasteurellaceae, and a lower abundance of Enterobacteriaceae, Veillonellaceae, and Rikenellaceae in GD patients. At the genus level, Prevotella_9 and Haemophilus were significantly increased, whereas Alistipes and Faecalibacterium were decreased in GD patients. Notably, the species Haemophilus parainfluenza was more abundant in GD patients.

What are the greatest implications of this study?
The findings support the hypothesis of gut microbial dysbiosis in GD, suggesting that changes in the gut microbiota may contribute to the disease’s pathogenesis. These insights could pave the way for novel therapeutic approaches targeting gut microbiota in GD treatment.

What Was Studied?

This study examined alterations in the gut microbiota composition of patients with Hashimoto's thyroiditis (HT). It aimed to investigate the relationship between intestinal dysbiosis and HT through quantitative and qualitative analysis of gut microbial diversity and composition using techniques such as PCR-DGGE, real-time PCR, and pyrosequencing of 16S rRNA genes.

Who Was Studied?

The study analyzed fecal samples from 29 HT patients and 12 healthy individuals aged 40–60 years. Patients were diagnosed based on elevated thyroid antibodies (TPOAb and TGAb) and other clinical markers, including TSH and T4 levels. Healthy controls had normal thyroid function and no history of antibiotic or probiotic use in the 60 days preceding the study.

What Were the Most Important Findings?

The study revealed significant gut microbiota dysbiosis in Hashimoto’s thyroiditis (HT) patients compared to healthy controls. HT patients exhibited an increased abundance of inflammatory phyla like Proteobacteria and decreased beneficial phyla such as Firmicutes and Bacteroidetes. At the genus level, Escherichia-Shigella and Parasutterella were elevated, while anti-inflammatory genera such as Prevotella_9 and Dialister were significantly reduced. Escherichia coli was particularly overrepresented, potentially contributing to intestinal barrier disruption and inflammation linked to thyroid autoimmunity.

Real-time PCR showed significant reductions in Bifidobacterium and Lactobacillus, essential for producing immune-regulating SCFAs, while alpha diversity indicated bacterial overgrowth in HT patients. Functional diversity measures showed no significant changes, pointing to microbial imbalance rather than increased functional diversity. Pyrosequencing confirmed these findings, demonstrating a distinct microbial profile in HT patients. These results highlight the role of gut dysbiosis in HT pathogenesis and suggest potential therapeutic strategies targeting microbiome restoration.

What Are the Greatest Implications?

This study highlights gut microbiota dysbiosis as a potential contributor to the pathogenesis of HT. The findings suggest that the overrepresentation of inflammatory and opportunistic pathogens, such as Escherichia coli and Escherichia-Shigella, coupled with the reduction of beneficial microbes like Bifidobacterium and Lactobacillus, may influence immune regulation and thyroid autoimmunity. Restoring microbial balance through probiotics, dietary interventions, or targeted microbiome therapies could serve as novel strategies for managing HT. These results underscore the critical role of gut health in autoimmune diseases and provide a foundation for developing microbiome-targeted interventions.

What was studied?

The research focused on investigating the potential role of gut microbiota in the pathogenesis of Multiple Sclerosis (MS), particularly relapsing-remitting MS (RRMS). It aimed to compare the fecal microbiota composition between RRMS patients and healthy controls, analyze the microbial diversity, and assess the predictive power of microbiota profiles in distinguishing disease status.

Who was studied?

The study included 31 RRMS patients, categorized based on their disease phase (active or in remission), and 36 age- and sex-matched healthy controls. The RRMS patients were between 18 and 80 years of age, met the McDonald diagnostic criteria for MS, and had an Expanded Disability Status Scale (EDSS) score between 1 and 6. The selection criteria excluded individuals with prior significant surgeries, current antibiotic or probiotic use, or a history of autoimmune diseases other than MS.

What were the most important findings?

Distinct Microbial Community Profiles: RRMS patients had significantly different gut microbiota compositions compared to healthy controls, with specific genera such as Pseudomonas, Pedobacter, Blautia, and Dorea showing higher abundance in RRMS patients, while genera like Adlercreutzia, Parabacteroides, and Lactobacillus were more abundant in controls.

Species Richness and Diversity: Active disease phase was associated with a trend towards lower species richness compared to healthy controls, while remission phase microbiota exhibited similar species richness to controls.

Predictive Power of Gut Microbiota: Using Random Forests (RF) and operational taxonomic unit (OTU) profiles, the study achieved significant classification accuracy in distinguishing RRMS patients from healthy controls based on gut microbiota composition.

Functional Implications: The functional analysis suggested alterations in pathways related to fatty acid metabolism, defense mechanisms, and glycolysis, indicating a broader impact of gut microbiota dysbiosis on metabolic functions.

What are the greatest implications of this study?

The findings underscore the importance of gut microbiota in the etiology and pathogenesis of RRMS, suggesting that dysbiosis may not only be a marker of the disease but also potentially contribute to its development and progression. These results open avenues for future research to explore gut microbiota as a therapeutic target or biomarker for MS. Understanding the specific roles of altered microbiota and their metabolic pathways could lead to new interventions to modulate the gut microbiome to manage or prevent MS. Moreover, the predictive model based on gut microbiota composition presents a novel approach for identifying individuals at risk of RRMS, offering the potential for early intervention and personalized treatment strategies.

What was studied?

The study investigated the role of cholestyramine as an additional treatment for refractory iodine-induced hyperthyroidism in a patient who did not respond to conventional therapies.

Who was studied?

A 52-year-old female patient with a history of goiter who developed iodine-induced hyperthyroidism following a CT scan with contrast. The patient had obstructive symptoms and was unresponsive to standard treatments, including dexamethasone, carbimazole, and propranolol.

What were the most important findings?

After adding cholestyramine, the patient’s FT4 levels decreased by 30% within 5 days and normalized by 12 days.

What are the greatest implications of this study?

Cholestyramine can be an effective adjunct therapy for managing refractory iodine-induced hyperthyroidism, suggesting a potential new treatment avenue for similar cases, such as Grave's Disease (GD). This case highlights the need for alternative treatments when conventional therapies fail and emphasizes the utility of cholestyramine in rapid thyroid hormone reduction.

What was studied?

This study examined the impact of fecal microbiota transfer (FMT) on a patient with refractory celiac disease type II (RCD II). The patient initially received FMT as treatment for recurrent Clostridium difficile infection (CDI), but the intervention unexpectedly resulted in full recovery of duodenal villi and resolution of celiac symptoms, suggesting a potential therapeutic role for microbiome manipulation in RCD II.

Who was studied?

A 68-year-old woman with a 10-year history of RCD II was the subject of this study. Despite adherence to a strict gluten-free diet, she experienced persistent villous atrophy and malabsorption. She had been receiving budesonide therapy and later underwent cladribine treatment, neither of which alleviated her condition. The patient was repeatedly hospitalized due to severe diarrhea, dehydration, and infections, and was ultimately treated with FMT for recurrent CDI.

What were the most important findings?

FMT not only resolved the patient’s CDI but also led to complete histological recovery of the duodenal mucosa. Before FMT, duodenal biopsies confirmed villous atrophy (Marsh IIIA) and an abnormal intraepithelial lymphocyte population (>80%). However, post-FMT, the patient experienced significant clinical improvement, gaining weight and becoming symptom-free. Follow-up biopsies at six months showed full villous recovery (Marsh 0), although 71% of intraepithelial lymphocytes remained aberrant.

Microbiome analysis of the FMT donor revealed a high Shannon diversity index (3.81), suggesting a diverse and resilient microbial community. Unfortunately, due to the lack of a pre-FMT stool sample from the patient, a direct comparison of microbiome shifts could not be conducted. However, the resolution of symptoms and histological improvement strongly indicate that microbiome alterations played a role in disease modulation. Given previous studies implicating gut dysbiosis in celiac disease pathogenesis, this case highlights a possible causal role of microbiota in maintaining the chronic inflammatory state of RCD II.

What are the greatest implications of this study?

This study provides compelling evidence that microbiome manipulation may be a viable therapeutic strategy for RCD II, a condition with limited treatment options and high mortality risk. The findings suggest that gut dysbiosis could be a key driver of persistent villous atrophy in RCD II and that FMT may help restore intestinal homeostasis. If confirmed in larger studies, this could shift the treatment paradigm for RCD II, potentially offering an alternative to immunosuppressive therapies or autologous stem cell transplantation. Given the poor prognosis associated with RCD II, the ability to restore mucosal integrity through microbiome-targeted interventions represents a significant advancement. Further research should explore optimal donor selection, microbial composition, and long-term effects of FMT in RCD II patients.

DOI: 10.7759/cureus.42362

What Was Reviewed?

This systematic review examined the comorbidity between endometriosis and systemic lupus erythematosus (SLE), two chronic conditions with significant implications for women's health. The review aimed to elucidate the prevalence, shared pathophysiological mechanisms, and risk factors linking these diseases, emphasizing immune dysregulation, genetic predispositions, and hormonal influences. The review synthesized findings from nine studies conducted between 2011 and 2021, including case-control, cohort, and systematic review methodologies.

Who Was Reviewed?

The review focused on studies of females aged 12-60, representing the pubertal to postmenopausal age range. The population comprised patients with diagnosed endometriosis and SLE. The studies predominantly included participants from diverse ethnicities and geographies, screened based on standardized inclusion criteria to establish the prevalence and interaction of these conditions.

What Were the Most Important Findings?

The review confirmed a statistically significant correlation between endometriosis and SLE, with women diagnosed with either condition at a heightened risk of developing the other. The findings implicated immune dysregulation, characterized by diminished cytotoxic T-cell activity and elevated humoral immune responses, as a central mechanism. Notable microbial associations include increased systemic inflammation mediated by cytokines such as interleukin-1, interleukin-6, and tumor necrosis factor (TNF-α). Genetic factors also played a role, with gene loci such as PTPN22 associated with increased susceptibility to both conditions. Surgical interventions like hysterectomy were linked to increased inflammation and subsequent autoimmune activation, while modified surgical techniques showed promise in mitigating risk.

What Are the Greatest Implications of This Review?

This review highlights the necessity for clinicians to adopt an interdisciplinary approach when managing patients with either endometriosis or SLE, as their comorbidity exacerbates disease burden and complicates treatment. It emphasizes the importance of targeted therapies to modulate immune response alongside careful evaluation of surgical and hormonal treatment strategies to minimize adverse outcomes. The findings suggest a potential for incorporating microbial and genetic markers into diagnostic and therapeutic protocols to improve outcomes.

What was reviewed?

The study reviewed the relationship between the gut microbiota and endometriosis, focusing on how the gut microbiota may influence the pathogenesis, diagnosis, and potential treatment of endometriosis through various mechanisms such as estrogen modulation, immune response, and inflammation.

Who was reviewed?

The review did not involve specific individuals as subjects of study but instead synthesized findings from various studies that investigate the gut microbiota’s involvement in patients with endometriosis. It includes analysis of microbial profiles and their correlations with the disease.

What were the most important findings?

Important findings highlighted that alterations in the gut microbiota are associated with endometriosis and could potentially influence the disease’s pathogenesis through mechanisms linked to hormonal balance, immune modulation, and inflammatory responses. Specifically, changes in bacterial diversity and specific bacterial groups (such as an increase in the Firmicutes/Bacteroidetes ratio) were noted in patients with endometriosis.

What are the greatest implications of this review?

The review suggests that targeting the gut microbiota might offer new strategies for the diagnosis and treatment of endometriosis. Understanding the role of the gut microbiota in endometriosis could lead to non-invasive diagnostic biomarkers and novel therapeutic approaches that involve modulating the gut microbiota through diet, probiotics, or even fecal microbiota transplantation.

What was reviewed?

This review article examines current evidence on the use of medical-grade honey (MGH) as a novel therapy for bacterial vaginosis (BV), a prevalent condition among women of reproductive age characterized by a dysbiosis of the vaginal microbiome. BV is associated with a reduction in protective, lactic acid-producing lactobacilli and an overgrowth of pathogenic anaerobes, often resulting in recurrent symptoms even after standard antibiotic treatment. The authors explore the multifaceted antimicrobial, anti-biofilm, prebiotic, probiotic, anti-inflammatory, antioxidant, and immunomodulatory properties of MGH, and how these may address the shortcomings of conventional therapies. The review synthesizes in vitro, animal, and limited clinical evidence, highlighting the mechanisms by which MGH can selectively inhibit BV-associated pathogens while supporting beneficial microbial populations.

Who was reviewed?

The review encompasses research involving a range of populations and experimental models: in vitro studies on pathogenic and commensal vaginal microbes; animal models, including rats and rhesus macaques, investigating the effects of honey or its constituents on vaginal flora and tissue; and small-scale clinical studies and case series with women experiencing BV or related gynecological disorders. The clinical evidence includes a pilot study using MGH in women with vaginal complaints (including BV), trials on honey-based therapies for cervicitis, and preclinical models examining the impact of honey on vaginal microbiota and tissue health. The reviewed populations predominantly comprise women of reproductive age, but also incorporate data from non-human models to elucidate mechanisms of action.

Most important findings

The review underscores that MGH exhibits broad-spectrum antimicrobial activity through multiple mechanisms—osmotic effects, acidic pH, hydrogen peroxide production, and diverse bioactive compounds (e.g., phenolics, flavonoids). Importantly, MGH's antimicrobial impact is selective: while it significantly inhibits BV-associated pathogens such as Gardnerella vaginalis and Atopobium vaginae, it generally spares or even promotes lactobacilli, which are central to a healthy vaginal microbiome. MGH also disrupts biofilms, a critical factor in BV recurrence and antibiotic resistance, by breaking down the extracellular matrix and preventing biofilm formation. Unlike antibiotics, which can further disrupt the microbiome and drive resistance, MGH supports restoration of the vaginal ecosystem via prebiotic and probiotic effects, encouraging growth of beneficial bacteria. Additional anti-inflammatory, antioxidant, and immunomodulatory properties may promote mucosal healing and reduce recurrence. Clinical evidence, though limited, suggests symptomatic and microscopic improvement in BV and related conditions with intravaginal MGH application.

Key implications

MGH represents a promising alternative or complementary therapy for BV, offering broad-spectrum antimicrobial action without promoting resistance and with the potential to restore a healthy vaginal microbiome. Its ability to eradicate biofilms and modulate inflammation gives it distinct advantages over conventional antibiotics, which are plagued by high recurrence rates, microbiome disruption, and increasing resistance. The favorable impact of MGH on lactobacilli and the microenvironment suggests a paradigm shift toward therapies that restore ecological balance rather than merely suppressing pathogens. However, robust clinical trials are urgently needed to confirm efficacy, optimal formulations, and long-term outcomes before routine clinical adoption.

What was studied?

This population-based nested case-control study investigated the associations between female genital tract infections, selected comorbidities, and infertility using data from the Taiwan National Health Research Database (NHIRD) between 2000 and 2013. The study specifically evaluated whether infections such as pelvic inflammatory disease (PID), bacterial vaginosis (BV), and endometritis, as well as comorbid conditions like obesity, lipid metabolism disorders, and abortion history, were linked to an increased risk of diagnosed infertility. The research leveraged the large scope of the NHIRD, which includes nearly the entire Taiwanese population, to provide robust epidemiological insights. The analysis involved both univariate and multivariate conditional logistic regression to adjust for confounding variables and to isolate the independent associations of different infections and comorbidities with infertility risk in women, stratified by age groups (≤40 and >40 years).

Who was studied?

The study included 18,276 women newly diagnosed with infertility and 73,104 age-matched controls without infertility, all identified from the NHIRD. Controls were matched by age (within three years) and index year and were required to have a history of pregnancy but no prior diagnosis of infertility or use of ovulation stimulants or gonadotropins. Exclusion criteria covered prior hysterectomy, bilateral oophorectomy, cancer, prior chemotherapy or radiotherapy, polycystic ovary syndrome, ovarian failure, endometriosis, adenomyosis, amenorrhea, and Turner syndrome. The mean age of the cohort was 31 years, and the population was predominantly Han Chinese women residing in Taiwan. Patients were further stratified into two age groups (≤40 and >40 years) to assess potential age-related interactions with infertility risk factors.

Most important findings

The most significant finding was a robust association between upper and lower genital tract infections and increased risk of infertility, evident even after controlling for comorbidities and other confounders. Specifically, pelvic inflammatory disease involving the ovary, fallopian tube, pelvic cellular tissue, and peritoneum showed odds ratios (OR) of 4.82 and 6.03 for infertility. Cervical, vaginal, and vulvar inflammation had even higher associations, with ORs of 7.79 and 6.65. Clinicians found that BV and endometritis were associated with infertility in univariate analysis, but multivariate models did not confirm these associations, indicating that other factors or confounders may mediate their effect. Comorbidities such as obesity, lipid disorders, dysthyroidism, and abortion initially showed associations with infertility, but these did not persist after adjustment. Importantly, the study did not examine specific pathogens, but referenced the role of Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Ureaplasma urealyticum, and Trichomonas vaginalis as potential microbial contributors to tubal factor infertility.

Key implications

These findings reinforce the central role of female genital tract infections, particularly upper tract involvement and lower tract inflammation, in the pathogenesis of infertility. The lack of an independent association with bacterial vaginosis and endometritis after adjustment suggests that not all genital infections contribute equally to infertility risk and highlights the importance of distinguishing between associative and causal relationships. For clinicians, this underscores the need for vigilant screening, diagnosis, and management of PID and lower genital tract inflammation as part of infertility workups. The study’s population-based design adds weight to these recommendations, advocating for targeted prevention and early intervention strategies that could mitigate the risk of infertility associated with genital tract infections. These microbiome-related insights are particularly relevant for developing microbiome signatures and risk-stratification tools in reproductive medicine.

What was reviewed?

This review article comprehensively examines the associations between bacterial vaginosis (BV), endometritis, pelvic inflammatory disease (PID), and infertility, with a particular focus on the underlying microbiome-related mechanisms. The paper synthesizes current evidence on how disruptions in the vaginal and endometrial microbiota, characterized predominantly by a loss of beneficial lactobacilli and an overgrowth of anaerobic bacteria, contribute to the pathogenesis of these gynecological conditions. The review covers diagnostic criteria, treatment options, recurrence issues, and the role of the vaginal and endometrial microbial signatures in affecting reproductive outcomes, both naturally and in assisted reproduction settings. It also explores potential mechanistic pathways linking these infections to infertility, including inflammation, immune responses, microbial toxin production, and increased susceptibility to sexually transmitted infections (STIs).

Who was reviewed?

The review synthesizes data from a broad range of studies involving women of reproductive age, particularly those diagnosed with BV, endometritis, or PID, as well as women experiencing infertility (including those undergoing fertility treatments such as in vitro fertilization [IVF]). It considers diverse populations, including women with tubal and non-tubal infertility, women with unexplained or idiopathic infertility, and those with recurrent implantation failure or miscarriage. The article also references clinical trials and meta-analyses, drawing on evidence from both symptomatic and asymptomatic women across multiple ethnic groups and geographic regions.

Most important findings

The review highlights that optimal vaginal health is typically characterized by a microbiota dominated by lactobacilli, which produce lactic acid and antimicrobial compounds, conferring protection against pathogenic bacteria. BV is marked by a depletion of these protective lactobacilli and an overgrowth of anaerobes such as Gardnerella vaginalis, Atopobium vaginae, Megasphaera spp., and others. This microbial imbalance is strongly associated with an increased risk of endometritis and PID, both of which are significant causes of infertility. Notably, more than 85% of PID cases are linked to BV-associated bacteria and/or STIs, but fewer than half involve classic pathogens like Neisseria gonorrhoeae or Chlamydia trachomatis, underscoring the importance of the broader vaginal microbiome.

BV increases the risk of acquiring STIs, which further amplify the risk of upper genital tract infections and infertility. Mechanistically, BV-related bacteria can induce genital tract inflammation, alter immune responses, produce enzymes that degrade cervical mucus, and facilitate pathogen ascension to the endometrium and fallopian tubes. Women with BV and non-lactobacillus-dominated endometrial microbiota have lower implantation and pregnancy rates, particularly in IVF settings. Chronic endometritis (CE) is highly prevalent among women with unexplained infertility and recurrent implantation failure, and cure of CE with antibiotics improves reproductive outcomes. Despite these associations, causality between BV and infertility is not fully established due to heterogeneity in diagnostic criteria, patient populations, and study designs.

Key implications

The review underscores the clinical importance of recognizing and treating BV, endometritis, and PID—especially in women with infertility or at risk of reproductive complications. Early diagnosis and appropriate antibiotic treatment for symptomatic BV and CE can improve fertility outcomes, particularly in IVF patients. The findings also call for a more nuanced understanding of the vaginal and endometrial microbiome, advocating for future research to refine the definitions of “normal” versus “abnormal” microbial states and to clarify the mechanisms linking microbial dysbiosis to infertility. Given the high recurrence rates and diagnostic challenges, integrating microbiome-based diagnostics and interventions (including probiotics) into preconceptional and fertility care may offer new avenues for improving women’s reproductive health.

What was studied?

This original research investigated the long-term effects of dietary quercetin supplementation on female fertility and ovarian physiology in mice, with a specific focus on the role of the enzyme transglutaminase 2 (TG2). Quercetin, a widely consumed flavonoid supplement, is known for its antioxidant properties, but its effects on female reproductive health remain poorly characterized. The study evaluated birth outcomes (number and size of litters, birth spacing) and detailed ovarian histology (folliculogenesis) in mice administered quercetin (5 mg/kg/day) for nine months. Two breeding periods were analyzed: one during prime reproductive age (2–6 months) and another during later reproductive age (8–11 months). The researchers also compared wild-type mice with TG2-null mice to determine whether the observed effects were mediated through TG2 inhibition.

Who was studied?

The subjects were C57BL/6 female mice, either wild-type or genetically modified to lack TG2 (TG2-null), and their offspring. Each experimental group consisted of four females and two males, with both wild-type and TG2-null genotypes represented. Mice were randomly assigned to receive either quercetin or vehicle via drinking water, and breeding outcomes were monitored during two distinct reproductive periods. The offspring of these dams were also analyzed for ovarian morphology and follicle counts at four weeks of age. Additionally, male fertility was assessed by mating quercetin-exposed males with untreated females to exclude male-mediated effects.

Most important findings

Dietary quercetin supplementation produced complex, age-dependent effects on female fertility and ovarian physiology in mice. In young wild-type females, quercetin reduced the total number of litters by approximately 60% and increased the interval between births (birth spacing), indicating a reduction in overall reproductive potential. Paradoxically, these same young females exhibited a nearly 70% increase in average litter size, a change associated with significantly enhanced ovarian folliculogenesis—specifically, an increase in mature antral follicles and a corresponding depletion of primordial and primary follicles. In older females, quercetin reversed its effect, reducing litter size. Importantly, TG2-null mice displayed similar changes in follicle development and litter size as quercetin-treated wild-type mice, and were unresponsive to additional quercetin, indicating that quercetin’s effects are predominantly mediated via TG2 inhibition.

Key implications

This study demonstrates that chronic dietary quercetin, at doses relevant to human supplementation, can adversely affect female reproductive potential by accelerating follicle maturation and depleting ovarian reserves, likely through inhibition of TG2. The findings suggest a risk of premature ovarian aging and reduced fertility with long-term quercetin use in females of reproductive age. The data also highlight TG2 as a novel regulator of ovarian aging and folliculogenesis. These insights are clinically relevant for counseling women considering quercetin supplementation and inform potential mechanisms underlying reproductive disorders, such as those observed in TG2-targeting autoimmune diseases like celiac disease. For microbiome signatures databases, the study underscores the importance of tracking host-microbe interactions influenced by dietary polyphenols and their systemic enzymatic targets.

What was reviewed?

This review examined the complex relationship between pelvic inflammatory disease (PID) and the genital microbiota. It focused on recent advancements in molecular microbiological techniques and their implications for understanding the diverse bacterial communities in both healthy and diseased states of the female genital tract. It also explored how changes in these microbial communities (dysbiosis), specifically bacterial vaginosis, could significantly increase the risk of PID, sexually transmitted infections (STIs), HIV, and adverse reproductive outcomes.

Who was reviewed?

The review analyzed findings from several clinical and molecular microbiology studies involving women diagnosed with pelvic inflammatory disease or other genital infections. It included detailed analyses of microbial communities identified through culture-based methods and advanced molecular techniques, such as 16S rRNA sequencing, PCR-based identification, and cloning and sequencing methods. Patient groups ranged from asymptomatic healthy individuals to women with symptomatic PID, endometriosis, salpingitis, and tubo-ovarian abscesses (TOAs).

What were the most important findings?

The most important findings were that PID is typically polymicrobial, involving a diverse range of pathogens beyond traditional culprits like Chlamydia trachomatis and Neisseria gonorrhoeae. Advanced molecular techniques revealed that bacterial vaginosis-associated bacteria (BVAB), including Gardnerella vaginalis, Atopobium vaginae, and several anaerobic species (e.g., Prevotella, Sneathia, and BVAB 1, 2, and 3), significantly associate with PID development. This contrasts with earlier beliefs that focused primarily on classic sexually transmitted pathogens. The data strongly indicate that vaginal microbiota disturbances, especially reductions in protective Lactobacillus species, substantially increase the risk of ascending infections to the upper genital tract.

Clinicians are increasingly recognizing novel microbial phylotypes and traditionally overlooked anaerobes in PID, especially in severe cases like TOAs. Anaerobes such as Prevotella, Bacteroides, and Peptostreptococcus have frequently emerged as critical players. The identification of BV-associated microbes in salpingitis and abscesses reinforces the microbial continuum from vaginal dysbiosis to upper genital tract infections, providing substantial evidence that microbial dysbiosis directly predisposes women to PID.

What are the greatest implications of this review?

This review significantly impacts clinical practice by underscoring the importance of maintaining a healthy vaginal microbiota to prevent upper genital tract infections. Clinicians should recognize BV as a critical modifiable risk factor for PID and associated complications, including infertility and ectopic pregnancy. The findings emphasize the urgent need for improved screening and treatment strategies for BV to reduce PID incidence and associated reproductive health complications. Additionally, molecular identification of novel pathogens stresses the necessity of broad-spectrum antimicrobial regimens capable of targeting a diverse microbial landscape, especially anaerobes. Future research must continue exploring the therapeutic and preventive potential of maintaining a healthy vaginal microbiome.

What was studied?

The study investigated the vaginal microbiome and metabolome of reproductive-age women to identify metabolic markers and microbial associations linked to bacterial vaginosis (BV). Researchers used a multi-omic systems-based approach, integrating deep 16S rRNA gene sequencing with metabolomic profiling of vaginal lavage samples collected from 36 women. This study sought to overcome the limitations of traditional diagnostic methods like the Nugent score and Amsel criteria, which have been criticized for inconsistency and inability to accurately capture symptomatic BV cases.

Who was studied?

The study involved 36 women of reproductive age, who varied demographically and behaviorally. Participants were clinically evaluated for BV using Amsel criteria and Nugent scoring. Vaginal lavage samples were collected from these women and subjected to both microbial and metabolic analyses. The cohort included both symptomatic and asymptomatic women, covering a diverse range of Nugent scores and BV symptoms, to enable the identification of associations between microbial taxa, metabolomic profiles, and disease status.

Most Important Findings

The study identified distinct microbial and metabolomic profiles associated with BV. It showed that microbial community composition, as assessed by 16S rRNA gene sequencing, reflected Nugent scores but poorly matched Amsel criteria. In contrast, metabolomic profiles were more aligned with Amsel-defined symptomatic BV, highlighting the potential diagnostic value of metabolic markers.

The researchers distinguished two symptomatic BV metabotypes (SBVI and SBVII), each linked to unique microbial and metabolic features. SBVI correlated with Mobiluncus spp. and Allisonella spp., while SBVII correlated with Hallella spp. Both metabotypes were marked by disruption of epithelial integrity but differed in microbial signatures and metabolic profiles.

Key microbial associations included increased abundance of Gardnerella spp. and Dialister spp. in samples with high Nugent scores. Dialister spp. correlated strongly with elevated levels of putrescine and cadaverine, compounds responsible for BV-associated odor. Mobiluncus spp. were associated with increased 2-methyl-2-hydroxybutanoic acid, linked to vaginal discharge, while Gardnerella spp. were connected to diethylene glycol, associated with vaginal pain. The study also noted that decreases in lactic acid-producing lactobacilli and increases in acetate- and propionate-producing bacteria characterized the BV state. Importantly, the relative abundance of Gardnerella spp. and Dialister spp. was not consistently associated with Amsel criteria, underscoring the complexity of the microbiome-symptom relationship​​​​.

Implications of this Study

This study advances understanding of BV by providing molecular-level evidence that the symptomatic state of BV cannot be attributed solely to microbial composition. Instead, it highlights that metabolic activity and metabolite production, driven by specific bacterial taxa, play a critical role in disease manifestation. The identification of two distinct symptomatic BV metabotypes suggests that BV is not a singular condition but may arise via different microbial and metabolic pathways. These findings imply that clinical diagnostics for BV should integrate metabolomic data alongside microbial profiling to improve accuracy and reduce misclassification based on Nugent score or Amsel criteria alone. These insights open avenues for targeted microbiome-based interventions and the development of metabolite-specific therapeutic strategies.

What was studied?

This integrated study analyzed the efficacy and safety of a single-dose 2 g oral formulation of secnidazole (SOLOSEC™) for the treatment of bacterial vaginosis (BV) in women. Drawing from two randomized, double-blind, placebo-controlled pivotal clinical trials, the researchers aimed to evaluate whether this simplified regimen could overcome the adherence challenges commonly associated with the current extended-dose treatments for BV. The study compared clinical cure rates, microbiological outcomes, and adverse event profiles between the secnidazole and placebo groups, providing a comprehensive efficacy and safety assessment to support regulatory approval and clinical use.

Who was studied?

The integrated analysis included 288 women who met all inclusion and exclusion criteria—169 were treated with 2 g of secnidazole, and 119 received a placebo. Participants ranged in age from 18 to 54 years, with a median of 31. The racial composition was diverse, with over 50% identifying as Black or African American. Participants were also stratified by the number of BV episodes in the past year (three or fewer vs. four or more), acknowledging the recurrent nature of BV in many women. All participants had to meet the four Amsel criteria for BV, ensuring consistency with FDA standards.

What were the most important findings?

The integrated analysis demonstrated that single-dose secnidazole significantly improved clinical outcomes compared to placebo. Patients treated with secnidazole were far more likely to experience complete resolution of symptoms, normalization of discharge and odor, and restoration of a healthy vaginal microbiome. Microbiological analysis showed that more patients achieved normal Nugent scores following treatment, which correlates with reduced presence of BV-associated anaerobic bacteria and increased dominance of beneficial Lactobacillus species. The drug was effective across both first-time and recurrent cases and provided consistent benefits regardless of race. Secnidazole targets key BV-associated organisms such as Gardnerella vaginalis, Atopobium vaginae, and Prevotella, while sparing protective lactobacilli. This microbial specificity aligns closely with the recognized dysbiotic profile of BV and suggests secnidazole may facilitate reestablishment of microbiome homeostasis. Adverse effects were mild and infrequent, most commonly involving vaginal yeast overgrowth and transient gastrointestinal discomfort, with no significant safety concerns emerging in the analysis.

What are the implications of this study?

The findings establish secnidazole as a compelling treatment option for BV that addresses both clinical symptoms and the underlying microbial imbalance. The one-dose regimen greatly enhances patient adherence, a crucial factor in reducing recurrence and treatment failure. Because secnidazole selectively targets harmful bacteria while preserving beneficial species, it supports the restoration of a healthy vaginal microbiome, a key goal in microbiome-based therapeutic strategies. The study also reinforces the validity of BV’s microbial signature as a foundation for targeted intervention. As such, secnidazole not only demonstrates therapeutic efficacy but also contributes to a growing paradigm of microbiome-conscious treatment approaches in gynecologic care.

What was studied?

The study investigated the antimicrobial activity of bovine lactoferrin (MTbLF) against clinical isolates of Gardnerella vaginalis (G. vaginalis), which is a key pathogen in the development of bacterial vaginosis (BV). The study also examined the potential synergistic effects of bovine lactoferrin when combined with commonly used antibiotics, metronidazole and clindamycin. It utilized a range of in vitro experiments to determine the dose-dependent effects of MTbLF and its ability to inhibit the growth of both metronidazole-resistant and susceptible G. vaginalis isolates.

Who was studied?

The study focused on 71 clinical isolates of Gardnerella vaginalis that were presumptively identified from vaginal samples collected from women diagnosed with bacterial vaginosis. The researchers subjected these isolates to antimicrobial susceptibility testing to evaluate their resistance profiles against metronidazole and clindamycin.

What were the most important findings?

The study found that MTbLF exhibited significant antimicrobial activity against G. vaginalis isolates, including those resistant to metronidazole. The inhibitory effect was dose-dependent and not strain-dependent, suggesting that MTbLF could effectively target G. vaginalis, regardless of the strain. Combining MTbLF with clindamycin enhanced the antibiotic's efficacy against G. vaginalis, producing a synergistic effect. This finding highlights the potential of MTbLF as an adjunctive treatment for BV, particularly in cases involving antibiotic-resistant strains. Additionally, the study confirmed that G. vaginalis strains were unable to utilize bovine lactoferrin as an iron source, contrasting with their ability to acquire iron from human lactoferrin, which may contribute to the pathogen’s resilience in the vaginal environment.

What are the implications of this study?

The study highlights the potential of MTbLF as an adjunct or alternative treatment for BV, especially in cases where traditional antibiotics like metronidazole and clindamycin are ineffective due to resistance. Given its iron-binding properties, MTbLF could help disrupt the growth of G. vaginalis by depriving it of essential iron, thereby hindering its ability to proliferate. The observed synergy between MTbLF and clindamycin could pave the way for more effective combination therapies. Furthermore, MTbLF’s ability to inhibit G. vaginalis, even in biofilm-forming states, highlights its potential in managing BV, a condition known for its recurring nature and complexity. These findings warrant further exploration, particularly in clinical settings, to assess the safety and pharmacokinetics of MTbLF in treating and preventing BV recurrence.

What was Studied?

This study investigated the relationship between dietary patterns and bacterial vaginosis (BV) in women. Researchers analyzed how different diets influenced BV risk, focusing on five major dietary patterns: "Healthy diet," "Unhealthy diet," "Ovo-vegetarian diet," "Pseudo-Mediterranean diet," and "Western diet."

Who was Studied?

The study included 144 women diagnosed with BV and 151 healthy controls. Participants were recruited from a gynecology clinic in Tehran, Iran, between November 2020 and June 2021. Researchers assessed dietary intake using a food frequency questionnaire and diagnosed BV using the Amsel criteria.

Most Important Findings

Women who followed an "Unhealthy diet" high in sugar, solid oils, red meat, sweets, fried potatoes, and refined grains had a significantly higher risk of BV. Those in the highest tertile of this diet were more than three times as likely to have BV compared to those in the lowest tertile.

Conversely, the "Ovo-vegetarian diet," rich in vegetables, beans, whole grains, and eggs, was strongly associated with a lower BV risk. Women in the highest adherence group for this diet had an 84% lower chance of BV compared to those in the lowest adherence group.

The study also observed a protective but not statistically significant effect of the "Pseudo-Mediterranean diet," which includes nuts, fish, olives, and olive oil. No clear association was found between BV and the "Healthy diet" or "Western diet."

Microbiome analysis linked the "Unhealthy diet" with a disruption in vaginal flora, favoring BV-associated bacteria like Gardnerella vaginalis, Bacteroides spp., Mobiluncus spp., and Mycoplasma hominis. In contrast, the "Ovo-vegetarian diet" promoted conditions favorable for Lactobacillus dominance, which helps maintain vaginal health.

Implications of the Study

This study reinforces the role of diet in vaginal microbiome balance and BV risk. Clinicians should encourage patients to reduce processed foods, refined sugars, and saturated fats while promoting a plant-based diet rich in fiber, whole grains, and essential nutrients. Future research should explore whether dietary modifications can serve as an effective strategy for BV prevention and treatment.

What was Studied?

The study examined the association between exposure to heavy metals, specifically lead, cadmium, and mercury, and the risk of bacterial vaginosis (BV) among American women. Using a cross-sectional design, the researchers analyzed data from 2,493 women aged 18 to 49 years who participated in the 2001–2004 cycles of the National Health and Nutrition Examination Survey (NHANES). They measured serum levels of these heavy metals and assessed BV status using Nugent scoring, aiming to clarify whether environmental exposure to heavy metals correlates with BV prevalence.

Who was Studied?

The study included 2,493 American women aged between 18 and 49 years. All participants were selected from NHANES datasets, which provide a representative sample of the U.S. population. The researchers collected vaginal swabs to diagnose BV using the Nugent score and measured serum concentrations of lead, cadmium, and mercury. They controlled for several covariates such as age, body mass index, socioeconomic factors, cholesterol levels, and physical activity to ensure reliable statistical analysis.

Most important findings

The study found a significant positive association between serum lead and cadmium levels and the risk of developing bacterial vaginosis. Specifically, women with the highest serum lead concentrations had a 35% increased risk of BV compared to those with the lowest levels. Similarly, higher cadmium levels were associated with a 41% increased risk of BV in fully adjusted models. However, the researchers found no significant association between serum mercury levels and BV risk.

Stratified analyses revealed that the positive association between lead exposure and BV was more pronounced in women aged 37 to 49 years, those with lower education levels, and those with a higher body mass index. For cadmium, the risk was especially higher among women aged 18 to 24 and 37 to 49 years, and among those of non-Hispanic white and black ethnicity. These results suggest that lead and cadmium may influence vaginal microbiota stability, possibly through immunotoxic or endocrine-disrupting mechanisms, contributing to vaginal dysbiosis and increased BV susceptibility.

Implications of this Study

This study provides the first epidemiological evidence linking heavy metal exposure to increased risk of bacterial vaginosis. The findings suggest that environmental pollutants may act as overlooked risk factors in BV pathogenesis by compromising host immune function, disrupting hormonal balance, and potentially altering the vaginal microbiome. Clinicians and public health officials should consider environmental heavy metal exposure as part of BV risk assessment and prevention strategies. Reducing heavy metal exposure through regulatory policies and patient education could offer an additional layer of protection against BV and its associated reproductive health risks. These results highlight the importance of integrating environmental factors into the broader framework of microbiome-related disease prevention.

What was studied?

This study investigated the bacterial biota in women with bacterial vaginosis (BV) and assessed the effects of two different concentrations of vaginal lactoferrin pessaries (100 mg and 200 mg) on the vaginal bacterial composition. The aim was to characterize the vaginal microbiota before, during, and after lactoferrin treatment.

Who was studied?

Sixty sexually active women of reproductive age (18–45 years old) with symptomatic acute BV were studied. The women were randomly assigned to two groups: one group received 200 mg lactoferrin vaginal pessaries, and the other received 100 mg lactoferrin vaginal pessaries.

What were the most important findings?

The study showed that lactoferrin treatment significantly altered the vaginal microbiota in women with BV. During the treatment, both 100 mg and 200 mg doses of lactoferrin reduced the abundance of bacteria commonly associated with BV, such as Gardnerella, Prevotella, and Lachnospira. Concurrently, the levels of Lactobacillus species increased. The most significant changes were with the 200 mg lactoferrin dose, which maintained the bacterial balance up to 2 weeks after treatment. In contrast, the 100 mg dose did not maintain the microbiota balance as effectively post-treatment, with an increase in Gardnerella and Prevotella species observed. The study also highlighted that Lactobacillus helveticus became the dominant species during and after treatment, a species not previously detected in the vaginal microbiome of these participants.

What are the implications of this study?

The findings suggest that lactoferrin could be a viable alternative therapeutic approach for BV, offering a non-antibiotic treatment option. By promoting the growth of Lactobacillus species and reducing pathogenic bacteria, lactoferrin helps restore a healthier vaginal microbiota. This approach may overcome some of the limitations of antibiotic treatments for BV, such as recurrence and resistance development. The emergence of Lactobacillus helveticus during lactoferrin treatment suggests the potential for new probiotic strains for BV management. These results also point toward the need for further research on the role of lactoferrin in maintaining long-term vaginal health.

What Was Studied?

This study investigated the composition and diversity of vaginal bacterial communities in women with bacterial vaginosis (BV) using high-resolution phylogenetic analysis. Researchers aimed to identify specific bacterial species associated with BV and determine their relationship to clinical diagnostic criteria. By employing deep sequencing of the 16S rRNA gene, the study provided a more precise taxonomic classification of BV-associated bacteria.

Who Was Studied?

The study analyzed vaginal swabs from 220 women with and without BV. Researchers diagnosed BV using Amsel’s clinical criteria and confirmed cases with Gram staining. The study examined bacterial communities in diverse participants, including Black and White women, to assess potential differences in microbiome composition by race.

Key Findings and Microbial Associations

Women with BV exhibited highly diverse and heterogeneous vaginal bacterial communities, unlike those without BV, whose microbiomes were dominated by Lactobacillus crispatus or Lactobacillus iners. The study identified Leptotrichia amnionii and Eggerthella sp. as the only bacteria significantly associated with all four Amsel’s diagnostic criteria for BV. Other BV-associated bacteria, including Gardnerella vaginalis, Atopobium vaginae, Prevotella spp., and Sneathia sanguinegens, correlated with specific diagnostic features, such as clue cells and amine odor.

The study also revealed distinct subgroups of BV-associated bacteria that co-occurred, suggesting metabolic interdependencies. Notably, Black women without BV had higher levels of certain BV-associated bacteria than White women, which may contribute to BV’s higher prevalence in this population. Additionally, the findings highlighted discrepancies between Amsel’s criteria and Nugent scoring, emphasizing the need for more refined diagnostic tools.

Implications of the Study

This study highlights the complexity of BV as a polymicrobial condition rather than an infection caused by a single pathogen. Identifying bacterial species at high resolution improves diagnostic accuracy and reveals potential microbial interactions that sustain BV. The research supports the need for microbiome-targeted therapies rather than broad-spectrum antibiotics, which often fail to prevent recurrence. Racial differences in vaginal microbiota composition suggest that BV treatment strategies should account for population-specific variations.

These findings emphasize the importance of advanced sequencing techniques in BV research, providing a foundation for future studies to develop better diagnostic criteria and treatment options.

What Was Reviewed?

This review provides a comprehensive synopsis of the current literature on bacterial vaginosis (BV), focusing on its epidemiology, recurrence, persistence, and treatment challenges. The authors examine the impact of BV on reproductive and sexual health, highlighting its association with sexually transmitted infections (STIs) and adverse pregnancy outcomes. Additionally, the review explores the role of the vaginal microbiota in BV pathogenesis, emphasizing the need for more effective long-term treatment options and standardized definitions for recurrent and persistent BV.

Who Was Reviewed?

The review synthesizes studies on women of reproductive age diagnosed with BV, including those with recurrent infections. It also explores research on the vaginal microbiota, sexual partners' role in BV transmission, and the effectiveness of current treatments. By analyzing epidemiological data from various regions, it highlights differences in BV prevalence and risk factors.

Key Findings and Microbial Associations

BV shifts the vaginal microbiota by depleting Lactobacillus species and allowing anaerobic bacteria like Gardnerella vaginalis, Atopobium vaginae, Prevotella spp., and Mobiluncus spp. to overgrow. This microbial imbalance disrupts the vaginal ecosystem and increases susceptibility to STIs, including Neisseria gonorrhoeae, Chlamydia trachomatis, and HIV. Even with metronidazole or clindamycin treatment, BV recurs in up to 80% of cases within three months. The review explores BV recurrence, showing how reinfection, an inability to restore a Lactobacillus-dominant microbiota, and bacterial biofilms contribute to persistent infections. Clinicians rely on Amsel’s criteria and Nugent scoring for diagnosis, but inconsistent definitions of recurrent and persistent BV complicate management. The review also examines partner treatment as a strategy to reduce BV recurrence, though past studies show mixed results.

Implications of the Review

BV remains a significant clinical challenge due to its high recurrence rates, unclear etiology, and association with reproductive health complications. This review calls for more research into microbiome-based therapies, improved diagnostic tools, and standardized definitions of recurrent BV. The findings suggest that future treatment approaches should not only target BV-associated bacteria but also focus on restoring a stable vaginal microbiota. Additionally, reconsidering partner treatment as part of BV management could be an avenue for reducing recurrence rates, provided that future studies can confirm its effectiveness.

What was Reviewed?

This narrative review examined the role of biofilms in bacterial vaginosis (BV), focusing on their contribution to treatment resistance and recurrence. The authors synthesized evidence from clinical studies and trials to evaluate the limitations of current antibiotic therapies and explored emerging solutions, such as biofilm-disrupting agents and probiotics, to improve BV management.

Who was Reviewed?

The review analyzed data from diverse patient populations in clinical studies, including women with recurrent BV. It incorporated findings from trials investigating biofilm-targeted therapies, such as enzymatic disruptors (e.g., dispersin B) and probiotics (e.g., Lactobacillus crispatus), to assess their efficacy in restoring vaginal microbiota balance.

What were the most Important Findings?

The review highlighted that BV-associated biofilms, primarily formed by Gardnerella vaginalis and Atopobium vaginae, shield pathogenic bacteria from antibiotics, driving recurrence. Major microbial associations (MMA) included polymicrobial anaerobic communities displacing protective Lactobacillus species. Probiotics and biofilm-disrupting agents (e.g., boric acid, Astodrimer gel) showed promise in clinical trials, with probiotics delaying recurrence by 51% and Astodrimer gel significantly reducing recurrence rates. Notably, Lactobacillus crispatus-based therapies were emphasized for restoring vaginal acidity and inhibiting biofilm formation.

What are the Implications of this Review?

The findings emphasize the need to shift from antibiotic-only approaches to multimodal strategies targeting biofilms. Clinicians should consider adjunct therapies like probiotics and biofilm disruptors to enhance treatment efficacy and reduce recurrence. The review also calls for further research into vaginal microbiome transplantation (VMT) and personalized therapies to address biofilm resilience.

What was Studied?

This cross-sectional study investigated the association between bacterial vaginosis (BV), past chlamydial infection, and tubal infertility in women undergoing IVF. The researchers analyzed vaginal swabs and serologic data from 286 women undergoing 344 IVF cycles to determine whether these infections impacted pregnancy rates or were linked to specific infertility causes.

Who was Studied?

The study included 286 women undergoing IVF treatment at a tertiary care infertility referral center in Glasgow, Scotland. Participants provided high vaginal and endocervical swab samples before oocyte retrieval, with serologic testing for Chlamydia trachomatis and BV diagnosis based on Gram staining and anaerobic culture.

What were the most Important Findings?

The study found strong, independent associations between tubal infertility and both BV (87.5% of BV-positive women had tubal damage) and past chlamydial infection (91.2% seropositivity in tubal infertility cases). Notably, BV and chlamydial infections were frequently asymptomatic, with no active chlamydial infections detected. Major microbial associations (MMA) included reduced Lactobacillus dominance in BV-positive women, alongside overgrowth of anaerobic bacteria. Despite these associations, pregnancy rates after IVF were unaffected by BV or past chlamydial infection, though BV-positive women had numerically lower implantation rates (15.2% vs. 31.0% in chlamydia-seropositive women).

What are the Implications of this Study?

The findings underscore BV as a potential pelvic pathogen contributing to tubal damage, independent of chlamydial infection. While IVF success rates remained comparable across groups, the high prevalence of tubal infertility in BV-positive women suggests that early screening and treatment of asymptomatic BV could prevent long-term reproductive complications. Clinicians should consider BV as a modifiable risk factor in infertility workups, particularly in cases of unexplained tubal pathology.

What was Reviewed?

This expert review examined the associations between bacterial vaginosis (BV), endometritis, pelvic inflammatory disease (PID), and infertility, synthesizing evidence from clinical studies, microbiome research, and treatment outcomes. The authors explored how BV-related dysbiosis contributes to upper genital tract infections and reproductive complications, while evaluating diagnostic challenges and emerging therapeutic strategies.

Who was Reviewed?

The review analyzed data from diverse populations of reproductive-age women, including those with infertility, recurrent BV, or PID. It incorporated findings from studies on vaginal and endometrial microbiota, clinical trials on BV treatments (e.g., antibiotics, probiotics), and research on immune and inflammatory responses linked to infertility.

What were the most Important Findings?

BV, characterized by reduced Lactobacillus dominance and overgrowth of anaerobes like Gardnerella vaginalis and Atopobium vaginae, was strongly associated with tubal infertility (3.3-fold higher prevalence in infertile women) and PID. Major microbial associations (MMA) included elevated levels of proinflammatory cytokines (IL-1β, IL-6, IL-8) in BV-positive women, which disrupt endometrial receptivity. Subclinical PID, often linked to BV, reduced pregnancy likelihood by 40%. Notably, Lactobacillus crispatus probiotics reduced BV recurrence by 15% compared to placebo, while endometrial microbiota dominated by non-lactobacilli correlated with lower IVF success rates. Chronic endometritis (CE), prevalent in 34%–66% of unexplained infertility cases, improved fertility outcomes post-antibiotic treatment, with cured CE showing a 76.3% pregnancy rate versus 20% in persistent cases.

What are the Implications of this Review?

The findings underscore BV as a modifiable risk factor for infertility, emphasizing the need for early screening and treatment to prevent PID and CE. Clinicians should consider Lactobacillus-based probiotics and biofilm-disrupting agents for recurrent BV. For infertility workups, endometrial microbiota analysis and CE testing are critical, particularly in cases of repeated implantation failure. Future research should prioritize longitudinal studies to clarify causal links between BV dysbiosis and infertility, while optimizing personalized therapies targeting the vaginal microbiome.

What was reviewed?

The paper provides a comprehensive review of bacterial vaginosis (BV), its association with biofilm formation, and challenges related to current treatment strategies. The review explores the microbial composition of BV, focusing on the primary pathogen, Gardnerella vaginalis, and the complex nature of BV biofilms, which contribute to the high recurrence rates of the infection. The review presents emerging therapeutic alternatives targeting BV biofilms, including natural antimicrobial agents and biofilm disruptors.

Who was reviewed?

The review examined various studies, clinical trials, and scientific literature that explored the microbial nature of bacterial vaginosis (BV), focusing on biofilm formation and its implications for treatment. It also reviewed the role of G. vaginalis and other anaerobic bacteria in the pathogenesis of BV, along with current and emerging treatment strategies targeting these biofilms. The review synthesized information from studies that investigated the efficacy of traditional therapies, such as metronidazole and clindamycin, as well as novel biofilm-disrupting agents like DNases, probiotics, and plant-derived antimicrobials.

What were the most important findings?

The review emphasizes the polymicrobial nature of bacterial vaginosis, with a marked decrease in beneficial lactobacilli species and an increase in anaerobic bacteria, such as Gardnerella vaginalis, Atopobium vaginae, Mobiluncus spp., Bacteroides spp., and Prevotella spp. A major highlight of the paper is the critical role of biofilms in BV pathogenesis, as these microbial communities exhibit significant resistance to conventional antibiotic treatments like metronidazole. This biofilm formation creates a dense matrix that protects the bacteria from immune system clearance and limits the effectiveness of standard therapies. Biofilms composed primarily of G. vaginalis are particularly resilient, contributing to treatment failure and the recurrence of BV. The review further discusses how researchers are exploring novel therapies, such as DNases, retrocyclins, probiotics, and plant-derived antimicrobials, to overcome biofilm-related antibiotic resistance. The paper also identifies the need for more research into multi-species biofilm interactions to develop more effective treatments for BV.

What are the implications of this review?

The implications of this review are significant for the clinical management of BV. The findings highlight the need for new treatment strategies that can specifically target biofilms, which are a major obstacle to the eradication of BV. Given the high recurrence rates of BV despite current antibiotic therapies, exploring alternative treatments that can disrupt biofilm structures, such as biofilm disruptors and natural antimicrobials, is essential. Clinicians may benefit from being aware of emerging treatments that could offer better outcomes, particularly for recurrent BV cases that do not respond well to standard treatments. Additionally, the review underscores the importance of considering the entire microbiome, including lactobacilli, when developing treatment plans to ensure that therapies do not disrupt the beneficial microbial community, which is crucial for vaginal health.

What was Studied?

This study examined how dietary indices, including glycemic load (GL), glycemic index (GI), the Healthy Eating Index (HEI), and the Naturally Nutrient Rich (NNR) score, influence bacterial vaginosis (BV) prevalence, progression, and persistence. Researchers aimed to determine whether overall dietary quality, rather than just individual nutrients, affects vaginal microbiome balance.

Who was Studied?

The study analyzed data from 1,735 nonpregnant women aged 15 – 44, primarily African American (85.5%), recruited from health clinics in Birmingham, Alabama. Researchers assessed annual dietary intake using the Block98 food frequency questionnaire and classified vaginal flora using Nugent Gram-stain criteria.

Most Important Findings

A higher glycemic load significantly increased the risk of BV. For every 10-unit increase in GL, the likelihood of BV progression and persistence rose. High-GL diets, which result in frequent blood sugar spikes, may contribute to vaginal flora imbalances and increased oxidative stress, reducing the body's ability to maintain a protective microbiome.

Conversely, women with higher NNR scores, which reflect greater nutrient density per calorie, had a lower risk of BV. This suggests that diets rich in vitamins, minerals, and fiber may help support a healthy vaginal microbiome. HEI scores above 70, indicating greater adherence to dietary guidelines, were associated with a reduced BV risk, but this association was only borderline significant after adjusting for confounding factors.

Unlike GL, which considers both carbohydrate quality and quantity, glycemic index (GI) showed no clear link to BV. Because GI only measures how quickly food raises blood sugar without accounting for quantity, it may not fully capture how diet affects vaginal health.

Implications of the Study

This study highlights the role of diet quality in vaginal microbiome health. Clinicians should counsel patients on the risks of high-GL diets and emphasize nutrient-dense food choices to lower BV risk. Future research should explore how dietary modifications influence BV outcomes and whether interventions targeting glycemic load can serve as preventive measures.

What Was Reviewed?

This review examines the drivers of bacterial vaginosis (BV) recurrence and the challenges and opportunities in partner treatment. BV is a prevalent vaginal condition with a high recurrence rate, often within six months of treatment. The review explores the mechanisms behind recurrence, including reinfection from untreated sexual partners, the persistence of BV-associated bacteria (BVAB), and the role of biofilms. It also discusses past research on whether treating male and female sexual partners can improve BV cure rates and the barriers to implementing partner treatment in clinical settings.

Who Was Reviewed?

The review evaluates studies involving women diagnosed with BV, particularly those who experience recurrent infections. It also incorporates research on the sexual partners of these women, analyzing the microbial composition of the male urethra and penile skin and how bacterial exchange between partners may contribute to reinfection. Clinical trials on partner treatment strategies, including those testing antibiotics like metronidazole and clindamycin, are also assessed.

Key Findings and Microbial Associations

BV recurrence has multiple causes, with reinfection from sexual partners being an overlooked factor. The review shows that BV-associated bacteria like Gardnerella vaginalis, Atopobium vaginae, and Prevotella spp. can transfer between partners, including heterosexual and same-sex couples. This supports the idea that BV may have a sexually transmissible component.

Past studies on partner treatment have had mixed results, leading to skepticism. Many were limited by small sample sizes, inconsistent diagnostic criteria, and short follow-ups. However, newer research suggests that when partners adhere to antibiotics, recurrence rates may drop. The review highlights challenges in partner treatment trials, including low participation and the need for therapies targeting bacterial biofilms and antimicrobial resistance.

Implications of the Review

BV’s high recurrence rate not only causes discomfort but also increases risks like preterm birth and STI susceptibility. This review calls for a fresh approach, including reconsidering partner treatment. While current guidelines do not recommend treating partners, emerging evidence suggests that doing so, alongside therapies that promote a stable, lactobacilli-dominated vaginal microbiota, may improve long-term cure rates. Future studies should refine partner treatment, enhance antimicrobial strategies, and develop microbiome-targeted therapies to prevent recurrence.

What was reviewed?

This review examines the current methods for bacterial vaginosis (BV) diagnosis and explores future opportunities for improving diagnostic accuracy. It provides an in-depth analysis of traditional clinical and microscopic diagnostic methods, their limitations, and the potential of emerging molecular, metabolomic, and proteomic approaches. The review also highlights the microbiome’s role in BV pathogenesis and discusses how advances in sequencing technologies and biomarker discovery could enhance diagnosis and treatment.

Who was reviewed?

The review synthesizes findings from multiple studies on BV diagnosis, including research on bacterial populations associated with BV, clinical diagnostic criteria, and emerging molecular techniques. It draws from a wide range of studies on vaginal microbiome composition, molecular assays, and point-of-care (POC) diagnostic tools.

What were the most important findings?

Bacterial vaginosis occurs when the vaginal microbiome shifts, reducing lactobacilli and increasing anaerobic bacteria like Gardnerella vaginalis and Atopobium vaginae. Traditional diagnostic methods, including Amsel’s criteria and the Nugent score, have been widely used for decades. However, both have limitations, especially in detecting asymptomatic cases.

Amsel’s criteria require at least three of four clinical signs: thin discharge, high vaginal pH, clue cells, and a fishy odor. The Nugent score relies on Gram staining and bacterial morphotypes. Both methods are subjective and prone to interobserver variability, leading to misdiagnosis, particularly in resource-limited settings.

Molecular diagnostic tools offer better sensitivity and specificity. Nucleic acid amplification tests (NAATs) detect multiple BV-associated bacteria in a single test, making diagnoses more accurate. Next-generation sequencing (NGS) has revealed that BV results from a polymicrobial community, not a single pathogen.

New diagnostic approaches include metabolomics and proteomics, which analyze metabolic byproducts and proteins linked to BV. The sialidase enzyme, produced by BV-associated bacteria, is a promising diagnostic marker. Proteomic studies have identified immune-related proteins that change in BV. These molecular markers could improve diagnostic accuracy and enable personalized treatments.

Artificial intelligence (AI) and machine learning are also being explored for BV diagnosis. AI models analyze microbiome data, metabolomic signatures, and patient outcomes to identify patterns. These advancements could enhance diagnostic precision, especially in clinical settings where fast, accurate, and cost-effective tests are essential.

What are the implications of this review?

The findings highlight the urgent need for improved BV diagnostics, especially in resource-limited settings where syndromic management is common. Relying only on symptoms often leads to misdiagnosis and unnecessary antibiotic use, increasing resistance. Shifting to molecular diagnostics and biomarker-based testing could improve accuracy, reduce misdiagnosis, and enhance treatment outcomes. A key takeaway is that BV diagnosis should go beyond bacterial identification. It should include microbial interactions, biofilm presence, metabolic activity, and immune responses. Rapid point-of-care molecular tests, combined with machine learning and biomarker-based approaches, could greatly improve BV diagnosis and management. Understanding microbial communities and biofilms in BV may also lead to better treatments, including microbiome-targeted therapies and potential vaccines. Since BV increases the risk of sexually transmitted infections, preterm birth, and reproductive issues, improving diagnostic accuracy is essential for better patient outcomes.

What Was Reviewed?

This review provides an in-depth exploration of bacterial vaginosis (BV), focusing on its etiology, diagnostic challenges, and treatment strategies. It explores the link between the vaginal microbiome and bacterial vaginosis, highlighting the shift from a Lactobacillus-dominated environment to one dominated by anaerobic bacteria like Gardnerella vaginalis and Atopobium vaginae. The review evaluates molecular and clinical diagnostic tools such as Amsel’s criteria, Nugent scoring, and PCR-based methods. Additionally, it highlights the limitations of antibiotic treatments due to high recurrence rates. It also explores emerging therapies, including probiotics, vaginal microbiota transplantation (VMT), and biofilm-targeting strategies​.

Who Was Reviewed?

This review synthesizes data from various studies examining the vaginal microbiome and its role in BV. It considers research on women of reproductive age from different geographic regions and ethnic backgrounds, recognizing the variability in vaginal microbiota composition. The review also addresses the broader clinical implications of BV, notably its links to sexually transmitted infections, pregnancy complications, and reproductive health​.

What Were the Most Important Findings?

The most significant finding is that BV is a polymicrobial shift, not an infection caused by a single pathogen. A healthy vaginal microbiome is dominated by Lactobacillus spp, but BV causes Lactobacilli decline and anaerobe overgrowth, including Gardnerella vaginalis and Prevotella spp. These bacteria form biofilms that contribute to antibiotic resistance and high recurrence rates.

The review highlights the flaws in traditional diagnostic methods. Amsel’s criteria and Nugent scoring are widely used but lack precision. PCR-based molecular diagnostics provide more accuracy and reliability. Emerging enzymatic and nanotechnology-based diagnostic tools offer potential advancements in BV detection.

Treatment challenges are another crucial aspect. Standard antibiotic therapies, including metronidazole and clindamycin, have a 50% recurrence rate within six months. This has driven interest in alternative approaches, including probiotics aimed at restoring Lactobacillus populations, vaginal microbiota transplantation (VMT) as a means of repopulating healthy microbiota, and biofilm-disrupting agents such as DNases and antimicrobial peptides. Additionally, the review explores the role of sexual transmission in BV persistence and the potential benefits of treating male partners​.

What Are the Implications of This Review?

The findings in this review emphasize the need for more effective diagnostic and therapeutic approaches for BV. The recognition of BV as a polymicrobial dysbiosis rather than a traditional infection suggests that future treatments should focus on restoring a healthy microbiome rather than eliminating bacteria. The high recurrence rate associated with antibiotic treatments highlights the need for strategies that address biofilm-associated resistance and microbiome resilience.

Probiotic-based interventions and vaginal microbiota transplantation could redefine BV treatment by offering long-term microbiome stability. Moreover, the identification of novel diagnostic biomarkers and rapid molecular techniques may enhance early detection and targeted interventions. Clinically, incorporating microbiome-focused therapies into gynecologic and obstetric care could improve reproductive health outcomes by reducing BV-related complications significantly. BV complications include increased susceptibility to sexually transmitted infections and adverse pregnancy events, emphasizing the need for innovative microbiome-based treatments urgently. The review ultimately advocates for a shift toward microbiome-informed medical strategies for managing BV.